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Abstract 
Modern tissue engineering (TE) scaffolds are expected to actively promote tissue repair as well as 
meeting the traditional requirements of non-toxicity, degradability and structural integrity. This thesis 
presents two novel bioactive hydrogel systems for bone and cartilage TE. A series of alginate hydrogels 
were developed in which all or a fraction of the calcium normally used for crosslinking alginate was 
replaced by bioactive strontium and/or zinc ions. Strontium was chosen for its ability to stimulate bone 
formation, while zinc is essential for alkaline phosphatase activity. Due to an interaction between the 
crosslinking ion and alginate type, the hydrogel properties could be tailored independently of the 
crosslinking ion used – meaning that varying biological and materials requirements can be 
accommodated. Strontium release from alginate gels was of a physiologically relevant magnitude, and 
alkaline phosphatase protein activity in Saos-2 cells was highest in strontium gels. Secondly, a biomimetic 
strategy for transforming growth factor beta (TGF-β) presentation and release was evaluated. TGF-β in 
vivo is secreted as part of an inactive latent complex, which is sequestered in a stable form within 
extracellular matrix until released by cells. TGF-β was therefore incorporated into poly(ethylene glycol)-
hyaluronic acid hydrogels in its latent form. When compared to free TGF-β, advantages were 
demonstrated in terms of lower protein adsorption to tissue culture plastic and relative biological 
inactivity. The latter implies that high doses may be loaded into TE scaffolds without exposing cells to 
excessive quantities of active growth factor, with TGF-β bioavailability then being controlled by gradual 
activation by cells. Increased metabolic activity and ECM deposition by bovine chondrocytes were seen 
after almost five weeks in culture with a single initial loading of LTGF-β. These innovations correspond to 
current TE trends, which seek to use biomimetic principles to evoke regenerative responses from 
transplanted or host cells, but to do so using technically and commercially feasible means.  
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Chapter 1  
 
Introduction and scope of thesis 
 
1.1 Tissue engineering: historical context and scaffolds 
Tissue engineering (TE) aims to generate replacement biological tissues and organs for a wide range of 
medical conditions involving tissue loss or dysfunction. The clinical scope of TE is enormous, with 
therapeutic potential in many of the ageing and lifestyle diseases prevalent in Western populations – such 
as heart disease, osteoarthritis and osteoporosis – as well as a host of other major afflictions including 
spinal cord injury, cirrhosis, type I diabetes, retinopathy and facial disfigurement (1). The general 
strategy is usually to seed cells within a scaffold, a structural device which defines the geometry of the 
replacement tissue and provides environmental cues that promote tissue regeneration (Figure 1.1). In 
many cases an in vitro maturation step may be included, to allow for newly seeded cells to attach to the 
scaffold, differentiate, and/or deposit functional ECM. These activities may be facilitated by growth factor 
treatment regimes, or mechanical conditioning for those devices expected to take on an immediate load-
bearing role such as tendon, cartilage, or heart valve replacements (2)(3). Alternatively the scaffold may 
be placed directly into the recipient (4)(5)(6). In this instance a compartment of the host’s own body 
functions as a bioreactor, supporting in situ maturation and – potentially – the early establishment of a 
blood supply; and raising the possibility of cell harvest, scaffold seeding, and implantation occurring in a 
single surgical event. Taking this approach one step further, the scaffolding material is sometimes 
inserted without cells; regeneration then relies on the recruitment of native cells into the implant and the 
subsequent deposition of ECM. Whichever approach is taken, the scaffold itself is critical to the success of 
the implant, and in many cases actively directs the behaviour of the cells within.  
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Figure 1.1: TE approaches. In traditional TE, cellularised scaffolds are given time to mature in vitro 
before being introduced into the patient, while for in vivo TE, the scaffold is implanted directly into the 
patient, with or without cells. These approaches are currently being applied in therapy for a range of 
tissues and organs, including those indicated (not an exhaustive list).  
 
The success of these principles can be seen from the large number of products in development or active 
use. A fast-growing arsenal of tissue replacement devices are in clinical trials or already approved as 
therapies for tissues including cartilage, bone, blood vessel and pancreas (1). These advances represent 
the culmination of more than thirty years of research. The roots of TE extend at least as far back as the 
1970s, with independent attempts from the groups of Green, Yannas and Bell – all at Massachusetts 
Institute of Technology – to create skin substitutes using cultured cell sheets, or collagen and 
glycosaminoglycans (GAGs) (7). A shift in emphasis from that of using natural scaffolds towards the use of 
synthetic polymers signalled the genesis of the field as we know it today, leading to the first use of a tissue 
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engineered device in a human, in 1991 (8).  In this procedure, a team led by Joseph Vacanti implanted a 
synthetic polymer scaffold, seeded with the patient’s own cartilage cells, into a patient with a congenital 
sternal deficiency (Poland’s syndrome). Also present was Vacanti’s brother Charles, who went on to 
develop the controversial ‘mouse with a human ear’ – ‘Auriculosaurus’. The modern understanding of the 
term ‘tissue engineering’ was consolidated with a highly cited 1993 paper by Langer and Vacanti (9). TE 
went from strength to strength through the 1990s, only to run into a period of gloom in the early 
millennium (Figure 1.2). Early TE efforts were plagued by product issues related to scale-up, shelf-life, 
quality control and distribution, and suffered from inappropriate business models and withdrawal of 
private finance in the early ‘00s (10)(11). Since then the field has matured, evidenced by the return of 
large scale investment and the first regenerative medicine companies becoming profitable (12).  
 
There are considerable scientific challenges involved in bringing TE products to the clinic in a cost 
effective manner, including generating large numbers of cells from small samples, and achieving adequate 
vascularisation to implanted material. But despite these challenges, significant progress has been made 
towards addressing the central aims of TE and indeed, sales of regenerative biomaterials now exceed USD 
240 million per annum (12). TE constructs for skin replacement were one of the earlier breakthroughs: 
TransCyte, a biosynthetic covering produced by Advanced Tissue Sciences Inc. (ATS), was approved by 
the U.S. Food and Drug Administration (FDA) in 1997, followed by several related materials. The first 
clinical trial of a TE organ was reported by Atala and his team in 2006, who carried out reconstructive 
surgery on seven patients with end-stage bladder disease using TE bladders (Figure 1.2) (13). Here, 
three-dimensional (3D) moulded polymers were seeded with the patients’ own cells expanded from 
biopsy. Thirty-one months later the engineered bladders displayed histologically normal trilaminar walls, 
and capacity and compliance were improved. Meanwhile growing numbers of patients are benefiting 
from TE techniques in clinical trials of vascular grafts and cartilage, among others (14)(2). Advances in 
scaffold design, as well as in cell culture and surgical techniques, promise to consolidate and extend these 
successes to a wider range of tissues and anatomical sites, and ultimately to large numbers of patients.  
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2010 Continuing legal disputes over use of embryonic stem cells in the U. S. 
2008 Successful transplantation of TE airway  
2007 
 Creation of induced pluripotent stem cells from adult human skin cells 
 Osiris named Biotech Company of the year 
 ~170 companies offering TE products or services, sales in excess of USD 1.3 billion; 
>1,000,000 patients treated; aggregate economic activity five-fold higher than in 
2002 
 Organogenesis breaking even, reinvesting profits; Apligraf® sales of USD 60 milllion 
per year 
2006 
 TE bladder appears in the Lancet 
 Launch of Proteus Venture Capital Fund, the first dedicated regenerative medicine 
fund 
2005             Carticel® becomes profitable 
2003             Organogenesis emerges from bankruptcy 
2002 
 ‘Integra® Dermal Regeneration Template’ by Intergra Life Sciences approved for 
treatment of severe burns  
 Organogenesis and ATS, both previously valued at USD 1 billion, file for bankruptcy 
 TE activity halved since 2000, loss of 800 full time employees, capital value of 
publically traded TE corporations drops from USD 2.5 billion to USD 300 million 
 Circe bioartificial liver completes Phase III clinical trial with statistically significant 
benefit for a subset of patients; FDA approval not granted as patient group was not 
identified in advance 
 42% increase in stem cell firms, coining of term “Regenerative Medicine” 
2001             President Bush restricts federal funding for embryonic stem cell research 
2000 
 Time magazine names Tissue Engineer as ‘Hottest Job’ for the future, 3000 people 
pursue TE careers 
 USD 580 million spent annually on TE research and development, public TE 
companies valued at USD 2.5 billion 
1998 
 FDA approves Apligraf®, first allogeneic TE product  
 Human embryonic stem cells isolated 
1997 
 TransCyte® by ATS becomes first US FDA approved TE product 
 Carticel® autologous cartilage implant approved by FDA 
1996 
The Tissue Engineering Society founded (now Tissue Engineering Regenerative 
Medicine International Society - TERMIS) 
1990s             USD 3.5 billion invested worldwide in TE, 90% from private finance 
Late 1980s             Early TE work in Massachusetts, term TE appears in literature 
Late 1970s             Cells combined with biomaterials in artificial skin and biohybrid pancreas research 
1968             First bone marrow transplant 
1950s             Organ transplantation with identical twins 
Date Event 
 
 
Figure 1.2: Tissue engineering timeline. TE gained in profile through the nineties, hitting a peak 
around the turn of the millennium, but several early commercial ventures failed and large-scale private 
financing was withdrawn. Improved business planning and a sounder scientific base have since propelled 
TE towards a new era of success (7)(13)(15)(12)(16).  
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1.2 Scope of thesis 
This thesis is concerned with how scaffolds can be made to actively support tissue repair. In recent years, 
TE scaffolds have come to be regarded not simply as passive cell carriers satisfying the minimum 
requirements of non-toxicity, degradability and structural integrity, but as instructive devices with the 
potential to be loaded with information that can be interpreted by transplanted or host cells (17). 
Materials can now be made to engage with cells in biologically-meaningful ways – for example by 
remodelling an artificial environment in a manner analogous to a natural ECM, or proliferating or 
differentiating in response to cues imposed by the chemist or biologist (5)(18)(19). The thesis consists of 
a literature review (Chapter 2) followed by two experimental chapters (Chapters 3, 4) describing novel 
hydrogel systems for bone and cartilage TE, respectively.  
 
The literature review is concerned with the principles of ‘bottom up’ scaffold design, according to which 
scaffolds are assembled in the lab from one or more constituent materials, with a major focus on 
engineering bioactivity. The opposing strategy – the ‘top-down’ derivation of decellularised extracellular 
matrix (ECM) from natural tissue – has generated some spectacular recent results and will be considered 
briefly in the Chapter 2 section 2.2.1 Extracellular matrix and ECM scaffolds. Particular attention 
throughout will be given to hydrogel scaffolds, although many of the strategies described are valid for 
different scaffold types. The review is divided into four main sections. The first section, 2.1 Engineered 
scaffolds: form and bulk properties gives a brief introduction to TE scaffolds, hydrogel crosslinking, 
and control of two important bulk properties of scaffolds – degradation and mechanics – with an 
emphasis on hydrogels. Following this, three sections are devoted to examining the types of cues to which 
cells respond, and how we might incorporate related signals into ‘bioactive’ scaffolds. 2.2 Bioactive 
scaffolds I: Physicochemical environment describes how cell adhesion sites, enzymatically degradable 
polymers, and physical properties of the matrix can be used to fabricate ‘artificial extracellular matrices’ 
that cells can interact with physically (a convenient oversimplification). 2.3 Bioactive scaffolds II: 
Growth factors discusses the use of growth factors within TE scaffolds, and in particular how advanced 
delivery strategies can improve functional outcome. Finally, 2.4 Bioactive scaffolds III: Complexity 
considers how commercial considerations are helping to drive the development of scaffold biomaterials 
with increasing functional complexity, while keeping other forms of complexity (structural, synthetic, 
procedural etc.) to a minimum.  
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Chapters 3 and 4 present novel bioactive hydrogel systems for bone and cartilage TE, respectively. 
Materials innovations that promote the regeneration of these tissues could help to satisfy major global 
demands, which exist due to the high incidence of complications following bone fracture, the high and 
increasing prevalence of osteoarthritis, and the drawbacks of current treatment options for these 
conditions (20)(21)(22)(23). In Chapter 3, a series of alginate hydrogels is described in which all or a 
fraction of the calcium normally used for crosslinking is replaced by bioactive strontium and/or zinc ions. 
Strontium was chosen for its ability to stimulate bone formation, while zinc is essential for alkaline 
phosphatase (ALP) activity. Calcium- and strontium-alginate hydrogels were assessed in terms of 
stiffness, degradation, and ion release, in order to determine how these properties were affected by the 
crosslinking ion and alginate type; to demonstrate control over these properties; and to evaluate the 
suitability of alginate as a slow release system for physiologically active concentrations of strontium. 
Saos-2 (human osteosarcoma cells) were encapsulated within hydrogels crosslinked by calcium-, 
strontium-, and/or zinc, with covalently coupled glycine-arginine-glycine-aspartic acid-serine (GRGDS) 
peptide to provide integrin anchorage sites. Total metabolic activity (alamarBlue® reduction) and lactate 
dehydrogenase (LDH) activity were assayed as measures of proliferation, to determine how the 
crosslinking ion(s) and material properties of the hydrogels affected cell viability. Osteogenic activity was 
evaluated by examining ALP activity and expression of the osteoblast phenotypic marker genes RUNX2, 
COL1A1 and BSP. This strategy relates to one of the main themes of the literature review as it is 
biologically inspired, yet technically simple, inexpensive, and flexible. It has the potential to be combined 
with other alginate-based systems for bone tissue engineering, or adapted to other tissue engineering 
applications, for example by choosing other bioactive ions such as cobalt (24).  
 
A second major theme of the literature review is how growth factors can be deployed to maximum effect 
via advanced schemes for their presentation and release. Chapter 4 explores the possibility of supplying 
transforming growth factor beta (TGF-β) within TE scaffolds in its inactive latent form, rather than as a 
free, active dimer. TGF-β in vivo is secreted as an inactive complex, non-covalently bound to a latency 
associated peptide (LAP), and via LAP to latent TGF-β binding proteins (LTBPs). The approach described 
here was to load TGF-β within TE hydrogel scaffolds while still complexed with LAP (‘latent TGF-β’, LTGF-
β). To explore some potential advantages of this approach, the concentrations of free and latent TGF-β 
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were measured over 48 hours on tissue culture plastic (TCP) as an indicator of their tendencies to adsorb 
to surfaces. The Smad3 phosphorylation responses of HFF-1 (human foreskin fibroblasts) to free and 
latent TGF-β were compared at different concentrations and in the presence of various pharmacological 
inhibitors of LTGF-β activation pathways, to infer how the dynamics of exposure to TGF-β might be 
altered by using the latent form. The utility of LTGF-β for cartilage TE was assessed by tethering the 
complex inside poly(ethylene glycol) diacrylate (PEGDA) and hyaluronic acid (HA) hydrogels, using 
Michael addition chemistry to conjugate the protein and crosslink the hydrogels. The biological activity of 
the PEGylated protein was investigated to ascertain whether the modification procedure had diminished 
its potency. Finally, bovine articular chondrocytes were cultured within the PEG-HA-LTGF-β hydrogels, 
and their viability and ECM deposition were examined as indices of TE success. The work presented in 
Chapters 3 and 4 provide proof-of-concept for these novel TE strategies, and in each case several routes 
for future optimisation or development are readily apparent. To begin, then, general consideration will be 
given to TE scaffolds: their form, bulk properties, and the many ways in which bioactivity can be 
engineered into them.  
20 
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Chapter 2  
 
Literature review 
 
2.1 Engineered scaffolds: Form and bulk properties 
2.1.1 Scaffolds and hydrogels 
TE scaffolds can take a variety of forms, although most can be classified as either solid, fibrous or 
hydrogel (Figure 2.1). Various engineering approaches can produce solid implants from polymers, 
ceramics or metals, which are relatively resistant to mechanical forces and incorporate an interconnected 
network of pores for cell movement and mass transport of nutrients. Porous solid scaffold fabrication 
techniques include particulate leaching, foaming by chemical means or by CO2 expansion, microsphere 
sintering, and phase separation, while electrospinning and phase separation are the principle means by 
which to create fibrous scaffolds (25)(26)(27)(28)(29). Technologically advanced options for solid or 
hydrogel scaffolds include a range of solid freeform fabrication (SFF) techniques. Some of these are 
computer assisted systems whereby the layer-by-layer deposition of materials including, potentially, 
cells, into a pre-specified 3D shape is achieved either through printing or by the extrusion of a polymer 
melt. Other groups have used laser beams to solidify polymers into complex shapes by 
photopolymerisation or sintering as they sweep over polymer liquids or layers of powder, respectively 
(30)(31). These technologies afford precise control over scaffold architectures, and when coupled to 
established medical imaging techniques they can produce solid TE devices fitted to the shape and 
dimensions of individual defect sites.  
 
However, damaged tissue should ideally be treated so as to minimise further injury to the surrounding 
tissue – and one minimally invasive way to achieve this is to inject a polymer matrix into the site of 
damage in the form of a hydrogel (with or without cells). Hydrogels are highly hydrated networks of 
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hydrophilic, crosslinked polymer chains. They can be formed from both synthetic or natural polymers, 
and crosslinked in a variety of ways. Commonly exploited synthetic polymers include poly(ethylene 
glycol) (PEG) and poly(methyl methacrylate), although a host of newer polymers are also under 
evaluation. Examples of natural polymers in common use include the proteins collagen, gelatin and fibrin; 
and the polysaccharides alginate, chitosan and agar (32)(33)(34). Where a gel is covalently crosslinked, it 
is known as a chemical hydrogel. These are often produced by reacting functionalised polymers with 
small molecule crosslinking functionalities, or alternatively by radical production through ultraviolet 
(UV) exposure or the use of redox initiators (Figure 2.1) (35)(36)(37). One chemistry that has been 
widely adopted is the Michael addition between thiols and acrylates or vinylsulphones, which proceeds at 
physiological pH over a period of a few minutes, and is well tolerated by cells (18). The PEG-HA gels used 
in Chapter 4 (Latent TGF-β hydrogels for cartilage tissue engineering) are crosslinked in this way.  
 
Conversely, the crosslinks of physical hydrogels consist of non-covalent interactions, such as hydrogen 
bonds, crystallised segments, or electrostatic or hydrophobic interactions (38). Alginate and pectin are 
examples of ionic gels: they crosslink in the presence of divalent or multivalent cations due to affinity 
between the positively-charged ions and the negative carboxylic acid groups of the polymers (39)(40). 
Alginate crosslinking is discussed further in Chapter 3 (Strontium- and zinc- alginate hydrogels for 
bone tissue engineering). Furthermore, specific interactions between biological molecules – which are 
typically enforced by non-covalent interactions – can also induce gelation. All the major classes of 
biopolymers can be grafted to polymer chains leading to gel formation by a variety of different 
interactions (Figure 2.1). Examples include complementary oligonucleotide sequences, oppositely 
charged peptides that dimerise into coiled-coil superhelices, and self-assembling peptide nanofibres 
(41)(42).  Heparin, an ECM polysaccharide that binds a multitude of proteins including growth factors, 
has been conjugated to PEG by Yamaguchi and co-workers, and the solution gelled by the addition of 
growth factors (44).  
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Figure 2.1: TE scaffolds, and hydrogel crosslinking. (Top) Hydrogel, fibrous and porous scaffolds are 
used in TE. Custom morphologies can be created using SFF techniques. (Bottom) Permanent, covalent 
links between polymer chains can be created by UV irradiation or through the use of reactive groups, with 
or without initiators, creating ‘chemical’ gels (bottom left). Physical crosslinks are reversible bonds based 
on a variety of non-covalent interactions, and this approach can be extended through the use of biological 
agents such as complementary oligonucleotides and oppositely charged peptides. Custom and porous 
scaffold images are from (31) and (48), respectively. Image of fibrous scaffold courtesy of Dr. Seth 
McCullen, Imperial College London.  
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Physical hydrogels have less aggressive reactivity than some chemical gels, and they are formed in 
equilibrium reactions which can be controlled by the solvent, salt concentration, pH or temperature. This 
raises the option of designing crosslinking groups so as to obtain materials that gel when introduced to a 
physiological environment, after moulding precisely to fill irregularly shaped defects. Thermally 
reversible polymers which undergo sol-gel transitions with increasing temperature are one such 
example. One way to engineer thermogelling systems is to synthesise block copolymers where the blocks 
have different solubilities in aqueous media. In this approach, PEG is usually coupled to hydrophobic 
blocks such as poly(caprolactone) (PCL) or poly(propylene fumarate). By varying the block length and 
molecular weight (Mw) of the copolymers, the sol-to-gel transition temperature can be coaxed into a 
physiologically useful range and mechanical performance optimised (45). An alternative is to make use of 
the temperature-sensitive polymer poly(N-iso-propylacrylamide) (PNIPAAm), which forms a solution 
below the lower critical solution temperature, and a gel at higher temperatures due to dehydration and 
aggregation (46). One novel application of this unusual property is in ‘cell sheet engineering’, whereby 
cells are grown to confluence on a sheet of PNIPAAm, and harvested as an intact monolayer simply by 
lowering the temperature to 20°C, causing the substrate to dissolve. This strategy has been deployed to 
excellent clinical benefit in corneal repair (47).  
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2.1.2 Controlling degradation 
Central to the TE approach is the use of non-permanent scaffold materials that, over time, become 
completely replaced by natural extracellular matrix. The objective is therefore to implant a scaffold that 
can persist in a robust state for long enough to allow for the formation of native tissue, but which will 
ultimately degrade and become replaced by newly synthesised matrix. In living tissues, cells migrate 
through natural ECM either by adapting their morphology to manoeuvre through a path of least 
resistance, or by clearing a trail through the matrix using secreted, locally activated or membrane bound 
proteases such as matrix metalloproteases (MMPs) and plasmin (49). Biomedical materials based on 
matrix constituents, like collagen, fibrin or hyaluronic acid, naturally harbour enzymatically-cleavable 
sequences – thus in many cases, natural scaffolds will eventually be cleared completely from the implant 
site.  
 
Where mammals lack the enzymes to break down the material – alginate for example, which is derived 
from brown algae – chemical modification and/or manipulating molecular weight may go some way 
towards achieving the desired effect.  Strategies applied to alginate have included gamma-irradiation to 
reduce molecular weight, encapsulation with microspheres containing the degradative enzyme alginate 
lyase, and periodate oxidation to increase the polymer’s susceptibility to hydrolysis (50)(51). 
Boontheekul and colleagues in the Mooney lab combined the latter approach with the use of a bimodal 
Mw distribution of alginate. Incorporating low Mw polymer accelerates degradation to the required 
speed, while the presence of high Mw chains prevents the loss of mechanical integrity that usually 
accompanies significant decreases in Mw.  
 
Likewise, several groups have introduced degradable groups into non-degradable synthetic polymers 
such as PEG. In one example, Kutty and co-workers synthesised a modified PEG containing ester bonds, 
and used this as the basis for semi-interpenetrating networks alongside either gelatin, collagen or 
hyaluronic acid (52). Where hyaluronic acid was used, encapsulated fibroblasts spread throughout the 
hydrogel in a continuous, three-dimensional network. More biomimetic modes of hydrogel degradation 
are discussed later in the section 2.2 Bioactive scaffolds I: Physicochemical environment.  
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2.1.3 Recreating tissue mechanics 
Many of the target tissues for tissue engineering exist to perform an essentially physical task, whether 
that be as part of the musculoskeletal, cardiovascular, or integumentary system. Artificial constructs 
which recreate the mechanical properties of the native tissue will tolerate the forces acting on them, 
minimise shear by deforming with their surroundings, and can also support the immediate mechanical 
needs at the implant site – and one need only to consider the example of an engineered heart valve to 
appreciate how essential this can be. However, the mechanics of living tissues are the product of a whole 
array of matrix components – their structures, abundance, organisation and interplay – and working to 
the complex mechanical specifications laid down by nature with our current toolkit is challenging. In 
some cases the best way to recreate these properties may be to perform in vitro conditioning, in which 
some aspect of the in vivo mechanical environment is simulated, prompting cells to deposit an ordered 
matrix (3). Often, however, the material itself may be optimised to possess mechanical properties 
approximating those of the target tissue. Each tissue presents its own set of demands: cortical bone, for 
example, is notable for its high strength and toughness while constructs for soft tissues such as muscle or 
skin need to be flexible and elastic. In many cases physical demands on scaffolding materials are 
complicated by the anisotropy inherent in most living tissues: the parallel arrangement of collagen fibres 
within tendons and the concentrically layered sheets of the intervertebral disc, for example.  
 
With their high water content and rubbery consistency, hydrogels are potentially excellent mimetics of 
many biological tissues. Research is ongoing into producing hydrogels with mechanical properties 
suitable for soft tissue replacement. Poly(vinyl alcohol) (PVA) hydrogels crosslinked by thermal cycling 
are unusual in that their stress-strain relationships display an exponential shape similar to that of many 
natural tissues (53). Their physical crosslinks consist of crystallites which form and grow during each 
thermal cycle, resulting, in effect, in a nanocomposite with the crystalline regions reinforcing an 
amorphous matrix. By stretching the sample after a single cycle the primary crystallites, which have 
dimensions of just a few nanometres, can be made to align along the direction of stress, and further 
cycling leads to their subsequent growth. Increasing the initial strain applied to the gel leads to a higher 
degree of crystallite alignment and therefore anisotropy, whereas the stiffness in both directions 
increases in proportion to the number of thermal cycles as the volume fraction of crystallites continues to 
grow. Millon et al. applied strain during thermal cycling to produce an anisotropic PVA hydrogel whose 
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stress-strain relationship matched very closely that of porcine aorta in both the longitudinal and 
perpendicular directions (53).  
 
In general, too much crosslinking leads to a brittle gel, but with too few crosslinks the material may be too 
weak to provide the necessary support. At the optimum range, a hydrogel will be both strong and elastic.  
Physical gels with reversible crosslinks, however, may tolerate higher strains than chemical gels due in 
part to the ability of the crosslinks to re-form once broken (54). Covalently crosslinked alginate gels 
under tension undergo very little deformation until a critical stress is reached, at which point the 
crosslinks suddenly ‘unzip’ along a propagating crack, resulting in catastrophic failure. Conversely, as 
stress builds within ionically crosslinked alginate, the polymer network rearranges via cycles of de-
crosslinking, chain slippage, and new bond formation. The load bearing area thus expands, and greater 
toughness is achieved (54).  
 
Of course, not all tissues are stiff, and some TE applications may have a specific requirement for very soft 
materials. The extreme softness of the vocal fold lamina propria (elastic modulus 100-1000 Pa) is 
essential for proper phonation and its function is easily impaired by scarring. This has motivated the 
development of soft (E ~ 500Pa) highly elastic gels of double cross-linked hyaluronic acid microparticles 
for vocal fold TE (55). The particles are synthesised by crosslinking with divinyl sulphone, then surface 
oxidised and lightly cross-linked together using hyaluronic acid modified with adipic dihydrazide. The 
gels exhibit controllable viscoelasticity, and a reduction in dynamic viscosity with frequency occurs at a 
similar rate as in human vocal fold mucosa. This and the previous examples demonstrate how TE 
scaffolds can be engineered to have bulk properties appropriate to their application; but in addition to 
these structural roles, materials can now be used to actively manipulate cells into behaving in particular 
ways. The next three sections on ‘Bioactive scaffolds’ examine different ways in which this can be 
achieved. Somewhat artificially, the first part of this discussion is organised around the ‘physicochemical’ 
environment, referring to those factors that (among other things) enable cells to interact with matrices on 
a physical level, for example by attaching to a synthetic material and degrading it in a protease-dependent 
manner. As to how we identify and implement factors which influence cell behaviour, our best clues come 
from nature’s own solutions. The next section therefore begins by considering natural extracellular 
matrix scaffolds.  
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2.2 Bioactive scaffolds I: Physicochemical environment 
2.2.1 Extracellular matrix and ECM scaffolds  
In the early 1960s, the orthopaedic surgeon Urist noted that demineralised bone matrix (DBM) – bone 
tissue from which all cells and mineral have been removed, leaving only ECM macromolecules –would 
induce bone formation in the surrounding tissues when implanted at an ectopic site (56). This 
observation led to the discovery of bone morphogenetic proteins (BMPs), growth factors with numerous 
physiological roles including in bone and cartilage development (57). ECM is usually a fibre-reinforced gel 
containing a tissue-specific array of proteins, glycoproteins and glycosaminoglycans including 
sequestered growth factors, hyaluronic acid, collagens, laminins, and fibronectin (58). It is primarily this 
molecular information which confers bioactivity: ECM supplies a vast amount of information that helps to 
regulate cells during development, tissue healing, during normal homeostasis, and in a huge number of 
pathological conditions including cancer (58). Several companies currently produce DBM commercially 
from cadavers for implantation in bone defects, and many other cadaver- or animal-derived 
decellularised ECM products have an inherent bioactivity sufficient to assist healing and have found 
clinical use. Products derived from the small intestinal submucosa of pigs are used routinely in 
reconstructive surgery (e.g. Oasis Wound Matrix®), and ECM derived from the pericardium of horses can 
be used as a reconstructive material in the dura mater layer of the brain meninges following a craniotomy 
(1).  
 
This approach has recently been propelled to the forefront of whole organ TE. In 2008 a 30-year old 
woman became the first person to receive a TE tracheal segment, a procedure that saved her left lung 
(15). The scaffold in this case was a decellularised human donor trachea that was repopulated with cells 
expanded from the patient’s bronchial mucosa and bone marrow. In contrast with traditional transplant 
surgery, the decellularisation protocol solved the problem of tissue rejection by removing virtually all 
traces of human leukocyte antigens – proteins which to a large extent determine tissue compatibility – 
with the consequence that the patient required no immunosuppressive drugs. As well as immediately 
restoring airway patency, the device facilitated the rapid development of an internal cellular lining and 
blood vessel network. This followed earlier work describing the reseeding of decellularised whole rat 
hearts with cardiomyocytes with restoration of some (minimal) level of function (59). More recently still, 
29 
 
similar work has been described in liver TE, and elsewhere whole rat lungs have been repopulated with 
neonatal rat lung epithelial and lung microvascular endothelial cells (60)(61). Upon transplantation, the 
lungs became perfused and ventilated – although to a lesser degree than the native contralateral lung – 
and blood samples demonstrated efficient gas exchange.  
 
Inspired by the intrinsic bioactivity of ECM, many groups have designed scaffolds based on direct mimicry 
of the ECM. One way of achieving this is to build materials from purified matrix constituents such as 
fibrin, collagen or gelatin (a low cost denaturation product of collagen), which contain various recognition 
elements that can be bound and interpreted by cells. HA is widely incorporated into scaffolds, and is used 
therapeutically as a putative lubricating factor in arthritic joints – although here and in TE it may also 
interact directly with cells via CD44 and other cell surface receptors (62). The ubiquity of ECM molecules 
such as collagens and HA in tissues has prompted the development of Extracel™, a modular ECM system 
based on derivatives of gelatin and HA (63). The components are combined in varying proportions to suit 
many different cell culture and in vivo applications, crosslinked with PEGDA and supplemented with 
additives such as heparin-bound growth factors as needed. For example, whereas equal quantities (w/w) 
of gelatin and HA are suitable for most tissue applications, a specialised composition enriched in HA (95:5 
w/w HA:gelatin) is required for vocal fold repair. In terms of more tissue-specific influences, a subset of 
BMPs are now used in TE devices including the tremendously successful INFUSE® (12). The use of growth 
factors in TE scaffolds will be discussed in detail in the section 2.3 Bioactive scaffolds II: Growth 
factors.  
 
Matrix constituents have disadvantages associated with purification and processing, and coupled with the 
desire for greater control over material properties, this has led to the investigation of fully synthetic 
bioactive systems. The ability to functionalise bioinert substances could improve the suitability for TE of a 
host of materials with remarkable properties, such as high strength synthetic polymers and 
(nano)composites for bone TE (64)(65). Of particular interest are systems amenable to minimally 
invasive delivery, including injectable or shape-memory materials that gel or regain their original form in 
response to stimuli such as UV illumination or physiological conditions (temperature, pH or solvent) 
(66)(45)(38)(67). Materials that do not adsorb protein, such as PEG gels, can effectively be used as a 
30 
 
blank canvas on which to confer bioactivity with the minimum amount of modification. This approach 
allows for a high level of control over the molecular influences presented to cells.  
 
2.2.2 Engineering cell adhesion  
Synthetic materials can be designed to interact with cells by emulating key molecular features of the ECM. 
One way to provide sites for integrin attachment in scaffolds is to include purified ECM proteins. In some 
cases specific functions of biopolymers can be attributed to small functional domains which may be 
included in place of the full protein (18)(43). The best known of these is the integrin-binding arginine-
glycine-aspartic acid (RGD) sequence found in many ECM proteins, including fibronectin, laminin, 
collagen type IV, fibrinogen, vitronectin, tenascin and thrombospondin (68)(69). Integrins are 
heterodimeric cell surface receptors which form part of the docking complex between ECM and the actin 
cytoskeleton. One third (8 of 24) bind RGD, and even in isolation this sequence can engage with integrins, 
allowing force generation for movement, providing behavioural cues, and for many cell types acting as 
survival signals – for without matrix attachment signals a cell may undergo a specialised form of 
apoptosis known as anoikis (70)(71). Therefore, the incorporation of adhesion proteins into a scaffold 
can support the migration, proliferation, differentiation and even the survival of its cell population. RGD 
modification alone is sufficient to transform alginate from a relatively inert polysaccharide into a 
substance that supports the formation of growth-plate like structures when mouse osteoblasts and 
chondrocytes are co-cultured within it (Figure 2.2) (72).  
 
 
 
Figure 2.2: Cell adhesive hydrogels. Formation of growth-plate-like structures in RGD-modified 
alginate hydrogels with co-transplanted osteoblasts and chondrocytes, showing cartilage (left), transition 
(middle), and bone and marrow space (right) regions. Magnification x200. From ref (72).  
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Since the late 1980s, RGD has been incorporated into a wide range of surfaces, scaffolds and hydrogels. 
Various structural variations have been investigated as means by which to increase binding affinity, 
including the use of a cyclic peptide conformation, optimal flanking amino acids (GRGDS is commonly 
used), and the inclusion of a PEG spacer arm in order to suppress protein adsorption and present the 
motif to cells in a sterically favourable fashion (73)(74). The concentration and spatial presentation of the 
peptide can profoundly affect cell response. For example Massia et al. determined that an average 
distance of 440 nm between RGD peptides was sufficient to enable fibroblast attachment and spreading, 
but a significantly higher density – an interpeptide distance of 140 nm – was required for focal contact 
formation and cytoskeletal reorganisation into stress fibres (75). The sequence proline-histidine-serine-
arginine-asparagine (PHSRN) from fibronectin binds synergistically with RGD, and has been shown to 
improve adhesion and focal contact formation when combined with RGD (69). In the intact protein, the 
synergy site (which includes, but is not restricted to, PHSRN) strengthens integrin-ECM bonds by 
engaging the alpha integrin subunit. Prior binding of RGD to the beta subunit and tensioning of this bond, 
usually through cytoskeletal contractility, are prerequisites for this secondary binding (76). When 
presented within biomaterials, the spacing between these two motifs may be an important factor to 
consider if this synergistic effect is to be achieved (69).  
 
It has been suggested that patterning of the RGD peptide into clusters may facilitate the binding of ECM 
adhesion complexes – large assemblies of integrins and various docking proteins which connect the 
cytoskeleton (indirectly) to the matrix. In agreement with this hypothesis, YRGD peptides support cell 
migration at considerably lower densities when presented in clusters than when evenly spread (77). 
There is also some evidence that different behavioural responses – namely adhesion, migration, 
proliferation and differentiation – are affected differently by various pattern parameters (number of 
ligands per cluster, distance between clusters, overall ligand density), suggesting a novel way by which to 
optimise cell behaviour (68). Aside from RGD, other adhesion sequences have been studied including 
IKLLI, IKVAV, LRE, PDSGR and YIGSR from laminin, DGEA from collagen I, and GEFYFDLRLKGDK from 
collagen IV (78)(79)(80). The IKVAV epitope can be presented at high density within hydrogels of self-
assembled amphiphilic peptides created by the Stupp group (43). These injectable gels have been shown 
to inhibit glial scar formation and to promote the regeneration of axons across the site of damage in a 
mouse compression model of spinal cord injury (42).  
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2.2.3 Active degradation of scaffold biomaterials 
ECM is frequently remodelled by cells during development, homeostasis and healing, a process which 
involves digestion by a variety of proteases – such as cathepsins and MMPs – followed by deposition of 
fresh matrix. As discussed earlier, many scaffolds are engineered to degrade by chemical hydrolysis, 
although this process must somehow be timed to keep pace with the cells’ ability to deposit new matrix. 
Cell-mediated scaffold degradation is more likely to generate a materials temporal profile in tune with the 
generation of new tissue, and can be engineered via the use of naturally degradable ECM constituents, or 
their substitution with short peptides. The latter approach is epitomised by the ‘synthetic ECMs’ 
pioneered by the Hubbell group. These innovative hydrogel materials are crosslinked by enzyme-
degradable peptide sequences, and a combination of cell-mediated degradation and integrin-binding 
allows the cells to migrate through the gel in a naturalistic process reminiscent of tissue remodelling 
(5)(18)(35)(81).  
 
In one example from this group, Pratt et al. developed a system whereby a vinyl-sulphate terminated PEG 
block was crosslinked with a cysteine-containing peptide by a Michael-type addition reaction (35). The 
crosslinking peptide, GCYKNRCGYKNRCG-NH2, contained three cysteine residues and two plasmin 
substrate sites (shown in bold). The rate of invasion of cells into this type of hydrogel can be changed by 
altering the enzymatic sensitivity of the MMP substrate peptide crosslinkers (by changing the amino acid 
sequence). Lower Mw PEG gives a higher crosslink density and a finer mesh, which slows down the 
movement of cells into the gels. At sufficiently high crosslink density it is even possible to exclude cells 
completely (81). Semi-interpenetrating networks of the thermogelling polymer PNIPAAm and 
poly(acrylamide) (PAA) crosslinked with MMP-degradable and integrin-binding peptides have been 
evaluated for bone regeneration. This polymer network allowed osteoblast invasion and supported new 
bone formation in vivo following injection into a treatment site in rat femora – even without the inclusion 
of cells or costly growth factors (6). 
 
Cleavage sequences can also be incorporated into multidomain peptides. One example is a recombinant, 
crosslinkable elastin-like protein which harbours an adhesion motif (REDV) and an elastase sensitive 
sequence. Cleavage of the latter yields a bioactive VGVAPG fragment intended to stimulate cell 
proliferation and enhance tissue repair (82). This functionality mimics the multilayered bioactivity of the 
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ECM, whereby enzymatic remodelling can liberate ‘cryptic sites’ contained within the amino acid 
sequences of ECM proteins. In fact it is becoming increasingly clear that fragments of many ECM proteins 
possess bioactivity – with effects ranging from cell migration to differentiation, proliferation and 
angiogenesis – which only becomes recognisable to the cells when the ECM is modified in some way  (83).  
 
2.2.4 Bioactivity of the physical environment 
ECM from every tissue of the body presents a unique gallery of molecular features to the cells residing 
within it, but each also possesses a specific set of physical properties. These encompass architectural 
features such as local topography and two- versus three-dimensionality; ECM stiffness; and intrinsic and 
extrinsic stresses and strains which may relate to static and dynamic loading, hydrostatic pressure, 
and/or fluid flow. As has already been discussed, scaffolds which recreate particular physical properties 
can potentially contribute towards the mechanical function of the tissue – but additionally, these physical 
cues may in themselves constitute another layer of biologically relevant information. Indeed, such stimuli 
may be a critical determinant of some cells’ physiological function. Hence, static and dynamic forces are 
applied to TE devices in a multiplicity of ways within specialised bioreactors, in order to mature TE blood 
vessels (pulsatile flow), cartilage (cyclic compression), ligament (tension), and other tissues prior to 
implantation (84). Equally, it is also possible to optimise cell behaviour by fabricating scaffolds with 
appropriate stiffnesses and/or architectures. For example, it has been recognised for some time that cells 
can respond to topographical cues, for example by orientating themselves along micropatterned ridges 
(85). Scaffold geometry was recently used to align cardiac muscle cells in order to elicit directional 
contractions, which are essential for efficient blood transfer (86). The crosslinking of microstructured 
honeycomb poly(glycerol sebacate) sheets was optimised to mimic the anisotropic stiffness of rat 
ventricular myocardium. These sheets possessed microscale pores in the form of two overlapping 
squares tilted at 45 degrees, which directed the alignment of neonatal rat heart cells. The resulting 
constructs displayed anisotropic electrical excitation thresholds as a result of this long-range order. 
 
The phenotypic effects of ECM stiffness have been a topic of intense research over the past few years, 
exemplified most prominently by the work of the Discher group in Philadelphia. In two studies they 
concluded that both skeletal and cardiac muscle striate optimally on substrates that mimicked the 
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stiffness of the native tissue (~10-12 KPa) (87)(88). Thus, only myotubes grown on physiologically stiff 
substrates formed striations, and cardiomyocytes assembled sarcomeres and beat at a physiological 
frequency (1 Hz) for longest when the substrate stiffness did not exceed physiological levels – conclusions 
with obvious implications for TE. In the latter study, the contractile work done by the beating 
cardiomyocytes peaked at this same level of stiffness. At higher rigidities (>> 10 KPa), the cells were 
contracting almost isometrically against an inflexible support, leading to high intracellular strains with 
disruption to the structures of cytoskeletal and docking (e.g. focal adhesion) proteins. On softer supports, 
however (<< 10 KPa), matrix deformation exceeded cellular deformation, but this movement was 
inefficient in terms of work done because the substrate itself offered little resistance. In other work, 
Engler and colleagues famously reported that the expression levels of neurogenic, myogenic, and 
osteogenic transcription factors by MSCs peaked on substrates with stiffnesses close to those of brain, 
muscle, and osteoid, respectively (89).  
 
Naturally these and other findings have generated interest in the biochemical bases for the ability of cells 
to sense and interpret ECM stiffness. It is clear that direct cellular mechanosensing mechanisms do 
operate, such as the tension-induced unfolding of talin rods: this conformational change exposes cryptic 
vinculin-binding sites, possibly promoting focal adhesion assembly (90). However ECM stiffness can also 
influence cells indirectly, for example via force-dependent interactions with ECM macromolecules. As we 
shall see in Chapter 4, TGF-β can be released from its latent complex in several ways, one of which 
involves a force-dependent conformational change of the latent complex (91)(92). This requires a 
minimum ECM stiffness of ~10 KPa to provide resistance against integrin-mediated traction (Figure 2.3). 
Regardless of how generalisable is this type of mechanism, it is clear that we should expect further 
research to reveal potent combinatorial effects of soluble, insoluble and mechanical influences on cells.  
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Figure 2.3: Force-dependent activation of TGF-β. (Left) TGF-β is sequestered in the ECM within a pro-
peptide (black) containing an RGD sequence, to which cell surface integrins can bind. (Middle) 
Contraction of the actin cytoskeleton against a stiff (> 10 kPa) substrate can cause the propeptide to 
undergo a conformational change, resulting in TGF-β release. (Right) On a soft (< 5 kPa) substrate, 
cytoskeletal contraction results in deformation of the matrix rather than the pro-peptide, and the TGF-β is 
not relinquished. Modified from ref (91). TGF-β latency and activation is discussed in detail in Chapter 4.  
 
Substrate stiffness, and cell adhesion, shape, and contractility appear to be intimately related. Cells will 
tend to adhere more strongly, spread more extensively, and develop prominent stress fibres on more 
rigid substrates (~35 KPa and upwards) (89)(17). As can stiff substrates favour osteogenic 
differentiation, so too can more spread geometries: human mesenchymal stem cells (MSCs) constrained 
to narrow cross-sectional areas or permitted to spread tend to differentiate towards adipocytes and 
osteocytes, respectively, when grown in medium that can induce either lineage (93). These findings, 
however – which derive from experiments conducted on two-dimensional surfaces – may not translate 
straight-forwardly to 3D cultures. Human MSCs encapsulated within alginate hydrogels are sensitive to 
gel stiffness despite maintaining a similar, rounded morphology in all conditions (94). On the other hand, 
more rapidly degrading alginate supports higher levels of bone formation than slowly degrading gels – 
and it is conceivable that cell shape could be a contributing factor here, for in other gel systems combined 
degradation and adhesion has been correlated with cell spreading (95)(52). Evidently, it will be 
challenging to dissect the effects of these inter-related factors, and caution must be taken in interpreting 
results from materials systems which cannot necessarily separate the effects of different stimuli. These 
and other physical factors continue to be investigated intensively and provide a complementary approach 
to the provision of molecular information to cells inside scaffolds. The next section returns to the 
molecular approach by considering how TE can benefit from scaffolds engineered to deliver growth 
factors in advanced, biologically-informed ways.  
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2.3 Bioactive scaffolds II: Growth factors  
2.3.1 Motivation 
Growth factors, such as TGF-βs, BMPs, vascular endothelial growth factors (VEGF) and platelet-derived 
growth factors (PDGF), are important signalling molecules in both development and tissue healing. Some 
of these proteins act as ‘morphogens’, determining the spatial arrangement of cell types within the 
developing embryo. They may also have profound effects in the control of tissue regeneration – for 
example, as we have already seen, BMPs can induce the formation of bone ectopically in muscle tissue 
(56). These observations have found resonance in stem cell research with the result that many growth 
factors are important components in the differentiation regimes for both adult and embryonic stem cells 
(2)(96)(97). In TE, the application of growth factors within biomaterials represents a powerful tool for 
controlling cell differentiation and function. Already, growth factors feature in a handful of commercially 
available TE products, one of which – Medtronic’s INFUSE® – represents the field’s biggest financial 
success to date (1)(12). This product attracted nearly USD700 million of sales in 2007 – an order of 
magnitude more than any of its competitor products. INFUSE® is supplied with powdered recombinant 
human BMP-2, which is reconstituted in water and added to a collagen sponge immediately prior to use.  
 
The possibility of using growth factors to promote cellular functions such as self-renewal, and the 
recruitment of endogenous repair cells into implanted materials, is also gaining currency (17). For 
instance, when murine muscle lacerations were treated by transplantation of myoblasts within RGD-
coupled alginate gels, recovery was dramatically improved by the inclusion of hepatocyte growth factor 
(HGF) and fibroblast growth factor-2 (FGF-2) (19). This combination of growth factors is active in muscle 
regeneration in vivo, and has the effect of stimulating quiescent satellite cells to undergo mitosis while 
preventing their terminal differentiation into skeletal muscle. Thus, as well as improving the survival of 
the transplanted cells, this hydrogel expanded myoblast numbers by stimulating proliferation and 
inhibiting differentiation until the cells had migrated out of the device. The result was a significantly 
greater muscle mass, smaller defect size, and greater contribution by the transplanted cells. In a second 
example, a TGF-β3-infused collagen I gel was deployed as a chemoattractant in a moulded polymer-
ceramic scaffold (98). The device was shaped to resemble the entire proximal articular condyle of the 
rabbit humerus, and was implanted acellularly. At 4 months the scaffold surface was covered with an 
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aggrecan- and collagen-rich, hyaline cartilage-like matrix. Those constructs containing TGF-β3 were 
thicker, denser, and became populated with 130% more cells than those with collagen alone, suggesting 
that circulating progenitor cells may have responded to the released growth factor by homing to the 
implant site. This approach is completely dependent on the availability and competence of progenitor 
cells, which in the elderly cannot be relied upon, but the in vivo generation of an entire articular surface 
from host cells convincingly demonstrates the exciting potential of material-growth factor combinations.  
 
2.3.2 Passive growth factor release strategies 
The uncontrolled use of growth factors in materials can lead to rapid release and inactivation, and 
consequently suboptimal functional outcomes. Furthermore, in developmental pathways and wound 
healing, different factors become active at different times, and growth factor release profiles that 
recapitulate these dynamics are likely to provide more leverage over cell behaviour than those that apply 
growth factors indiscriminately. The development of controlled delivery strategies is therefore a priority 
in this area of research. Materials schemes based on optimised degradation rates or diffusive properties 
of polymers have been designed with this in mind (Figure 2.4) (99)(100). Where retarded release of 
growth factor protein is required, one option is to fabricate loaded microspheres using the double 
emulsion technique, whereby primary (water in oil) and secondary (oil in water) emulsions generate 
aqueous pockets of dissolved proteins within polymer droplets (101). The droplets can then be dried into 
beads, which can be seeded within a scaffold, or else fused together to fabricate an entire scaffold 
(microsphere sintering) (102)(99). As the microspheres degrade, so the pockets of dissolved morphogens 
are gradually freed. Alternatively, polymer coatings can be created using chemical vapour deposition or 
co-electrospinning – a variation on the electrospinning technique which produces core-shell fibres in a 
one-step process (103)(104). Furthermore, by combining approaches, the sequential release of two or 
more growth factors may be contrived in order to expose cells to a temporal scheme of events designed to 
recreate some aspects of developmental pathways or wound healing (99).  
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2.3.3 Biomimetic growth factor release strategies 
Although most efforts to date have concentrated on evaluating the effects of freely diffusible forms of 
growth factors in solution, most in fact function at interfaces in vivo, bound to ECM components or as part 
of membrane complexes (105). Whilst concern undoubtedly arises over the cellular accessibility and 
activity of surface-immobilised proteins, even relatively simple tethering of a growth factor to a 
biomaterial matrix can elicit desired biological responses (106)(107). For example TGF-β1 covalently 
tethered to PEG retained its ability to stimulate matrix production in vascular smooth muscle cells over 
seven days in culture (108). A novel, biomimetic strategy for the delivery of TGF-β within scaffolds is the 
subject of Chapter 4. More precise, site-specific couplings can be engineered through the use of 
recombinant proteins into which additional amino acids are introduced at the termini, for example 
Cysteine-tags or enzyme substrate sequences enabling proteolytic release (109).  
 
More natural mechanisms of growth factor binding and release are also being pursued. In vivo, GAGs – 
mostly as components of proteoglycans – play key roles in growth factor activity including sequestering 
them within the matrix, preventing their degradation, and presenting them to cell surface receptors. GAGs 
are complex molecules with tissue specific distribution and multiple physiological functions. They 
possess characteristic linear structures of repeating hexosamine-uronic acid disaccharide units (110). 
Heparin, and heparan-, chondroitin-, keratin- and dermatan-sulphate GAGs (HS, CS, KS, DS, respectively) 
also have tightly regulated regiospecific sulphation patterns, which determine their specific interactions 
with proteins (111)(112). These interactions can be essential for growth factors’ physiological effects. 
FGF-1, for example, requires HS binding for dimerisation and receptor activation (113).  
 
Heparin sequesters numerous morphogens into the matrix by binding them with high affinity until they 
are liberated by cellular remodelling – and for this reason has been widely incorporated into TE scaffolds 
as a slow release mechanism for growth factors (Figure 2.4) (114)(115). Pratt et al. have exploited this 
natural system by attaching peptides with a heparin binding domain to PEG within hydrogels (35). The 
peptide associates with heparin via electrostatic interactions, and the bound heparin acts as a bridge 
between the scaffold and growth factor. Thus, a range of different growth factors can be indirectly 
tethered to the polymer matrix. Once immobilised, the growth factor can be released through the 
breakdown of heparin by cell-derived enzymes. In this way, release of growth factors can be made to 
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occur in synchrony with cellular remodelling rather than by simple diffusion. One prominent example in 
which systems for controlling growth factor release and presentation have been effectively employed is 
the inducement of blood vessel growth into scaffolds. This application will be used to illustrate the 
potential of rationally-designed release schemes to improve TE functional outcomes.  
 
 
 
Figure 2.4: Presentation and release of growth factors from TE scaffolds. Anticlockwise, from top: 
growth factors within TE scaffolds may be loaded into polymers whose rate of degradation or diffusive 
properties can be modulated to tailor release rate, and which may be combined into systems releasing 
multiple factors with distinct kinetics (99)(100). The exposure of cells to different growth factors with 
time may therefore imitate developmental pathways and healing responses. An alternative to presenting 
growth factors in soluble form is to bind them to a surface in either random or specific orientations, with 
the possible use of a spacer molecule (106)(107)(108). Non-covalent associations with matrix 
components, particularly glycosaminoglycans (GAGs), can effect slow release and in some cases may 
potentiate binding to membrane receptors (114)(115). Cell demanded release is based on the presence of 
protease-sensitive peptide sequences within the growth factor protein (116)(109).   
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2.3.4 Vascularising scaffolds  
Creating a functional vasculature is one of TE’s most fundamental challenges, and consequently TE 
successes to date have been most notable in thin or avascular structures such as skin, bladder and 
cartilage. Surgical approaches whereby implants are sited alongside a rich external blood supply are 
likely to complement materials strategies which attempt to induce or organise vessel formation, either de 
novo (vasculogenesis) or by sprouting of existing vessels (angiogenesis) (13). Endothelial cells have an 
inherent ability to form tubular structures but it is essential that these are stabilised if regression is not to 
occur. Permanent blood vessels are supported by smooth muscle cells and pericytes as well as the 
endothelial component, and several studies have shown the potential of co-culture with various cell types 
to improve the longevity of vascular networks (117)(118). Pericytes and endothelial cells in co-culture 
produce tissue inhibitor of metalloproteinase (TIMP) -3 and -2, respectively, which stabilise vessels by 
arresting the matrix breakdown that is associated initially with vascular invasion and lumen formation, 
but also ultimately with regression (Figure 2.5) (119). Several materials-based approaches have 
employed VEGF, a potent angiogenic factor involved in the early stages of blood vessel formation. VEGF 
has a narrow therapeutic concentration range, above which capillary formation is prolific but aberrant: 
the resulting structures are malformed, leaky, and unstable, regressing quickly upon withdrawal of VEGF 
(120). Furthermore VEGF has a half-life of <90 minutes in the circulation, hence the need for it to be 
delivered via biomaterials that can release it in low concentrations on a timescale of weeks (121). An 
interesting scheme devised to this end involved the production of a recombinant VEGF variant, which was 
enzymatically incorporated into fibrin matrices, and released upon matrix breakdown by cell-produced 
enzymes (122). The release rate was accelerated by the selection of VEGF isoforms with a plasmin 
cleavable sequence near the conjugation site. Interestingly, durable vessel formation and in vivo 
vascularisation was enhanced with this VEGF molecular variant compared to native VEGF in a mouse 
model despite a lower upregulation of VEGF receptor 2 (the receptor through which VEGF exerts its 
effects on endothelial cells).  
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Figure 2.5: Vascularisation of tissue engineering scaffolds. Centre/bottom: new blood vessels form 
initially by endothelial cell organisation into tubes, which are later stabilised by smooth muscle cells and 
pericytes. From left: many attempts to induce this process within TE scaffolds have involved the use of 
vascular endothelial growth factor (VEGF). A low level of sustained release is demanded as burst release 
results in the formation of unstable, leaky vessels (120). Subsequent release of platelet-derived growth 
factor-BB (PDGF-BB) helps to recruit smooth muscle cells, which favours vessel maturation (123). 
Materials strategies for releasing growth factors are indicated in Figure 2.4. Gene transfer has been used 
to generate populations of cells that constitutively express either VEGF, or a stabilised variant of hypoxia-
inducible factor 1α (HIF-1α). In the latter case, the protein translocates to the nucleus where it initiates a 
hypoxic response involving the activation of a host of genes and upregulation of angiogenic growth 
factors (124). Co-culture of different cell types leads to paracrine and membrane interactions that can 
enhance angiogenesis. Endothelial cells (EC) and pericytes in co-culture increase the production of tissue 
inhibitor of metalloprotease (TIMP) -2 (EC) and -3 (pericytes), which inhibits tube regression (119).  
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Other groups have taken a combinatorial approach to growth factor delivery whereby VEGF is released in 
tandem or sequentially with other growth factors involved in the orchestration of angiogenesis, such as 
PDGF-BB, FGF-2 and Angiopoietin-1 and -2 (117)(121). PDGF-BB is important in recruiting smooth 
muscle cells to stabilise nascent vessel walls; when packaged with VEGF-A inside alginate hydrogels the 
two growth factors show distinct release kinetics, apparently due to their different affinities for alginate 
(123). Used therapeutically, this material stimulated the formation of mature, smooth muscle cell-
associated blood vessels, and improved cardiac function in a rat model of myocardial infarction. Yet 
another possible avenue is to use gene transfer such that cells constitutively produce low levels of VEGF 
or other desired proteins. One target is the transcription factor hypoxia-inducible factor 1α (HIF-1α), 
which holds the key to intracellular detection of hypoxia, which can lead to upregulation of VEGF and 
other proteins involved in the cascade of angiogenesis (124). A gene was delivered which encoded a 
stabilised form of HIF-1α, which lacked the oxygen sensitive degradation domain present in the native 
form and could therefore initiate angiogenic events under normoxic conditions. The plasmid was 
packaged within designer peptides, one of which incorporated a factor XIIIa substrate sequence as a 
means to immobilise the DNA within a fibrin gel (Figure 2.5).  
 
Clearly, although vascularisation of scaffolds remains an inadequately resolved challenge, encouraging 
developments are being made in this area. Overall, these and previous examples demonstrate that current 
biological understanding and materials technology can be applied to create sophisticated scaffolding 
biomaterials, loaded with complex physical and molecular information, with leverage over cell behaviour. 
These expanding possibilities, however, raise the question of whether, in TE, it is always appropriate to 
aim for the most biomimetic materials solution or whether, in some cases, less is more. This question 
forms the basis for the final section of this review.   
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2.4 Bioactive scaffolds III: Complexity 
2.4.1 Commercial considerations in tissue engineering  
While it is becoming possible to use materials to influence cell behaviour by encoding complex 
information within their physical and chemical structures, in commercial TE, financial considerations 
dictate that synthetic and procedural complexity must be kept to a minimum. To compete successfully in 
the marketplace, TE scaffolds must be not only clinically efficacious, but also cost-effective. This raises the 
dilemma that over-engineering TE devices may make their translation to clinical use unlikely. An 
emerging philosophy within TE is that rather than attempting to recreate the complexity of living tissues 
ex vivo, we should aim to develop synthetic materials that establish key interactions with cells in ways 
that unlock the body’s innate powers of organisation and self-repair. The following discussion considers 
ways in which scaffold biomaterials can be made to deliver optimum performance despite limited 
structural complexity. To begin, examples will be given of how the functions of various types of 
biomolecule (particularly proteins and polysaccharides) can be distilled into structurally simpler, 
synthetic mimics.  
 
2.4.2 Simplifying biomolecules 
We have already seen that certain features of proteins can be reproduced in short integrin-binding or 
protease-digestible peptides. Although they may only have a fraction of the activity of the complete 
protein they can be included at very high concentration and are easy to synthesise and functionalise. This 
approach can be extended to other protein functional domains, for example in growth factor-mimicking 
therapeutics. Here, some of the growth factor function is condensed into relatively short peptide 
fragments, typically of 30-40 amino acids (125)(126), which usually correspond to the receptor-binding 
region of the protein. The concentrations of these peptides required to elicit biological effects are 
variable, and in some cases exceed those of the native proteins by orders of magnitude. Some, however, 
bind their respective receptors with comparable affinities to recombinant growth factors, and can trigger 
signal transduction leading to appropriate cell responses. Angiogenesis has been induced by one FGF-2 
mimetic peptide at similar concentrations to recombinant FGF-2 (126). This molecule contains two 15-
amino acid receptor binding domains and a 9-amino acid heparin binding sequence. Furthermore such 
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mimetics can have demonstrable effects at the whole-organism level: a 15 amino acid peptide, based on 
the neural cell adhesion molecule binding site for FGF-receptor-1, imparted to rats a long-lasting 
improvement in memory upon intracerebroventricular administration (127). A further advantage to 
these mimetics is their relatively high stability relative to native growth factors, such as BMP-2, that are 
necessarily used in supraphysiological doses. 
 
Even active compounds bearing no relation to the primary structures of growth factors can be identified 
from peptide or small molecule libraries. As many cytokines and growth factors and their receptors are 
arranged in dimers, bi- or oligovalency can enhance the activity of these compounds. The covalent 
dimerisation of a 20 amino acid erythropoietin (EPO) mimetic peptide increased its affinity for the EPO 
receptor 100 fold (128). Mice erythropoiesis assays, which measure the incorporation of radioactive 59Fe 
into the blood, revealed a similar increase in in vivo potency of this peptide, although its activity still 
remained orders of magnitude short of native EPO. More generally, a wide and expanding palette of small 
molecules and ions such as retinoic acid, dexamethasone and thyroid hormones (to name a few of many) 
are known to influence differentiation (129)(130). Bioactive glasses such as PerioGlas® can be made to 
release various ions including calcium and silicon, which can effect upregulation of genetic pathways 
relevant to bone differentiation (131)(132). The bioactive glass ‘BCT001’ additionally releases strontium 
to help combat osteoporosis (Chapter 3 of this thesis describes a related strategy using alginate 
hydrogels).  
 
The ability to bind growth factors and thus modulate cellular functions can be recreated in synthetic GAG 
mimetics (111)(112). Synthetic, sulphated di- and tetra-saccharides in side chain positions along a 
polymer backbone can successfully compete with neural CS for growth factor binding, despite non-native 
molecular architectures. One of these glycopolymers, a polymerised CS tetrasaccharide, had similar 
potency to neural CS (111). Interestingly, non-specific chemical sulphation of hyaluronic acid, which 
naturally occurs in a non-sulphated form, induces less extensive structural rearrangements of adsorbed 
and covalently bound fibronectin, translating into a higher level of cell attachment (133). Alginate can 
also be chemically sulphated to yield a polymer with binding affinities to growth factors (e.g. VEGF, PDGF-
BB, and HGF) comparable to or higher than heparin and with the ability to enhance FGF-induced blood 
vessel formation (134). A sulphated and carboxylated dextran derivative potentiated VEGF binding to its 
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receptors, resulting in angiogenic effects, and even incorporating sulphonated monomers (sulphopropyl 
acrylate potassium) into poly(acrylamide) gels increases the uptake of serum proteins (135)(136). These 
materials carry the advantages of scalable chemical synthesis, more closely defined material properties, 
and more abundant starting materials, and are gaining interest as replacements for heparin and CS as 
modulators of growth factor release and activity. 
 
In addition to binding a broad spectrum of proteins, small oligosaccharide domains present within larger 
GAG sequences can also regulate cellular function through their involvement in specific structural 
interactions with their binding partners (112)(137)(138)(139). Tetrasaccharides, for example, represent 
the minimal CS epitope necessary to stimulate neuronal growth, and the anticoagulant activity of heparin 
has been localised to a pentasaccharide motif that interacts selectively with antithrombin (140)(141). 
Thus, in the same way that short peptide sequences have been used to isolate specific protein functions, 
oligosaccharide fragments may emulate the function of proteoglycans while keeping structural 
complexity to a minimum (142). Understanding of structure-function relationships within 
polysaccharides is far behind that of proteins and nucleic acids, due to the difficulty of obtaining 
structurally defined oligosaccharides in bulk from natural polysaccharides, complicated chemical 
synthesis, and inadequate sequencing methods (143). The pace of progress in this field is accelerating, 
but for the time being, the full potential of these advances remains unrealised.  
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2.4.3 Controlling cells with simple chemistry 
As well as introducing defined molecular recognition elements into biomaterials, recent studies have 
focussed on exploiting more basic chemistry to influence cell fate, potentially paving the way for 
structurally simple, yet cell-instructive, biomaterials. In the absence of adhesion peptides, cells interact 
with scaffolds via adsorbed protein, and in this regard hydrophilicity is a key consideration. Whereas 
hydrophobic scaffolds tend to adsorb protein in sub-optimal configurations (with hydrophobic residues 
displaced towards the scaffold surface), hydrophilic polymers adsorb protein in a hydrated interfacial 
phase wherein the proteins are more likely to retain their native conformation (144). In one study, 
introducing different functional groups to surfaces changed the conformation of adsorbed fibronectin 
leading to altered integrin binding, such that indices of osteoblastic differentiation (expression of bone 
markers, alkaline phosphatase activity and mineralization) were significantly upregulated on OH and NH2 
functionalised surfaces compared to CH3 and COOH (145). There is considerable interest in utilising such 
simple chemistry to improve cell responses in favour of particular applications. Recently, a number of 
studies have described high throughput arrays for the systematic evaluation of large numbers of 
biomaterials-cell interactions (146)(147)(148). These investigations typically involve robotic spotting of 
polymer islands (3456 in one example) onto a glass slide coated with a non-adhesive polymer such as 
poly(hydroxyethyl methacrylate), which prevents cell migration between spots (147). Following cell 
culture, standard immunohistochemical techniques and microarray scanning can be performed. This 
provides a way of identifying polymers that support desired responses from specified cell types, for 
example those that promote human embryonic stem cell (ESC) differentiation to specific lineages (148). 
 
Another approach has been to select chemical functionalities based on their resemblance to characteristic 
chemical features of particular ECMs. The bio-inspired use of sulphonate groups within hydrogels has 
already been described, mimicking their presence in GAG chains and increasing protein uptake (136). 
This approach is well established in bone TE, where there exist many examples of materials incorporating 
anionic chemical moieties that improve mineral deposition, for example by NaOH treatment of scaffold 
surfaces or via the incorporation of functionalised monomers such as methacrylated amino acids (GlyMA, 
SerMA, AspMA, GluMA) (149)(150). This practice stems from the observation that many glycoproteins 
involved in bone mineralisation display a high proportion of negatively charged amino acids. For example 
bone sialoprotein possesses two polyglutamic acid sequences, while osteopontin contains a run of 10-12 
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aspartic acid residues (151). Phosphate groups also nucleate mineral, and although often delivered in 
soluble form in vitro (as β-glycerophosphate) can be incorporated covalently into scaffolds: Wang et al. 
describe a photo-crosslinked hydrogel prepared from poly(ethylene glycol)-di-(ethylphosphatidyl 
(ethylene glycol)methacrylate) and poly(ethylene oxide) diacrylate (152). Osteoblasts (bone forming 
cells) within the scaffold produce alkaline phosphatase, an enzyme which cleaves the phosphoester 
linkages in the polymer, releasing phosphoric acid. This promotes mineralisation as the phosphoric acid 
reacts with calcium in the medium to form insoluble calcium phosphate.  
 
Moreover, these chemical groups may also be instructive to cells. In a recent study, small defined 
chemical groups were incorporated into PEG gels, and encapsulated human mesenchymal stem cells 
differentiated towards cells of those tissues which the functional groups chemically resembled (67). Thus, 
those cells cultured in gels with charged phosphate groups increased expression of RUNX2 (CBFA1; an 
early bone transcription factor), produced a collagen-rich pericellular matrix, and synthesised 
osteopontin. Hydrophobic t-butyl groups pushed cells towards an adipocytic (fat cell) lineage, 
demonstrated by upregulation of the transcription factor PPARγ and the deposition of intracellular lipid 
deposits. It is unknown (and for practical purposes, arguably irrelevant) whether the role of the chemical 
modifications was to act directly on the cells, or to cause the preferential accumulation of particular cell-
derived molecules, these molecules in turn providing behavioural signals to cells. An example of the latter 
mechanism in action is the ability of mineral deposits to sequester osteopontin, which improves cell 
adhesion and viability within phosphate-containing PEG gels (153). Whatever the modes of action, the 
complexity of biomaterials could be massively reduced if the essential chemical character of ECM 
influences could be distilled into simple chemical functionalities. A summary of the various ways in which 
relatively simple molecules can mimic the molecular information within the ECM is given schematically in 
Figure 2.6.  
 
Figure 2.6 (overleaf): Synthetic mimics of biological structures. Many characteristics of ECM 
macromolecules have been reproduced in simpler compounds with biologically inspired structures. (a) 
Certain protein functions, including integrin binding for cell attachment and protease degradability, can 
be isolated to short amino acid sequences. These sequences can be combined with synthetic polymers or 
incorporated into complex peptides to enable cells to attach to or break down the material, respectively 
(43)(68)(69)(154)(81)(82). (b) Some glycoproteins involved in bone mineralization, such as [continued] 
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(Figure 2.6 continued) bone sialoprotein, possess runs of negatively charged amino acids. Peptides that 
incorporate these sequences, and synthetic polymers with negatively charged chemical groups, can 
display improved mineral‑nucleating activity (149)(149)(150)(155)(156). (c) Growth factor action has 
been demonstrated in peptides possessing receptor‑binding domains; heparin binding sequences may 
also be included to aid growth factor sequestration (125)(126). Random peptide libraries have allowed 
the identification of peptides with affinity to particular receptors, and dimerization of these molecules in 
some cases can improve receptor binding and physiological response (128). Growth factor action is 
sometimes potentiated through the actions of glycosaminoglycans (GAGs) such as the binding of heparan 
sulphate to the FGF‑1/FGF receptor 2 complex. This specific interaction can be achieved using short 
heparin oligosaccharides (137). (d) Furthermore, the protein‑binding function of ECM GAGs such as 
chondroitin sulphate can be mimicked by grouping sulphated oligosaccharides by polymerization, by 
sulphating natural carbohydrates such as dextran, or by sulphonating synthetic polymers (111)(133) 
(134)(135)(136)(157).   
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2.4.4 Discussion and broader implications 
The relatively short history of industrial TE has proven that the provision of efficacious products is not in 
itself sufficient to ensure commercial success; there is a clear need to consider more than just biological 
and clinical factors. The solutions to this challenge lie at every phase of product development, beginning 
with identifying the simplest functional performance required to resolve a defined clinical problem. 
Organogenesis Inc. and ATS suffered heavily as a result of their overestimating the number of chronic 
wounds cases that were best solved by high-tech, tissue engineered skin substitutes (respectively, 
Apligraf®, and Dermagraft®, Dermagraft® now produced by Advanced Biohealing) as opposed to acellular 
products that facilitate ongoing repair (11)(12).  
 
Evidently, a careful appraisal of the job in hand will reveal that the broader cost and treatment 
implications for any biomaterials approach vary with several interrelated factors including the form of 
the device, the mode of delivery, the nature of the cellular component, and regulatory implications. To 
elaborate briefly, injectable matrices help to tackle problems of surgical invasiveness while TE products 
in sheet form confront problems related to nutrient supply by limiting diffusional distances. Moreover, 
materials that can recruit endogenous cells into scaffolds avoid the expense and difficulties associated 
with culture, storage and distribution of cells, not to mention immune considerations.  
 
In terms of actual materials complexity, simplifying biomolecules as just described is one possible 
response. Another is to develop adaptable products or systems. A large number of commercially viable 
products for connective tissues are based on purified ECM components, particularly collagens and CS, 
representing a relatively generic ECM backdrop compatible with many cell types, which can thus be used 
in a range of different applications (1). The modularity of the Extracel system mentioned earlier is a 
particular advantage for niche markets such as vocal fold repair, where the cost of development may be 
high relative to volume of sales (63). Similarly, the synthetic process used by the Hubbell group allows 
any thiolated proteins or peptides to be included in PEG hydrogels by reaction with bis(α,ω-
vinylsulfone)poly(ethylene glycol) before crosslinking – achieving a modular system in which a bioinert 
polymer background can be decorated with any combination of bioactive compounds (18). Thus, 
bioactivity can be conferred onto previously bioinert synthetic polymers, potentially generating materials 
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that combine versatile material properties and inexpensive production with flexible control over cell 
behaviour.  
 
Encouragingly, it is clear that in some cases, comparatively simple materials in combination with an 
appropriate cellular component can support a high level of tissue organisation (4)(72). Simply creating an 
environment that is permissive for cell-cell interactions may enable cells to self-organise into more 
complex multicellular structures (such as blood vessels) than we could ever hope to impose ourselves. 
Furthermore, scaffolds with intelligently optimised mechanical and structural features – stiffness and 
RGD clustering, for instance – need not necessarily be any more costly to produce than their less well-
tuned counterparts. The potential of these features to direct aspects of cell behaviour illustrates that 
functional sophistication need not necessarily be synonymous with high manufacturing costs. Many 
laboratories in their own ways are actively pursuing simple but effective solutions to TE problems, such 
that the TE ideal of structurally simple, yet functionally complex, biomaterials is becoming a plausible 
possibility for the near future.  
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2.5 Conclusions  
There was much excitement associated with TE when it emerged as a new field in the early 1990s. This 
positivity led numerous efforts to turn nascent concepts into reality, using technology still in its infancy, 
with often disappointing results. Now, TE is entering a period of fruition, with many promising animal 
and human trials published and several products approved (1). Humans are already benefiting from lab- 
built organs. In constructing their tissue engineered bladders, Atala and his team used relatively simple 
moulded polymers optimised for mechanical compliancy (13). But as has been discussed, the capabilities 
already exist to produce far more complex scaffolds. Much is still unknown about the mechanisms by 
which tissues form and heal, yet already insights from developmental biology and other biological 
disciplines are actively guiding the development of intelligent materials that work with nature’s own 
mechanisms of repair.  
 
The last decade has seen an increasing use of biomimetics in scaffold design, aimed at producing matrices 
which engage cells on a molecular level, coaxing them into remodelling a synthetic implant into genuine 
tissue. Advanced biomaterial approaches taking advantage of growth factor activity are just beginning to 
trickle through product development pathways. Growth factors are costly and impose demands on 
processing and storage conditions, but the enormous success of INFUSE® shows the potential commercial 
viability of these material/growth factor combinations (12). It is promising that the outcome of growth 
factor administration can be improved enormously with the use of technically simple slow release 
schemes, such as delivery using polymers. Such considerations may prove critical for the resolution of 
complex TE challenges such as that of vascularisation of constructs. The work described in Chapter 4 
relates to this theme in that it describes an innovative approach for the delivery of TGF-β, which carries 
the potential benefits of improved growth factor stability, diminished biological impact of high initial 
loading and burst release, and the potential for the active release of growth factor by cells. Furthermore, 
interest is also growing in the exciting possibility of using simple chemistries to influence cell behaviour, 
and in the development of a range of therapeutics with intrinsic or modulating growth factor activity, 
including designer carbohydrates. With a biology-driven, but commercially-refined approach, commercial 
tissue engineering should flourish. In keeping with this philosophy, the next chapter describes a flexible, 
technically simple and inexpensive strategy for improving osteogenic differentiation within alginate 
hydrogel scaffolds.  
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Chapter 3  
 
Strontium- and zinc-alginate hydrogels for bone tissue engineering 
 
3.1 Introduction 
Long bone fractures account for an estimated 10% of non-fatal injuries in the USA, and complications are 
common (20). Delayed union, for example, occurs in 16-100% of all fractures (depending on severity), 
and nonunion in 4-10% (20). Where proper healing does not take place, the direct treatment costs and 
social burden of these injuries are compounded by the need for further – sometimes multiple – surgical 
procedures. Current best-practice for bone induction at the fracture site is to graft autologous bone from 
the iliac crest, but the supply of this tissue is limited. Enduring pain at the donor site affects 18-31% of 
patients 24 months postoperatively, and the procedure can also lead to blood loss, infection, haematoma, 
iliac wing fracture, vascular and nerve injuries, dysesthesia, and scarring (20). The development of bone 
replacement materials to supersede autografts is thus an important healthcare objective, and tissue 
engineering substitutes are beginning to show promise in this regard (1).  
 
Alginates are abundant natural polysaccharides with excellent biocompatibility provided they are 
sufficiently well purified (158). With the addition of calcium, they form hydrogels quickly and reversibly 
under physiological conditions, which break down with controllable kinetics as crosslinking ions are lost 
(159)(51). These hydrogels are used across several bioengineering disciplines including tissue 
engineering and drug delivery, and more recently as a platform system for basic biological research 
(160)(94) (161). Within tissue engineering, published work details their usage as scaffolds for bone 
(162), cartilage (163)(164)(165)(160), hepatic (166), cardiac (167), and pancreatic islet repair 
(168)(169) among others. Part of the reason for this spread of applications is the ability to control the 
material properties of alginate gels, such as stiffness and degradation, and to modify their chemistry 
towards particular requirements (170)(171)(51)(159). In its natural form alginate is biologically inert 
and adsorbs protein poorly, thus some level of modification is usually required to help drive appropriate 
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cell behaviour. It is readily functionalized via its carboxylic moieties, and the extent of cell interaction can 
be extrinsically controlled through the addition of macromolecules or peptides.  
 
In the area of bone tissue engineering, alginate has been supplemented with various additives in order to 
improve the osteogenic response of encapsulated cells. Bioactivity can be improved by providing 
anchorage sites for cell attachment, for example by incorporating the major structural protein collagen I 
or its derivative gelatin into the device (32) (162). An alternative but related tactic is to introduce the cell-
adhesive motif RGD in the form of short peptides conjugated directly to the alginate chains (172). In one 
example of this approach, RGD-modified calcium-alginate gels were used to deliver osteoblasts and 
chondrocytes subcutaneously into mice. This lead to the formation of mature bone, cartilage, and marrow 
at the implant site, and histological examination revealed multicellular aggregates resembling the growth 
plate zone of long-bones (72).  
 
Alginate can be blended with various calcium phosphates (32), which are chemically similar to bone 
mineral, and depending on chemistry and microstructure may be osteoinductive (173). These ceramics 
may also become involved in non-covalent interactions with ECM proteins and glycoproteins, mimicking 
those occurring in bone matrix in vivo and helping to retain secreted proteins inside the scaffold 
(32)(174). A number of groups have investigated strategies for incorporating growth factors or related 
peptides into alginate gels. Most have involved BMP-2, co-delivered with TGF-β3 (175) or VEGF (176), 
overexpressed by transfection (177), or replaced by short (~20 amino acids) synthetic peptides derived 
from the full native sequence (178). Even unmodified alginate alone may support bone formation when 
injected under the periosteum, a putative source of progenitor cells (4).  
 
One commonality of these studies is that calcium was chosen as the crosslinking ion in all cases, but 
alginate can be gelled by a number of other divalent and multivalent cations including Sr++, Zn++ and Ba++ 
(40)(179). Structurally, alginates are copolymers of (1,4)-linked α-L-guluronate (G) and β-D- 
mannuronate (M) residues, which occur both in homopolymeric regions – denoted G blocks and M blocks, 
respectively – and in alternating sequence (MG blocks; Figure 3.1). Gelation of an alginate solution occurs 
via a non-covalent crosslinking mechanism involving the chelation of divalent or multivalent cations into 
cavities created by the alignment of two or more alginate chains (39)(180)(181)(182). The assembly of 
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these ‘egg-box’ structures into larger junctional complexes causes the sol-gel transition (Figure 3.1). The 
cooperative binding of divalent cations to G blocks is highly selective, with affinity increasing in the order 
Zn++<Ca++<Sr++<Ba++ (40). This relationship shows some correlation with ionic radius (Figure 3.2), 
suggesting that this selectivity is related to the steric fit of ions within ‘egg box’ cavities. Although G blocks 
have generally been regarded as the predominant crosslinking fraction of alginate, M and MG blocks are 
also capable of forming gels (180)(183). Again, this property is ion-dependent: barium crosslinks M 
blocks more effectively than calcium and strontium, whereas the reverse is true of pure MG blocks (179). 
These distinctive outcomes provide opportunities to tailor the materials properties towards particular 
applications. The long-term encapsulation of bacteria for fermentation or pancreatic islets for 
transplantation, for example, both demand long-lived gels. One way to achieve this is to use barium, 
which has exceptionally high affinity to high G alginate (168)(184)(179)(40).  
 
 
 
Figure 3.1: Alginate structure and gelation. (Left) Alginate monomers showing (1,4)-linkages, and 
polysaccharide fragment (159). G = α-L-guluronate, M = β-D-mannuronate. (Right) Idealised schematic of 
calcium binding to alginate in egg-box dimers and intra-cluster associated multimers. Zigzag lines 
represent G blocks, wavy lines represent M and MG blocks, and circles represent calcium (or other 
divalent /multiva multivalent) ions. Note that in the dimer structure, the ratio of calcium to G residues 
(and hence COOH groups) is 0.25, whereas in the multimer it is 0.5.  
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Figure 3.2 Correlation between affinity for 92% G and 92% M alginates and ionic radii of some 
metal ions. Note that 92% G alginate is mostly composed of G blocks and the 92% M of mostly M blocks. 
Affinity data is from ref. (40), and ionic radii are from ref. (185). 
 
There is furthermore an opportunity – virtually unexplored – of selecting ions based on their known 
biological effects. Strontium, complexed in the form of strontium ranelate, has recently been licensed in 
the EU as a treatment for osteoporosis. It has the ability – unique among osteoporosis drugs – to increase 
bone mass through the concurrent activation of osteoblast (bone forming) activity and suppression of 
osteoclast (bone resorbing) function (186). We have recently demonstrated that the dissolution products 
of strontium-substituted bioactive glasses both increased osteoblast proliferation and alkaline 
phosphatase activity, and inhibited calcium phosphate erosion by osteoclasts (187). Zinc is essential for 
proper skeletal development and acts as a cofactor for a multitude of enzymes including ALP, which is 
central to the bone mineralisation process (188). Zinc increases ALP activity in Saos-2 (osteosarcoma) 
cells and has been investigated as a dopant in β-tricalcium phosphates for bone regeneration, with 
encouraging results (189)(190).  
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In this work it is proposed that a simple adjunct to the bone tissue engineering approaches described 
above could be the substitution of all or a fraction of the calcium usually present in alginate gels for other 
ions with relevance to bone physiology – in this case, strontium and zinc ions. According to this scheme 
the alginate gel acts as a slow release reservoir of bioactive ions which help to drive osteoblast activity 
and promote the deposition of bone matrix within and around the scaffold (Figure 3.3). In this chapter, 
selected material and biological effects of strontium and zinc substitution in alginate gels are investigated 
and described. The results demonstrate that important properties of alginate hydrogels such as their 
degradation rates are strongly influenced by strontium incorporation, but these properties can be 
controlled independently of the crosslinking ion due to qualitatively different interactions between 
strontium and calcium with different alginate types. An in vitro model was used to demonstrate how this 
principle can be employed to optimise cell proliferation. The results suggest that calcium, strontium and 
zinc alginate hydrogels have improved osteogenic properties compared to two-dimensional tissue 
culture, and cells grown in strontium-crosslinked gels had the highest levels of ALP activity. This general 
approach can be adapted to different applications with varying materials and biological requirements.  
 
 
 
Figure 3.3: Experimental concept. Alginate solution is crosslinked into a hydrogel by calcium, 
strontium, and zinc ions. The ions are gradually released as the gel degrades, leading to sustained 
biological action on encapsulated or nearby cells.  
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3.2 Materials and Methods 
3.2.1 Materials 
Two types of sodium alginate were obtained from FMC biopolymer, rich (55-65%) in either G (Protanal 
LF200DL) or M (Protanal LF200M) residues. These alginates will be referred to as “AlgG” and “AlgM”, 
respectively. A modified version of AlgG, with the peptide GRGDS covalently attached to the polymer 
chains via the alginate carboxylic groups, was kindly provided by Luis Rojo Del Olmo. This modified AlgG 
will be referred to as AlgG-RGD. Millipore 5.0μm Durapore membrane filters were used for casting gels. 
Inductively coupled plasma (ICP) reference solutions were from MBH analytical Ltd and analytical grade 
HNO3 was from VWR. All other chemicals and solvents were from Sigma unless stated. The human 
osteosarcoma cell line Saos-2 was purchased from ECACC and used at passages < 15. Transwell inserts 
(12 mm diameter, 3.0 µm pore size) were Corning brand. All cell culture reagents, phosphate buffered 
saline (PBS), the LIVE/DEAD® viability kit, and alamarBlue® were from Invitrogen (GIBCO). Lactate 
dehydrogenase (LDH) activity was assayed using Promega Cytotox 96 kits. Except for Trizol reagent 
(Invitrogen), all RNA extraction and quantitative real-time polymerase chain reaction (qPCR) reagents 
including primers (Quantitect) were from QIAGEN. For the ALP assay, p-Nitrophenyl phosphate (pNpp) 
tablets were from Sigma and diethanolamine substrate buffer was from Thermo Scientific.  
 
3.2.2 Preparation of alginate gels for materials characterisation 
Autoclaved sodium alginate solutions in 10mM HEPES buffer (150mM NaCl, 10mM KCl, pH 7.4) were 
dispensed into cylindrical moulds of 16mm diameter and 10mm height, secured at either end by a 
membrane filter. To ensure complete crosslinking, these were left overnight in stirred 100 mM solutions 
of CaCl2 and SrCl2 alone or in combination as specified in Table 3.1 (160). The filters permitted the 
diffusion of ions into the mould while preventing alginate release.  
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Gel group Gel 
Alginate 
concentration (% 
w/v) 
Alginate type Crosslinking solution 
G.Ca 
3G.Ca 3 
AlgG 
100 mM CaCl2 
2G.Ca 2 
1G.Ca 1 
M.Ca 3M.Ca 3 AlgM 
G.Sr20 3G.Sr20 3 AlgG 
80 mM CaCl2 
+ 20 mM SrCl2 
G.Sr 
3G.Sr 3 
AlgG 
100 mM SrCl2 
2G.Sr 2 
1G.Sr 1 
M.Sr 3M.Sr 3 AlgM 
 
 
Table 3.1: Gel formulations used for materials characterisation, including gel codes referred to in 
the text. 
 
3.2.3 Compressive testing 
Within 1 hour of being released from the diffusion chambers, the gels were tested in unconfined 
compression using an Instron 5866 with a 500N load cell, at a constant rate of deformation (5mm/min). 
Compressive extension and reactive force were recorded using BlueHill 2 software, and modulus (E) was 
calculated from stress-strain curves over the first 1 mm of deformation (approx. 10% strain).  
 
3.2.4 Swelling, degradation and ion release 
Blotted gels were placed in vials and covered with PBS. At intervals the PBS was aspirated and retained 
for ICP analysis of ion concentrations, the gel was weighed within the vial, and fresh PBS was added. 
Measurements were taken every 2 hours for the first 8 hours, then at increasing time intervals until 
complete degradation had occurred, i.e. when the gel mass fell to zero. The day of peak swelling was 
chosen as the most reliable indicator of gel stability, and will be referred to as the ‘lifespan’ of the gel. To 
detect ions released from strontium-containing gels, PBS samples were acidified in 3.5% v/v HNO3 (final 
concentration) and filtered, and dilutions were made in the same PBS/HNO3 solution. Samples were 
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analysed for strontium content (plus calcium where applicable) by a Perkin Elmer 2000DV ICP optical 
emission spectrometer calibrated against reference solutions of 1, 5 and 20 ppm. Samples with an ion 
concentration above 20ppm were diluted to between 2 and 20ppm and reanalysed. The total ion release 
from all gels (including calcium where applicable) was corrected for the ions present in the crosslinking 
solutions and expressed as a ratio of ions to carboxylic acid groups in the alginate. Rates of release were 
calculated between days 1-5, days 5-10, and day 10 onwards.  
 
3.2.5 Cell culture and toxicity of crosslinking solutions  
The Saos-2 osteosarcoma cell line was chosen to model osteoblast behaviour, due to their ability to 
deposit a mineralising collagenous matrix under appropriate inductive stimuli (191)(192). The cells were 
maintained in serum-containing medium (RPMI + 10% v/v foetal bovine serum, FBS, + 1 mM l-glutamine) 
and passaged at 60-80% confluence according to standard procedures. Potential crosslinking solutions 
were assessed for toxicity using alamarBlue® reagent. Confluent Saos-2 in 48-well plates incubated in 1 
ml crosslinking solutions for 30 minutes. The solutions tested were: PBS, 100 mM SrCl2, and ZnCl2 at 0, 1, 
2, and 5 mM plus either CaCl2 alone, or 20 mM SrCl2 plus CaCl2, to a total concentration of 100 mM (all in 
HEPES buffer). The cells were rinsed once more in PBS and the solutions were replaced with cell culture 
medium. 24 hours later, medium was exchanged for 10% v/v alamarBlue® reagent in phenol red-free cell 
culture medium. The plates were incubated for 4 hours and fluorescence was measured at 590 nm 
emission with 540 nm excitation. The absorbance of the experimental samples (FluorE) was normalised 
to starting values (FluorC, alamarBlue® solution not exposed to cells) according to the formula:  
             
      
 
3.2.6 3D cell encapsulation and culture 
Double strength AlgG and AlgM solutions in HEPES buffer (as above) were supplemented with AlgG-RGD 
and autoclaved, which has previously been shown not to affect RGD biofunctionality (75)(193). These 
were mixed in equal volume with a suspension of Saos-2 in cell culture medium (phenol red-free RPMI + 
10% v/v FBS + 1 mM l-glutamine), to final concentrations of 2% w/v alginate and 150 µM RGD and a final 
cell density of 2.5 x 106 cells.ml-1 (72). This mixture was dispensed into transwell inserts bathed in 100 
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mM solutions of CaCl2, SrCl2 and/or ZnCl2 in HEPES buffer (combinations are given in Table 3.2). For 
viability studies 200 μl gels were cast in 12 mm diameter inserts, and for gene and protein expression 
experiments 6.5 mm diameter inserts were used to make 40 μl gels. Crosslinking proceeded for 30 
minutes at 37°C as previously reported (164), and the solutions were replaced with media, which was 
changed the following day and every 2 or 3 days. Tissue culture plastic (TCP) controls were cultured 
alongside alginate gels.  
 
Gel 
Composition of crosslinking solution 
CaCl2 (mM) SrCl2 (mM) ZnCl2 (mM) 
Ca100 100 - - 
Sr100 - 100 - 
Sr20 80 20 - 
Zn1 99 - 1 
Sr20.Zn1 79 20 1 
 
Table 3.2: Composition of alginate crosslinking solutions used in cell studies, including gel codes 
referred to in the text. The alginate concentration was 2% (w/v), and the type of alginate (AlgG or AlgM) 
is specified in the main text as appropriate. 
 
3.2.7 Cell viability within alginate hydrogels  
To visualise Saos-2 within alginate gels, the gels were thinly sliced, stained with LIVE/DEAD® reagent (1 
µM calcein + 1 µM ethidium homodimer-1 in PBS) for 30 minutes at room temperature, and then imaged 
using an Olympus IX51 inverted microscope equipped with a mercury bulb and FITC/TRITC filters. LDH 
activity and the alamarBlue® assay were chosen as two independent indicators of cell number. 
AlamarBlue® testing was performed on intact gels at days 1 and 7, as described above but with a 2.5 hour 
incubation period. Fluorescence was then expressed as a percentage of that of Ca100 gels at 24 hours.  
 
For LDH, gels were frozen in PBS on days 0, 7, 14 and 21. At a later date they were defrosted, placed in 1.2 
ml TissueLyser tubes with 5 mm steel balls. They were disrupted in a TissueLyser II bead-mill 
homogeniser (QIAGEN) for 15 minutes at 20 Hz, and finally treated with 0.1% Triton-X for 30 minutes to 
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lyse any remaining cells. Samples were then assayed using a CytoTox 96 kit according to the 
manufacturer’s instructions: briefly, lysate was mixed with an equal volume of substrate solution, 
incubated at room temperature in the dark for 30 minutes, the reaction was stopped (acidic Stop 
Solution) and absorbance was read at 490 nm. It was determined in advance through standard curve 
comparisons that the sample preparation procedure did not compromise the performance of the LDH 
assay (see Appendix I: Validation of LDH sample preparation).  
 
3.2.8 Osteoblast activity within alginate hydrogels 
Osteoblast activity of Saos-2 cells was investigated by qPCR on osteoblast marker genes and ALP protein 
activity. A hybrid procedure incorporating Trizol extraction with RNeasy purification was used for RNA 
extraction. At day 21, gels were homogenised in 1 ml Trizol in a QIAGEN TissueLyser II until completely 
disrupted; typically this took no more than 10 minutes at 30 Hz. The samples were centrifuged at 12,000 
g for 10 minutes in a centrifuge cooled to 4 °C. The supernatant was transferred to a new tube and mixed 
with 150 µl chloroform. The RNA-containing aqueous phase was isolated as per the standard Trizol 
procedure and mixed well with an equal volume of 70% ethanol. The precipitated RNA was transferred to 
an RNeasy spin column, and purified and resuspended in RNase-free water according to the standard 
RNeasy protocol. Some of the troubleshooting steps taken to determine this as an effective means of 
collecting good quality RNA from alginate hydrogels are summarised in Appendix III: RNA extraction 
troubleshoot. RNA was quantified using a NanoDrop 1000, diluted to ≤ 80 ng.µl-1, and immediately 
reverse transcribed using a Quantitect RT kit (manufacturer’s instructions). 10x and 100x dilutions were 
made in RNase free water. qPCR was performed on a Corbett Rotor-Gene using Rotor-Gene SYBR green 
PCR master mix and Quantitect exon-spanning primers for RUNX2, COL1A1 and BSP. Primer validation is 
discussed in Appendix IV: qPCR primer validation. RUNX2 encodes the essential osteoblast 
transcription factor of the same name (also known as CBFA-1), and collagen I (COL1A1) and bone 
sialoprotein (BSP) are major bone ECM components. Expression of these genes was normalised against 
the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Data was analysed using 
the delta-delta Ct method, comparing gene expression to that of untrypsinised cells collected at baseline. 
ALP enzyme activity was assayed using 1 mg.ml-1 pNpp in diethanolamine substrate buffer for 5 minutes 
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with absorbance taken at 405 nm. Cell free hydrogels were run alongside samples to correct for non-
specific background activity. 
 
3.2.9 Statistical analysis 
Analysis of Variance with Tukey’s post-tests, and Independent samples T-tests were used for compressive 
modulus, gel lifespan, LDH, and ALP activity data. Non-parametric tests (Kruskal-Wallis and Mann-
Whitney) were used for qPCR results. All statistical tests were run on SPSS for Windows, and P < 0.05 was 
considered significant.   
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3.3 Results and discussion 
3.3.1 Strontium substitution does not alter initial stiffness of alginate hydrogels 
In the initial phase of this study, calcium- and strontium-alginate gels were characterised in terms of 
stiffness (E), degradation and strontium release in order to evaluate how ion type, alginate type, and 
alginate concentration influence these properties, and to demonstrate the ability to tailor gel properties. 
The stress-strain curves of gels tested in unconfined compression were highly linear (R2 > 0.99) over the 
first 1 mm (~10%) strain (Figure 3.4, Table 3.3).  
 
 
 
Figure 3.4: Representative stress-strain plot for alginate 
gels over first 1 mm (~10%) strain. 3G.Ca gel shown. 
Modulus = 345 KPa, R2 = 0.9999. 
 
Type of gel 
R2 over first 1mm 
deformation 
1G.Ca 0.9984 
2G.Ca 0.9999 
3G.Ca 0.9998 
3M.Ca 0.9996 
1G.Sr 0.9977 
2G.Sr 0.9999 
3G.Sr 0.9999 
3M.Sr 0.9996 
 
Table 3.3: Average linear 
correlation factors (R2) values for 
first 1mm deformation of alginate 
gels under compression.  
 
 
The modulus (E) of G.Ca gels (refer to Table 3.1 for gel codes) increased linearly with increasing alginate 
concentration, from 38 ± 2 kPa (1G.Ca) to 348 ± 8 kPa (3G.Ca; Figure 3.5), in close agreement with 
published data (160), and was roughly 45% lower for AlgM gels (196 ± 3 kPa, 3M.Ca). E of strontium gels 
was close to that of calcium gels, both with AlgG (75-109% E of G.Ca gels) and AlgM (97% E of 3M.Ca), 
suggesting that strontium substitution had little to no effect on stiffness (Figure 3.5). From this we can 
infer that under the conditions tested, the degree of crosslinking was unaffected by the gelling ion. 
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Assuming constant crosslinking functionality, crosslinking density is proportional to the effective 
network chain concentration ve/V (mol/cm3), which in turn is proportional to E at constant temperature 
as can be seen from the equation:  
  
 
 
 
   
 
Where E is Young’s modulus in dyne/cm2, R is 8.314 x 107 in dyne.cm/mol.K, and T is the temperature in 
K (194). Hence, ve/V and by extension crosslinking density (assuming equal functionality) was the same 
regardless of the ion used. This is unsurprising considering that the cations used to cast these gels were 
delivered in large excess, and thus it may be supposed that all carboxylic acid groups were saturated with 
bound ions.  
 
 
 
Figure 3.5: Modulus (E) of alginate hydrogels crosslinked with calcium and strontium over first 1 
mm of compressive deformation (~10% strain). Effect of alginate type P < 0.001; Effect of crosslinking 
ion P = 0.044. Mean ± SD, n ≥ 5.  
 
3.3.2 Crosslinking ion(s) and degradation behaviour can be independently varied  
Alginate gels immersed in solution gradually lose crosslinking ions, leading first to swelling (as tensile 
resistance to osmotic swelling becomes weaker), and eventually to degradation as the polymer chains 
separate. The gels in this study swelled in PBS to 200-300% initial mass (Figure 3.6) before beginning to 
disintegrate. Under the conditions tested, the 3G.Ca and 3M.Ca gels had a lifespan of around 4 ± 0 and 4 ± 
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1 days, respectively (Figure 3.7). G.Sr gels were remarkably stable in comparison (effect of ion P < 0.001). 
The 3G.Sr composition persisted for 58 ± 5 days before the onset of degradation, which was almost fifteen 
times as long as the corresponding calcium gels. This behaviour is consistent with the higher affinity for G 
blocks of strontium over calcium (40)(179). Partial strontium substitution had almost as pronounced an 
effect: substituting just 20% of the calcium for strontium increased the lifespan to 53 ± 3 in 3G.Sr20 gels, 
although the actual fraction of strontium within these gels may have exceeded the 20% present in the 
crosslinking solution due to preferential accumulation of strontium ions in G blocks. Despite this high 
stability, the lifespan of the G.Sr gels was tailorable down to 4 ± 1 days by reducing the concentration of 
alginate to 1% w/v. Thus, although strontium substitution left E essentially unchanged, gel lifespan was 
significantly extended.  
 
The stabilising effect of strontium on AlgG gels was greatly diminished when AlgM was used. Here, 
lifespan was increased from 4 ± 1 (3M.Ca) to 15 ± 1 days (3M.Sr), which was only around 25% as long as 
the lifespan of the equivalent AlgG gels. Again this is compatible with work showing that the selectivity of 
G blocks for larger ions does not apply to M blocks (40). It seems therefore that strontium substitution 
has a qualitatively different effect on the stability of AlgG and AlgM gels. This interaction is of great 
practical interest as it allows one to decouple the biological and material effects of the crosslinking ion. 
Specifically, the favourable effects of strontium on bone cells can be utilised in applications requiring 
either long or short lifespans, which can be achieved by choosing alginate rich in either G or M residues 
respectively. 
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Figure 3.6: Weight profiles of alginate gels swollen in PBS. a) Calcium-alginate gels, b) Strontium-
alginate gels. Note that time is plotted on a log axis. Mean ± SEM, n = 6.  
 
 
Figure 3.7: Gel lifespan (day of peak swelling) for alginate gels of different compositions. Effect of 
alginate type P < 0.001; effect of crosslinking ion P < 0.001; interaction between ion and alginate type P < 
0.001. Mean ± SD, n = 6.  
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3.3.3 Strontium release from alginate hydrogels is of a physiologically-relevant magnitude 
The potential of alginate gels to provide a slow-release reservoir of bioactive ions was investigated using 
ICP. Strontium was released from the alginate gels in a rapid burst over the first 8 hours (representing the 
clearance of excess ions from the 100 mM crosslinking solutions) followed by a phase of slower release 
(Figure 3.8). Strontium release gradually diminished over the first 5-10 days before settling to an 
approximately constant rate. The rate of steady release was fairly constant, such that linear trend lines 
fitted from day 10 all had R2 values of > 0.92 (Table 3.4), and furthermore was sustained until complete 
degradation of the gels had occurred (Figure 3.8; compare Figure 3.6). The ratio of total released ions to 
carboxylic acid groups was between 0.24 and 0.46 in all cases, which fits well with the stoichiometry of 
calcium binding to alginate, which is 0.25 within egg-box dimers and 0.5 for the repeating units of 
multimers (39). 
 
 
Figure 3.8: Cumulative strontium release from alginate gels as measured by ICP. Crosses indicate 
the day of maximum swelling, i.e. the onset of gel degradation.  
 
Strontium release from AlgG gels increased with alginate concentration, and the release from the 3G.Sr20 
gel was around a third of that of 3G.Sr at days 1-5 and around half at days 5-10 (Table 3.4). The highest 
rates of strontium release were seen in the AlgM gel, which is consistent with the faster degradation of 
these gels (Figure 3.7). Here, 5.4 µM Sr++ per gram of gel were released daily from days 5-10, then 1.4 
µM.gram-1.day-1 from days 5-10, and finally a steady rate of 0.5 µM.gram-1.day-1 was maintained until total 
degradation had occurred (at day 29; see Figure 3.8). Release rates of calcium were considerably higher 
than those of strontium over the first 10 days (5.1-9.6 µM calcium.gram-1.day-1 cf. 1.4-5.4 µM 
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strontium.gram-1.day-1 for 3G and 3M single ion gels) but these gels were shorter lived and therefore only 
released ions for the first 10 days.  
 
Gel Ion 
Rate of ion release (µM.g-1.day-1; R2 in brackets) 
Days 1-5 Days 5-10 Day 10 onwards 
3G.Ca 
Ca++ 
5.06 9.58 N/A 
3M.Ca 6.75 6.80 N/A 
3G.Sr20 
Ca++ 2.45 1.28 0.44 (0.92) 
Sr++ 1.28 0.69 0.18 (0.96) 
3G.Sr 
Sr++ 
3.71 1.53 0.15 (0.92) 
2G.Sr 3.12 1.27 0.17 (0.93) 
1G.Sr 1.92 0.46 0.23 (0.99) 
3M.Sr 5.40 1.40 0.51 (0.99) 
 
Table 3.4: Rates of calcium and strontium release from alginate gels, in µM per gram of gel per day. 
R2 values are given in brackets as an indicator of steady release from day 10. Rates of Ca++ and Sr++ release 
are shown for days 1-5, days 5-10, and from day 10 onward. N/A = not applicable (gels had degraded by 
day 10).  
 
The figures in Table 3.4 can be converted to daily concentration estimates (in mM) for the cell culture 
system used by dividing the quoted figures by ten – based on the gels having a density of 1 and 
comprising 10% of the volume of the culture system.  Thus, the concentration of strontium in the medium 
for the 3G.Sr formulation increased by approximately 0.37 mM daily over the first 5 days, then by 0.15 
mM to day 10.  The daily release estimates for all strontium gels except 1G.Sr and 3G.Sr20 therefore fall 
within the in vitro physiologically active range for strontium of 0.1 – 1 mM and above for the first 10 days 
of culture, falling below this range thereafter (186)(187). 3M.Sr alginate gels, however, released 
strontium most rapidly (0.54, 0.14, 0.051 mM.day-1 at days 1-5, 5-10, and 10 onwards, respectively), 
Allowing for media changes every 2-3 days and higher local concentrations inside the gels, strontium 
concentrations probably reached biologically relevant levels even towards the end of the culture period. 
Indeed, the levels detected in the serum of patients treated with strontium ranelate are towards the lower 
end of the active range (0.12 mM), suggesting that in vivo strontium may accumulate at the bone surface, 
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becoming available locally at much higher concentrations (195). These figures may overestimate the 
release in cell culture medium as alginate gels are less stable in PBS, and still less can they predict the in 
vivo situation, but they are nonetheless useful as order of magnitude estimates and for assessing 
differences between formulations. The higher release from AlgM gels and with increasing alginate 
concentrations immediately suggest two ways of optimising strontium release (further options are 
discussed below).  
 
3.3.4 1 mM ZnCl2 was chosen for three-dimensional culture of Saos-2 in gels  
In addition to the calcium and strontium gels previously characterised, zinc was included in two of the gel 
formulations for the 3D cell culture experiments (refer to Table 3.2 for gel codes). Zinc exerts its 
biological effects at micromolar concentrations (189) and is acutely toxic at millimolar concentrations, 
therefore the toxicity of various potential crosslinking solutions was assessed before being used for cell 
encapsulation. A significant (p < 0.001) toxic effect of zinc was apparent at 1 mM concentrations over just 
30 minutes (30-40% reduction in activity), and ZnCl2 at 2 and 5 mM was progressively more damaging. 1 
mM was chosen for alginate crosslinking because the limited toxic effect seen on TCP was likely to be 
attenuated by the dilution of the ions as they diffused through the alginate solution. The crosslinking 
solutions lacking zinc were no more toxic than PBS.  
 
 
Figure 3.9: Toxicity of potential crosslinking solutions. Relative total metabolic activity (alamarBlue® 
fluorescence) of Saos-2 cells 24 hours after 30 minute exposure to potential crosslinking solutions. Total 
molarity of crosslinking solutions including ZnCl2 = 100 mM. Effect of zinc p < 0.001. * 1 mM ZnCl2 versus 
no zinc p < 0.001. Mean ± SD, n = 6.  
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3.3.5 High stability of strontium-AlgG gels impedes proliferation; viability is rescued by AlgM 
The peptide GRGDS, incorporating the cell-adhesive sequence RGD, was incorporated into alginate gels to 
improve viability by enabling cells to attach to the gel (72). Pilot investigations into Saos-2 viability 
confirmed that, as expected, the inclusion of GRGDS peptide improved cell survival (these experiments 
are described in Appendix IV: Pilot experiments in cell viability).   
 
The choice of crosslinking ion(s) significantly affected LDH activity when Saos-2 were cultured in AlgG 
gels (P < 0.001). LDH activity from Saos-2 cultured in Ca100 and Zn1 gels increased marginally to day 7 
and, except for Ca100 gels at day 21, continued to increase thereafter (Figure 3.10). Conversely, in all 
gels containing strontium (Sr100, Sr20, Sr20.Zn1), LDH activity declined during the first week of culture. 
There was some recovery from day 14 in the Sr20Zn1 and Sr20 groups, and at day 21 in the Sr group. The 
trends were very different for AlgM gels, which supported higher levels of proliferation in all five ion 
groups compared to AlgG (p < 0.001). Furthermore the degree of proliferation was similar in all five 
groups regardless of the crosslinking ion(s) used (effect of ion P = 0.082). For both AlgG and AlgM groups, 
proliferation was greater on TCP than in any of the hydrogels.  
 
AlamarBlue® reduction by Saos-2 was also dependent on alginate type and crosslinking ion. Within AlgG 
gels, alamarBlue® fluorescence increased from between 59 ± 8 and 74 ± 9 % of day 1 TCP levels (Sr100 
and Zn1 gels, respectively), to between 62 ± 11 and 98 ± 13 % at day 7 (for the same gels;  
Figure 3.11). Again, there was a significant difference at day 7 between gels made with and without 
strontium, with lower activity occurring in strontium-containing gels (p < 0.01). Conversely, there was no 
significant difference in day 7 activity between AlgM formulations with and without strontium (p = 
0.129), and greater increases in activity were seen than in AlgG gels. Saos-2 increased their activity from 
between 59 ± 5 and 101 ± 10 % of day 1 TCP activity at day 1 (Sr100, Ca100 gels, respectively), to 
between 145 ± 23 (Ca100) and 177 ± 27 % (Sr20.Zn1) at day 7. Over the same period, cells grown on TCP 
roughly tripled in number, which was around 2.3 times the proliferation seen in AlgG gels, and 1.6 times 
that within AlgM gels.  
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Figure 3.10: LDH activity of Saos-2 cells encapsulated in 2% w/v RGD-alginate gels and grown on 
TCP, relative to day 0 gels. Results for AlgG gels, AlgM gels, and TCP are displayed separately for clarity. 
Effect of crosslinking ion p < 0.001; * strontium-containing gels vs non strontium-containing gels at day 7 
p < 0.001. Effect of crosslinking ion p = 0.082. Effect of alginate type at all time points p < 0.001. Mean ± 
SD, n = 6.  
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Figure 3.11: AlamarBlue® reduction by Saos-2 cells, encapsulated in 2% w/v RGD-alginate gels 
and grown on TCP, relative to day 1 TCP (background subtracted). Results for AlgG gels, AlgM gels, 
and TCP are displayed separately for clarity. Effect of alginate type at 1 day N.S. (p = 0.864) and 7 days p < 
0.001. For AlgG gels at day 7, effect of Sr versus no Sr p < 0.01 and effect of ion p < 0.05. * Sr versus Ca and 
Zn gels at day 7 p < 0.05. For AlgM gels at day 7, effect of Sr versus no Sr N.S. (p = 0.526) and effect of ion 
N.S. (p = 0.129).Mean ± SD, n = 6.   
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LIVE/DEAD® imaging at later timepoints revealed that dead cells tended to be isolated from other cells, 
whereas the majority of live cells were commonly present in large clusters (Figure 3.12). In general, 
these clusters were first noted at the (softer) periphery of gels, and were less numerous in AlgG gels than 
AlgM – especially with formulations containing strontium.  
 
 
 
Figure 3.12: LIVE/DEAD® images of clusters of Saos-2 cells within 2% w/v AlgM RGD-alginate gels 
after 21 days of culture. Live cells appear green and dead cells red. Arrows indicate isolated dead cells, 
and arrowheads point to clusters of live cells. Fluorescent microscopy; 40x magnification; scale = 200 µm.  
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Scaffold degradation is central to the tissue engineering approach, and allows for cell behaviours such as 
growth and migration as well as the gradual accumulation of matrix. Indeed, LIVE/DEAD® and LDH 
results revealed a strong correspondence between the degradation characteristics of the alginate gels and 
the ability of cells to grow and divide within them. The persistence of strontium-supplemented AlgG gels 
appeared not only to obstruct growth during the initial 1-2 weeks of culture, but even to cause cell death 
over the first week (Figure 3.10). This tendency may be related to cell isolation per se (lack of cell-cell 
contacts and paracrine signalling), limited diffusion of nutrients and signalling factors, or both (196). 
While LDH activity declined over the first week in strontium-containing AlgG gels, alamarBlue® activity 
increased slightly – a discrepancy which may be explained by the changing diffusive properties of these 
gels as they swell over time. The alamarBlue® results somewhat underestimate total metabolic activity 
due to the relatively slow diffusion of reagent through the gels. This error is greater at day one because 
the gel structure is more compact early on.  
 
In contrast to the strontium-containing AlgG formulations, the more rapidly degrading Ca100 and Zn1 
AlgG gels supported proliferation from the earliest timepoints (Figure 3.10). This was also consistent 
with the observation that clusters of proliferating cells tended to form initially at the swollen edges of 
gels. Fortunately it was possible to rescue proliferation in strontium-containing gels by using more 
rapidly degrading gel formulations: with AlgM the distinction between gels with and without strontium 
was lost, and neither LDH nor alamarBlue® activity revealed significant differences between the five gel 
sets. Together, these results indicate that crosslinking alginate hydrogels with strontium and zinc does 
not inhibit cell proliferation provided that the gels degrade rapidly enough to permit growth. This points 
towards using AlgM for applications where short term action and cell proliferation is required, such as 
fracture healing, in which the fracture callous forms rapidly (days to weeks). AlgG gels may be suited to 
situations in which the materials are delivered acellularly, or where cell proliferation is not required. In 
previously reported studies, strontium-alginate microcapsules supported significantly higher viability 
and sulphated GAG accumulation over long term culture of intervertebral disc cells, which within the 
mature disc are sparsely distributed and rarely divide (197)(198). In the present study, the dual 
characteristics of faster degradation and higher strontium release suggested that the AlgM gels would be 
the more suitable choice for the remainder of the experiments.  
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3.3.6 Osteoblast genes are upregulated in  alginate gels; ALP activity is highest in Sr100 gels 
Saos-2 were cultured in AlgM gels crosslinked with different ions in order to investigate whether the 
inclusion of strontium and/or zinc stimulated upregulation of the osteoblast marker genes COL1A1, BSP 
and RUNX2, and higher ALP protein activity. Saos-2 have remarkably stable gene expression over many 
passages in culture (199), and indeed expression levels for the TCP group did not deviate far from 
baseline values (Figure 3.13; relative expressions: COL1A1 0.76 ± 0.23, BSP 3.31 ± 0.94, RUNX2 0.87 ± 
0.64). This consistency provides some validation of the data overall. Upregulation of COL1A1, BSP and 
RUNX2 was seen in all gel groups compared to TCP (p < 0.001), but there were no consistent differences 
between the five gel compositions (p > 0.17). The mean relative expression of all four genes was very 
similar in Ca, Sr and Sr20 gels. Zn1 produced the highest mean expression, and Sr20.Zn1 the lowest 
among gel groups, of BSP and RUNX2, but these differences were not significant (p > 0.64). RUNX2 is a 
transcription factor central to the process of osteoblast differentiation, with many bone matrix-related 
and other genes under its control (200). Its upregulation therefore suggests an increase in osteoblast 
activity of Saos-2 grown in gels, and higher COL1A1 and BSP expression and ALP activity furthermore 
indicate increased deposition of a mineralising matrix. The apparent osteogenic effect of the alginate gels 
may be a consequence of three- versus two-dimensional culture and/or of ion release (201)(202)(203). 
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Figure 3.13: Gene expression of Saos-2 cells grown on TCP or in 2% w/v AlgM RGD-alginate gels at 
day 21, relative to day 0 TCP. COL1A1, BSP and RUNX2 shown, as indicated. Mean ± full range of values, 
n ≥ 3 from two independent experiments. * Effect of TCP versus gels p < 0.001 for all genes; effect of 
crosslinking ion: COL1A1 p = 0.91, BSP p = 0.53, RUNX2 p = 0.26. 
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ALP protein activity was then quantified using the pNpp assay (Figure 3.14). Given that this enzyme is 
membrane bound and thus should only be present in cells, ALP activity was normalised to cell number 
(determined using LDH activity). In agreement with the general trend of the qPCR data, ALP activity per 
cell was higher in Saos-2 cultured in gels than on TCP (P < 0.001). Furthermore, activity was highest in 
Sr100 gels, and this was significant against all other groups except Zn1 (P < 0.05). ALP in Zn1 gels was 
also significantly higher than Ca gels (P < 0.05). The reduction in normalised ALP activity seen in the TCP 
group could be due to confluence effects, as ALP activity in Saos-2 is known to decrease post-confluence 
(192)(204). This phenomenon may have similarities with the reduction in ALP activity seen in 
postmitotic osteoblasts (205).  
 
 
 
 
Figure 3.14: Alkaline phosphatase (ALP) activity per cell of Saos-2 grown on TCP or in 2% w/v 
AlgM RGD-alginate gels with different crosslinking ions. The dotted line represents baseline (day 0) 
activity, determined for Saos-2 in Ca100 gels. Mean ± SD, n = 6. Effect of gels versus TCP P < 0.001. * Sr100 
vs Sr20 and SrZn P < 0.05; ** Sr100 vs Ca100 and TCP P < 0.001; * Zn versus Ca100 P < 0.05.  
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In summary, the results indicate that COL1A1, BSP and RUNX2 expression increased in cells cultured 
within alginate gels compared to TCP, and likewise, higher ALP activity was seen in the gel groups than on 
TCP (Figure 3.13, Figure 3.14). Cells in this study spread on TCP while remaining more compact in 3D 
gels (Figure 3.12), but an effect of cell shape seems unlikely: in two dimensions, spread rather than 
rounded morphologies tend to favour the osteoblast phenotype (at least in MSCs) (93). Although there 
were no consistent differences in gene expression between the different gel formulations, statistically 
significant differences in ALP activity were seen between gel groups. The highest activity at both 7 and 21 
days occurred in strontium gels and the lowest in calcium (excluding TCP), strongly indicating that 
strontium alginate gels may have improved osteogenic properties over calcium alginate. It was 
hypothesised that cocktails of two or three ions might elicit a stronger response than strontium alone, but 
the activity in mixed ion gels did not appear to improve on Sr100 gels. The higher strontium release from 
the Sr100 gels compared to the Sr20 gels is a likely explanation for this (Figure 3.8, Table 3.4).  
 
The notion of engineering biomaterials to release osteogenic ions has been explored by several groups 
including ours, but these attempts have focussed predominantly on delivery via ceramics 
(187)(206)(190)(207)(208). This study demonstrates that alginate could be considered as an alternative 
medium for the steady release of bioactive ions, but also highlights the option of choosing alginate as a 
carrier for osteoinductive ceramics. Ceramics, being sparingly soluble, could also set the gel and could be 
formulated to achieve a working time appropriate for injectable or moldable systems. Meanwhile the 
alginate could hold particles or powder together and buffer the escape of dissolution ions to prolong their 
retention at the implant site. Alternatively, embedding strontium-AlgG microparticles within an AlgM gel 
could be an attractive way of prolonging the timeframe of strontium release while allowing the bulk gel to 
degrade quickly to permit cell proliferation or invasion. Another potential strategy might be to use a 
mixture of ions with synergistic or complementary physiological effects. For example, we are currently 
evaluating the use of cobalt in tissue engineering scaffolds due to its ability to activate the hypoxia 
pathway (24). This is an important pathway in many aspects of development and regeneration including 
skeletal, so to combine cobalt with strontium and/or zinc could be an interesting next step.  
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3.4 Conclusions 
RGD-modified high M strontium alginate gels have favourable strontium release profiles, degrade quickly 
enough to permit cell proliferation, and support higher alkaline phosphatase activity than calcium gels. 
This data broadly supports the premise of this work – that alginate hydrogels may be used as slow release 
reservoirs for bioactive strontium ions to enhance osteogenic activity and/or differentiation – and 
suggests that strontium alone may be more effective than combinations of more than one ion. Overall, this 
work presents a novel tissue engineering strategy which is compatible with previous innovations, can be 
adapted to different tissue engineering needs, and opens several avenues for further development. 
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Chapter 4  
 
Latent TGF-β hydrogels for cartilage tissue engineering 
 
4.1 Introduction 
The human and economic cost of osteoarthritis (OA) is rising. Due to ageing populations and increasing 
life expectancies, OA is expected to become the world’s fourth leading cause of disability by 2020, up from 
the sixth leading cause in 1990 (22). The pain and loss of mobility that accompany this debilitating 
condition mean that a quarter of affected individuals are unable to perform major activities of everyday 
life (21). In the UK alone in the year 2000, 80,000 hip and knee replacement operations were performed 
at a cost of over £400 million, and the total cost to the UK of the condition is estimated at around 1% of 
Gross National Product (21). Disturbingly, many of those suffering from disabling joint pain do not 
consult their GP – over half in one study – apparently considering OA an inevitable, and intractable, part 
of ageing (21).  
 
Where conservative treatment fails, surgical options for OA divide broadly into reparative and 
reconstructive techniques (209). Reparative techniques seek to promote neocartilage formation, for 
example by bleeding of the joint surface (microfracture), which recruits progenitor cells to the lesion. 
However, the resulting tissue is frequently found to be fibrotic and mechanically inadequate. 
Reconstructive techniques such as mosaicplasty, in which an osteochondral plug is transplanted from an 
unaffected area, are technically challenging and superior clinical outcomes are as yet unproven (209). 
Likewise, the utility and cost-effectiveness of autologous chondrocyte implantation is still under question 
(209) (23). Furthermore, these approaches are not amenable to the repair of large scale defects such as 
occur in OA, where the entire joint may be affected. Thus far, whole or partial joint replacement is the 
only option in such circumstances, carrying major surgical risks as well as drawbacks related to fixation 
of the implants to bone, and aseptic loosening – which may require corrective surgery. There exists 
therefore an urgent unmet need for scalable regenerative solutions to OA, which can reliably induce the 
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formation of functionally acceptable neocartilage, and resolve difficulties of integration at the donor site 
(209). The development of ‘smart’ biomaterials is one area showing huge promise in terms of optimising 
the regenerative response of host or transplanted cells, and doing so in a cost-effective manner (210).  
 
Commercially available biomaterials-based products for cartilage repair based on alginate, collagen, 
fibrin, HA, chitosan, poly(glycolic acid)/poly(lactic acid) (PGA/PLA), and self-assembling peptides are 
currently in clinical or preclinical trials (211)(1). For example, crosslinkable esterified and thiolated 
derivatives of HA are marketed as HYAFF® (Fidia advanced biopolymers) and Glycosil™ (Glycosan 
Biosystems, Inc.), respectively. HA is a major constituent of cartilage and synovial fluid, and these 
products appear to assist cartilage repair when transplanted with primary chondrocytes, MSCs, or ESCs 
(2)(212)(213).  
 
Yet to break through into clinical use include biomaterials strategies that attempt to mimic the zonal 
organisation of articular cartilage, for instance by zoning of articular chondrocytes into discrete deep, 
middle and superficial layers of a PEG hydrogel (214). Also in development are scaffolds incorporating 
growth factors or other bioactive compounds to enhance cellular response. Proteins or compounds of 
interest have included insulin-like growth factor 1, basic FGF (FGF-2), parathyroid-related protein, BMPs 
and Dexamethasone; but especially, the three transforming growth factor betas (TGF-β1-3; Box 1) 
(215)(216)(217)(211)(218). Within cartilage TE, TGF-β is of particular interest due to its central role in 
chondrogenesis, and for its tendency to increase differentiation (at the expense of proliferation) and to 
stimulate ECM deposition (219). In one recent study, large-scale cartilage regeneration was achieved 
within a cell-free bioreactor system by incorporating TGF-β3 into PCL-hydroxyapatite composite 
scaffolds moulded to resemble the entire articular surface of rabbit humeral condyles. The addition of 
TGF-β3 resulted in enhanced recruitment of progenitor cells and the establishment within four months of 
a uniform covering of articular cartilage (57).  
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4.1.1 Box 1: TGF-β superfamily and signalling 
TGF-β1-3 are members of the TGF-β superfamily of signalling proteins, which encompass the BMPs, 
activins and inhibins, and Nodal and Nodal-related proteins among others (220). They are produced by 
and act on almost all cell types, with highly pleiotropic effects. They help to regulate growth, proliferation, 
differentiation, apoptosis, matrix production, and epithelial-to-mesenchymal transitions, and play central 
roles in embryogenesis, wound healing, immunological functions and carcinogenesis. Loss of one isoform 
may be partially compensated for by the remaining variants; nonetheless, null mutations in any one TGF-
β gene are lethal either perinatally or neonatally (57).  
 
The canonical signalling pathway for TGF-β1-3 involves ligand binding to a type II cell surface receptor 
(TβRII), which recruits and phosphorylates a type I receptor (TβRI, alternatively Alk5). This sets in 
motion a chain of events culminating in the nuclear localisation of phosphoryated Smad protein and 
transcription factor complexes, as shown schematically in Figure 4.1. Within the nucleus these 
complexes bind to Smad-binding elements or other DNA recognition sequences determined by the co-
transcription factors, eliciting phenotypic effects that depend on the cell type, timing, and physiological 
context (57).  
 
 
Figure 4.1: TGF-β signal transduction. TGF-β binding to TβRII leads to phosphorylation of TβRI (Alk5). 
Phosphorylated TβRI in turn phosphorylates Smad proteins (Smad2 and Smad3). These are thought to 
associate in a trimer with Smad4, also known as the co-Smad. Further association with transcription 
factors (TF) and transport through nuclear pores result in transcriptional regulation (221).  
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As already discussed in some detail, sophisticated growth factor delivery strategies have been shown to 
improve the functional outcome of biomaterials interventions, in cartilage TE and elsewhere. Recall from 
Chapter 2 that fine control over concentrations and temporal release profiles of VEGF and PDGF were 
essential to optimise the quality of neovessel formation in vivo (page 36) (222)(122)(123). Sustained 
release strategies are likely to important for in vivo TE because a single loading of growth factor must lead 
to sustained action over days to weeks, in contrast to in vitro studies in which medium can be changed as 
often as desired. Controlled growth factor delivery strategies for cartilage TE have included loaded 
microparticles of poly(lactic acid-co-glycolic acid), alginate or gelatin, polyion nanoparticles, heparin to 
retard release of TGF-β3, and the use of self-assembling peptides carrying a binding sequence for TGF-β1 
which enhanced growth factor retention; this delivered better histological outcomes at 12 weeks than 
peptides without the binding motif (215)(223)(216)(217)(224).  
 
Although undoubtedly promising, there is a marked contrast between the relative simplicity of these 
approaches and the exquisite control exercised over TGF-β bioavailability in vivo. TGF-β is secreted by 
cells as part of an inactive latent complex, allowing for several layers of regulation (Figure 4.2). The ~100 
KDa small latent complex (SLC) derives from a single gene product, the TGF-β propeptide, which 
assembles homodimerically within the cell via several disulphide bridges. During intracellular processing, 
the propeptide is cleaved into N-terminal and C-terminal fragments, the LAP and mature TGF-β 
respectively (219)(225)(226). The LAP has high affinity for TGF-β and thus the two remain in close non-
covalent association as the SLC. Binding occurs at a hydrophobic interface which masks the receptor 
binding region of TGF-β; this association stabilises TGF-β conformation and confers latency until 
activation occurs via one of several cell-dependent processes (see below) (227)(225). Four mannose-6-
phosphate residues are added to LAP as part of extensive glycosylation before export, and are required 
for association with TGF-β. An RGD motif within LAP is indispensible for binding to integrin receptors 
(91).  
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Figure 4.2: TGF-β latent complex and ECM association. Latency associated peptide (LAP) and 
transforming growth factor beta (TGF-β) comprise the small latent complex (SLC). The large latent 
complex (LLC) additionally includes latent TGF-β binding proteins (LTBPs). Based on a figure from (91).  
 
The SLC may be exported directly or, more usually, further bound to LTBPs via a single disulphide bond 
on LAP Cysteine-33 (Cys-33), constituting the large latent complex (LLC). LTBPs share a high level of 
homology with fibrillins 1 and 2 – ECM proteins capable of forming fibrils on their own, or else 
contributing to large elastic fibres together with tropoelastin (219)(228). LTBPs can thus be targeted to 
fibrillin fibrils or elastic fibres, as well as structurally unrelated ECM components such as fibronectin. In 
this way, ECM provides a ready supply of sequestered latent TGF-β, which only becomes active under 
appropriate physiological (or pathological) conditions.  
 
TGF-β activation is a complex, tightly regulated process as would be expected for a cytokine with such 
multitudinous and potent effects. It occurs via at least two distinct mechanisms in vitro – protease and 
integrin-dependent – although there is considerable overlap between these two modes. Proteolytic 
cleavage of LAP can be effected by numerous serine proteases and MMPs, unmasking receptor binding 
sites and releasing TGF-β with or without some residual portion of LAP (220). Integrin binding to the RGD 
motif on LAP, combined with tractional forces exerted by the cell, can enable receptor binding either by 
liberating TGF-β completely or by inducing a conformational change in the SLC that exposes TGF-β. A 
relatively stiff (> 10 KPa) substrate is necessary in this case to resist cell-generated tension: with overly 
compliant substrates, the force exerted by the cell is accommodated by deformation of the matrix rather 
than of LAP, and the activating conformational change does not occur (Figure 2.3) (229)(92). 
Interactions are thought to exist between protease- and integrin-dependent mechanisms, including 
situations whereby integrin binding promotes cleavage by bringing the SLC and membrane-bound MMPs 
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into apposition (91). Interactions with the matrix glycoprotein thrombospondin-1 can induce 
conformational changes in LAP which permit receptor binding. Also known to cause activation are 
physical stimuli such as heat, reactive oxygen species, and extremes of pH (220)(230). A summary of 
these factors and the molecular players involved are given in Table 4.1.  
 
Physical stimuli Proteases  Integrins Other  
Heat 
Extreme pH 
Reactive oxygen species 
Matrix-metalloproteases: 
     MMP-2 
     MMP-3 
     MMP-9 
     MMP-13 
     MMP-14 (MT-1 MMP) 
Serine proteases: 
     Plasmin 
     Thrombin 
     Urokinase  
     Tissue-type plasminogen activator 
     Elastase 
     Chymase 
     Tryptase 
     Furin  
αvβ1 
αvβ3 
αvβ5 
αvβ6 
αvβ8 
α5β1 
α8β1 
αIIbβ3 
Thrombospondin-1 
Glycosidases 
 
Table 4.1: Physical and molecular factors involved in latent TGF-β activation. Also shown (in grey) 
are integrins known to bind, but not necessarily activate, latent TGF-β. Compiled from information in 
(91), (220), and (230).  
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Despite the existence of these elaborate biological means of controlling TGF-β availability, no attempt to 
present TGF-β in its latent form within a biomaterial has yet been described. At least three generic and 
procedural benefits to using latent TGF-β within TE scaffolds can be postulated:  
 Enhanced stability over free TGF-β, which is a ‘sticky’, hydrophobic protein tending to adhere to 
tissue culture plastic in vitro and raising concern over possible protein fouling/aggregation.  
 Higher loading and improved exposure kinetics due to the inactivity of latent TGF-β and the 
potential for active release of TGF-β by cells according to local demand. The provision of TGF-β in 
an inactive form implies that the high doses required to sustain chondrogenesis for days to 
weeks may be loaded into TE scaffolds without exposing cells to excessive quantities of active 
growth factor, with TGF-β bioavailability then being controlled via gradual activation by cells.  
 The option to conjugate the TGF-β indirectly (e.g. via LAP) rather than directly to the TGF-β, 
which is likely to diminish its biological activity.  
This work describes novel poly(ethylene glycol)-hyaluronic acid-latent TGF-β (PEGDA-HA-LTGF-β) 
hydrogel scaffolds for cartilage TE. Recombinant human commercial SLC (henceforth referred to as latent 
TGF-β, LTGF-β) was shown to have a lower tendency to adsorb to TCP than free TGF-β, and its relative 
inactivity was demonstrated using Smad3 phosphorylation as an indicator of TGF-β signalling in human 
foreskin fibroblasts (HFF-1). To assess the potential of this strategy for cartilage TE, LTGF-β was 
PEGylated via lysine residues using Traut’s reagent and PEGDA, and the resulting PEGylated TGF-β (PEG-
LTGF-β) was biologically active. Bovine chondrocytes were encapsulated within PEGDA-HA-LTGF-β 
hydrogels. It was found that a single high loading of PEG-LTGF-β can stimulate metabolic activity of 
bovine chondrocytes over almost five weeks in culture and lead to higher protein accumulation than gels 
without TGF-β over the same timescale, although total LDH activity at 34 days was similar to that of TGF-
β-free hydrogels. Several ways are suggested in which this strategy could be developed in order to 
maximise the functional benefits for cartilage TE.  
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4.2 Methods 
4.2.1 Materials 
Recombinant human SLC (TGF-β1 plus LAP-β1; hereafter referred to as latent TGF-β or LTGF-β), 
recombinant human free TGF-β1, and TGF-β1 Quantikine ELISA kits were purchased from R&D Systems 
Europe Inc. (Abingdon, Oxfordshire, U.K.). Free TGF-β was reconstituted in 4 mM HCl + 0.1% w/v BSA, 
and aliquoted and frozen immediately at -20°C as directed by the supplier. LTGF-β was stored as supplied 
(250 µg.ml-1 in glycerol) at -20°C. PEGDA (Mw 4000) was synthesised by Helena Chia (University of 
California, Los Angeles; work-shadowed by Elsie Place), who also kindly provided the photoinitiator 
Irgacure 2959. Glycosil™ (thiolated HA) was obtained from Glycosan Biosystems, Inc. (Salt Lake City, UT, 
U.S.A.). Bovine serum albumin (BSA), lysozyme from chicken egg white, and cytochrome C from bovine 
heart were all from Sigma-Aldrich (Dorset, U.K.).  
 
For sodium dodecyl sulphate polyacrylaminde gel electrophoresis (SDS-PAGE) and Western blotting, 30% 
acrylamide/bis 29:1, polyvinylidine difluoride membranes (PVDF), filter papers, and secondary antibody 
(Goat anti-Rabbit IgG-horseradish peroxidase conjugate) were all from Bio-Rad Laboratories, Inc. (Hemel 
Hempsted, Hertfordshire). N,N,N’,N’-Tetramethylethylenediamine (TEMED), ammonium persulphate 
(APS), Tween, double strength laemmli sample buffer, RIPA buffer and phosphatase inhibitors were 
purchased from Sigma-Aldrich. The 5x loading buffer and PageRulerTM prestained protein ladder were 
from Fermentas (York, U.K.); and Imperial protein stain, and Pierce Enhanced Chemiluminescence (ECL) 
Western Blotting Substrate, and Restore Western Blot Stripping Buffer were from Thermo Scientific Inc. 
(Cramlington, Northumberland, U.K.). Methanol was from VWR (Lutterworth, Leicestershire, U.K.), and 
sodium dodecyl sulphate (SDS), glycine and Tris Base were from Fisher Scientific (Loughborough, 
Leicestershire, U.K.).  
 
Human foreskin fibroblasts (HFF-1) were obtained from ATCC-LGC (Teddington, Middlesex, U.K.) and 
used at passages <8. All cell culture reagents, antibiotics, PBS, and alamarBlue® were from GIBCO 
(Invitrogen Ltd., Paisley, Renfrewshire, U.K.), except the Insulin-Transferrin-Selenius Acid + Linoleic Acid 
premix (ITS+ premix) which was from VWR. Pronase from streptomyces griseus and EDTA-free Complete 
Mini protease inhibitors were from Roche Ltd. (Basel, Swizerland), and the protease inhibitors 
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Marimastat and CP471474 were from Tocris Bioscience (Bristol, U.K.). The TGF-β receptor inhibitor SB-
431542 was purchased from Ascent Scientific Ltd. (Bristol, U.K.), and RGD peptide was from BAChem AG 
(Bubendorf, Swizerland). Collagenase type I from clostridium histolyticum, aprotinin, leupeptin 
hemisulphate, plasmin from human plasma, manganese chloride, blebbistatin, neutral buffered formalin 
(NBF), and 4’,6-Diamidino-2-phenylindole dihydrochloride (DAPI) were from Sigma-Aldrich. Rabbit 
polyclonal antibodies against Smad3 (ab28379), Collagen I (ab34710), Collagen II (ab34712), and 
Collagen VI (ab6588), and rabbit monoclonal antibody against phosphorylated Smad3 (phosphoSmad3; 
ab52903) were purchased from Abcam (Cambridge, U.K.). ProLong Gold antifade coverslipping medium 
and fluorescent secondary antibody were from Invitrogen (Goat anti-Rabbit IgG-AlexaFluor 488). 
Promega (Southampton, U.K.) Cytotox 96 kits were used to assay LDH activity, and Bradford reagent was 
from Bio-Rad. All other chemicals and reagents were purchased from Sigma-Aldrich unless stated.  
 
4.2.2 Stability of free and latent TGF-β  
All plasticware (6-well plates and microcentrifuge tubes) was coated overnight in sterile 1% w/v BSA in 
PBS and air-dried before use. Solutions of free or latent TGF-β (2 ng.ml-1 in DMEM) were incubated at 
37°C in 6-well plates (5 ml per well). 200 µl aliquots were snap frozen in liquid nitrogen at 1, 2, 4, 8, 24, 
and 48 hour timepoints. TGF-β concentrations were determined by ELISA according to the 
manufacturer’s instructions. This assay specifically recognises uncomplexed (free) TGF-β1, and gives very 
limited signal when LAP is bound. LTGF-β samples were therefore activated with 20% v/v 1M HCl for 10 
minutes to dissociate the TGF-β dimer from the LAP, and neutralised using the same volume of 1.2 M 
NaOH + 0.5 M HEPES, as directed by the manufacturer. The ELISA was initiated immediately after 
neutralisation and within 30 minutes of defrosting the samples. Concentrations were normalised using a 
log-log plot of concentration versus absorbance for TGF-β1 standards of 0-2000 pg.ml-1.  
 
4.2.3 Activity of free, latent and PEGylated latent TGF-β  
To investigate fibroblast signalling response to TGF-β, HFF-1 were grown to 50-80% confluence on 8-well 
glass chamber slides for immunocytochemistry, or 100 cm2 petri dishes for Western blotting. Cells were 
serum-starved in DMEM with 0.2% w/v BSA for 24 hours ahead of all signalling experiments. Negative 
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(no TGF-β) and positive (free TGF-β at either 1 or 10 ng.ml-1) controls were included with every 
experiment, and the results were only considered if these wells showed clear and appropriate responses, 
i.e. weak to no staining in negative controls and strong nuclear staining in positive controls. Where 
necessary, ELISA was performed on activated samples ahead of the experiments to precisely determine 
the TGF-β content of the LTGF-β formulations. Where applicable this will be described as ‘free equivalent’ 
concentrations. HFF-1 were exposed for 1 hour to free TGF-β, LTGF-β, or PEGylated LTGF-β (PEG-LTGF-
β) in DMEM at the specified free equivalent concentrations. LTGF-β samples requiring acid activation 
were prepared at 10x final concentration, acidified and neutralised as described in the previous section, 
brought to the final volume and used immediately. Plasmin digestion of LTGF-β was carried out at 37°C 
using 0.01 U.ml-1 plasmin for either 90 or 180 minutes, then arrested by the addition of 7.5 µg.ml-1 
aprotinin. Where indicated, manganese chloride was included at 500 µM.  
 
4.2.4 Inhibition of LTGF-β activity  
Cells (HFF-1, chondrocytes) were serum starved for 24 hours prior to experimentation. To assess 
signalling responses to varying doses of ligand, they were exposed to a ten-fold dilution series of free or 
latent TGF-β in DMEM, from 0.001-10 ng.ml-1 (or free equivalent), for 1 hour. To investigate inhibition of 
LTGF-β activity, free or latent TGF-β were used at concentrations of 10 ng.ml-1 (or free equivalent) in 
DMEM for 1 hour, with or without the following treatments in combinations specified in the relevant 
sections. For inhibition of protease action, either Roche protease inhibitors (1 tablet per 10 ml) plus 
Marimastat and CP471474 (both at 1 µM) (PIMC), or a custom mixture of aprotinin (7.5 µg.ml-1), 
leupeptin hemisulphate (25 µM), Marimastat and CP471474 (ALMC) were used. The TGF-β receptor I 
(Alk5) inhibiting molecule SB-431542 was used at 10 µM, soluble RGD peptide at 5 mM, and the 
nonmuscle myosin IIa inhibitor blebbistatin was used at 100 µM. Cells were pretreated with inhibitors for 
1 hour before, as well as during, stimulation.  
 
4.2.5 Immunocytochemistry 
For immunostaining, slides were rinsed in Tris buffered saline (TBS), fixed in 10% v/v NBF for 15 
minutes at room temperature, permeabilised in 0.1% v/v Triton-X for 10 minutes, and blocked in 3% w/v 
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BSA for 1 hour (all solutions in TBS). Slides were rinsed three times in TBS between each step. Samples 
were stained overnight at 4°C in primary antibody solution (anti-phosphoSmad3, 1:100 in TBS), rinsed 
three times in TBS, then stained with Goat anti-rabbit IgG-AlexaFluor 488 at 1:2000 in TBS. Nuclei were 
counterstained with DAPI (1.8 µM in water) and air dried before coverslips were applied.  
 
4.2.6 Confocal microscopy 
Imaging of antibody-stained sections was performed on a Leica SP2 upright confocal microscope running 
Leica LAS software, under a 20x objective lens. Offset and gain were set manually at the beginning of each 
session. AlexaFluor 488 was excited at 488 nm with an Argon laser and emission was collected between 
500-550 nm; DAPI was excited under UV (351 nm) and collected at 430-490 nm. The two fluorophores 
were excited separately and images were acquired between frames to avoid bleed-through of DAPI to the 
green channel. Stacked images were collected at 1.5 µm intervals with four times line averaging and 
reconstructed as maximum intensity projections in Volocity Demo software (Perkin Elmer Inc., Waltham, 
MA, U.S.A.).  
 
4.2.7 Western blotting 
Cells were rinsed twice in cold PBS, and the petri dishes were placed on ice. Cells were lysed in 100 µl 
RIPA buffer containing protease and phosphatase inhibitors, for 10 minutes with occasional agitation 
with a cell scraper. The lysate was collected and spun at 10,000 g in a cooled (4°C) centrifuge for 10 
minutes. The supernatant was transferred to a fresh tube and snap frozen. Later, protein was quantified 
using Bradford reagent (800 µl water + 1 µl sample + 200 µl Bradford reagent), with absorbance 
measured at 595 nm against BSA standards in RIPA buffer. Samples were prepared by heating for 10 
minutes at 95°C in laemmli sample buffer, and typically 20-30 µg total protein was loaded per well.  
 
To make the acrylamide gels for SDS-PAGE, 10% v/v acrylamide solutions were prepared in running gel 
buffer (375 mM Tris Base, 3.5 mM SDS, pH 8.8) and crosslinked with 8.7 mM TEMED and 8.8 mM APS 
between 1.5 mm Bio-Rad casting plates. Stacking gel solution (5% v/v acrylamide, 125 mM Tris Base, 3.5 
mM SDS, pH 6.8) was crosslinked with 13.4 mM TEMED and 4.4 mM APS. 20 µl sample, or 7 µl protein 
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ladder, was loaded per lane, and separation typically proceeded for 1-1.5 hours at 100 V and 400 mA 
powered by a Bio-Rad PowerPac Basic™ (running buffer 25 mM Tris Base, 192 mM glycine, 3.5 mM SDS).  
PVDF membranes were activated in methanol (20 minutes) and 1 hour was allowed for the transfer at 
100V and 400 mA (transfer buffer 20% v/v methanol, 25 mM Tris Base, 192 mM glycine). The membrane 
was blocked in 5% w/v BSA in TBS with 0.1% v/v Tween (TBS-T) and probed overnight at 4°C on a 
shaker with anti-phosphoSmad3 antibody at 1:1000 in TBS-T. The membrane was rinsed four times for 
10 minutes in TBS-T before the addition of secondary antibody (Goat anti-Rabbit IgG-HRP, 1:3000 in TBS-
T) for 1 hour at room temperature. The membrane was rinsed again (4 x 10 minutes in TBS-T), and 
chemiluminescence was performed according to the manufacturer’s instructions. Membranes were 
wrapped in clingfilm and imaged in a Biospectrum® 500 Imaging System (Ultra-Violet Products Ltd., 
Cambridge, UK) with VisionWorksLS software (version 6.8), for ten minutes in the dark for 
chemiluminescence, and 0.1 seconds under transillumination to capture the protein ladder. Membranes 
were stripped in stripping buffer for 10 minutes, rinsed in TBS-T (4 x 10 minutes), blocked as before, and 
imaged to confirm removal of antibody. The membranes were then reprobed with anti-Smad3 antibody 
(1:1000 in TBS-T) and imaged as already described. Chemiluminescence and transilluminated images 
were superimposed in Adobe Photoshop CS5 to ascertain the positions of the protein marker bands, and 
adjusted using the histogram function (‘levels’) to better visualise the chemiluminescent signal.  
 
4.2.8 PEGylation of model proteins and LTGF-β  
LTGF-β and the model proteins BSA, lysozyme, and cytochrome C were modified by reaction with Traut’s 
reagent and PEGDA. The model proteins were prepared as 4 µM solutions in sodium phosphate buffer 
(SPB; 3 mM sodium phosphate monobasic, 89 mM sodium phosphate dibasic, pH 8.0) and the LTGF-β was 
used as received. Traut’s reagent was prepared as an 8 mM working solution and PEGDA dissolved to 14 
mM, both in SPB. The protein of interest, PEGDA and Traut’s reagent were combined in BSA-coated 
microcentrifuge tubes in a 4:11:3 ratio and left for 1 hour at room temperature. In negative control 
samples, Traut’s reagent was replaced by SPB. For the model proteins, EDTA was included in the SPB at 
either 5 mM (= SPEB) or 100 mM (= SPEB+) where indicated. The final concentrations of reactants, for 
LTGF-β, were Traut’s reagent 1.3 mM, PEGDA 8.5 mM (acrylate endgroups 17 mM), and LTGF-β 55.5 
µg.ml-1. SDS-PAGE was performed as described in the previous section, and gels were stained with 
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Imperial protein stain for 1 hour and destained overnight in 20% v/v methanol, 10% v/v acetic acid. 
Aliquots of the reacted LTGF-β (PEG-LTGF-β) were either measured by ELISA (manufacturer’s 
instructions) or frozen immediately at -80°C.  
 
4.2.9 TGF-β release from PEGDA hydrogels 
LTGF-β, PEG-LTGF-β, or LTGF-β negative control reaction samples (no Traut’s reagent) were added to 
PEGDA solutions (10% w/v plus 4.5 mM Irgacure 2959 photoinitiator in PBS) to approximately 10 ng.ml-1 
or free equivalent. The polymer solutions were pipetted between glass slides separated by a 1 mm glass 
spacer and polymerised 3 cm from an 8-watt, 365 nm UV source (UVP, Cambridge, UK) for 15 minutes. 6 
mm diameter gels were cut using a biopsy punch, rinsed in PBS to remove unpolymerised material, and 
placed under 270 µl 1% w/v BSA solution in PBS, in BSA-coated microcentrifuge tubes. The gels were left 
at room temperature, and the BSA solution was exchanged at 0.25, 1, 2, 4, 8, and 24 hours. At 24 hours, 
the solutions were acidified with 60 µl 1M HCl to dissociate the free TGF-β dimer from the LAP, and final 
samples were collected at 48 hours. Concentrations of released TGF-β were determined by ELISA 
according to the manufacturer’s instructions. Total (starting) TGF-β content was determined using the 
unpolymerised PEGDA solutions diluted 20x in BSA/PBS.  Weight measurements were recorded 
throughout the experiment in order to correct for gel swelling when calculating the amounts of released 
TGF-β.  
 
4.2.10 Cell culture and isolation of bovine chondrocytes 
HFF-1 were grown in serum-containing medium (DMEM + 10% FBS + 1 mM glutamine) and passaged at 
60-80% confluence according to standard cell culture procedures. Bovine articular chondrocytes were 
harvested from calf metacarpophalangeal joints within 8 hours of sacrifice. Briefly, distal fore- and 
hindlimbs were disinfected thoroughly, skinned, and dissected in a class II biological safety cabinet. 
Cartilage from the articulating surfaces was removed, diced finely, and digested for 1 hour in pronase (2 
mg.ml-1 in high glucose DMEM with GlutaMax + 10 mM HEPES + 1% v/v antibiotic/antimycotic) at 37°C. 
The pronase solution was then exchanged for collagenase (0.4 mg.ml-1 in high glucose DMEM with 
GlutaMax + 10 mM HEPES + 1% v/v antibiotic/antimycotic + 5% v/v FBS) and the tissue was maintained 
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at 37°C overnight under constant (rolling) agitation. Cells were counted the following morning, plated at 
5 x 104 cells.cm-2 and cultured in high glucose DMEM with GlutaMax plus 10% FBS, 284 µM ascorbic acid, 
and 1% v/v antibiotic/antimycotic. Cells were either used the following morning (passage 0), or frozen 
and grown for 2 passages at a later date, as indicated.  
 
4.2.11 Chondrocyte encapsulation in LTGF-β hydrogels  
Bovine chondrocytes were encapsulated in LTGF-β hydrogels for cartilage tissue engineering. Two 
experimental repeats were performed, with minor procedural differences as indicated. Glycosil™ (HA) 
was reconstituted in sterile water to 50% final volume, and PEGDA dissolved separately in PBS to 50% 
final volume; the PEGDA solution was then filter sterilised and separated into two vials, one to include 
PEG-LTGF-β. In the first experimental repeat, a previously reacted aliquot of PEG-LTGF-β was defrosted, 
whereas for the second repeat, the LTGF-β was reacted on the day as described in the section ‘PEGylation 
of model proteins and LTGF-β’. Bovine chondrocytes were harvested, counted, and suspended in the 
PEGDA solutions, the PEG-LTGF-β was added to one of the two vials, and the HA and PEGDA/ 
chondrocytes (with or without PEG-LTGF-β) were mixed in equal volumes. The polymers crosslink by 
reaction between acrylates (PEGDA) and thiols (HA); the free acrylates on PEG-LTGF-β also react with the 
thiolated HA, tethering the protein in place. For the first experimental repeat, the final concentrations 
were 1% w/v HA, 2.5% w/v PEGDA, 50 ng.ml-1 PEG-LTGF-β (free equivalent), and 5 x 106 
chondrocytes.ml-1, and for the second experimental repeat final concentrations of 0.75% w/ HA, 2% w/v 
PEGDA, 500 ng.ml-1 PEG-LTGF-β (free equivalent), and 4.5 x 107 chondrocytes.ml-1 were attained. This 
mixture was immediately dispensed into transwell inserts of pore size 5.0 µm: 150 µl per 12 mm 
diameter insert (first experimental repeat) or 50 µl per 6.5 mm diameter insert (second experimental 
repeat). Two sets of gels were prepared without TGF-β and one set with PEG-LTGF-β. After approximately 
5 minutes, 2 ml serum-free chondrogenic medium (high glucose, phenol red-free DMEM + 1 mM sodium 
pyruvate + 1% v/v ITS+ premix + 0.1 µM dexamethasone + 284 µM ascorbic acid + 1% v/v 
antibiotic/antimycotic; (218)) was added to each well. Two groups (no TGF-β and PEG-LTGF-β) received 
serum-free medium as described, whereas for the third group (free TGF-β) the medium was 
supplemented with 10 ng.ml-1 free TGF-β, which was added freshly at each medium change. The medium 
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was changed the following day and every two days thereafter. Gels were cultured for either 28 days (first 
experimental repeat) or 34 days (second experimental repeat).  
 
4.2.12 Biochemical analysis of chondrocyte activity 
To investigate cell death over the culture period, used medium was collected and frozen at -80°C until the 
end of the experiment. The amount of LDH released into the medium by dead cells was measured using a 
Cytotox 96 assay according to the manufacturer’s protocol. Total metabolic activity was assayed at 
approximately 5 day intervals using alamarBlue® reagent according to the manufacturer’s instructions. 
Briefly, 10% v/v alamarBlue® in serum-free medium was left in wells for 4 hours (2 ml) or 2 hours (1 ml) 
for the first and second experimental repeats respectively, and the absorbance of the samples was read in 
duplicate at 570 nm with background subtraction at 600 nm. The absorbance of the experimental 
samples (AbsE) was normalised to starting values (AbsC, alamarBlue® solution not exposed to cells) 
according to the formula:  
         
    
 
At day 34 of the second experimental repeat, LIVE/DEAD® staining was performed, and gels were 
assessed for total protein content and LDH activity to estimate cell number. For LIVE/DEAD® staining, an 
approximately 1 mm thick section was cut from the periphery of one gel of each group, and incubated at 
room temperature in LIVE/DEAD® reagent (1 µM calcein + 1 µM ethidium homodimer-1 in PBS) for 15 
minutes before imaging. Confocal microscopy was as described above (page 86) except that 488 nm 
excitation with 500-550 nm emission were used for calcein, 561 nm excitation with 580-700 nm emission 
were used for ethidium, the two fluorophores were captured simultaneously, and 5 µm steps were used 
between stacked images. For LDH and total protein, gels were weighed and then homogenised in 0.5 ml 
150 mM NaCl for 15 minutes at 30 Hz in a QIAGEN TissueLyser II. Aliquots for LDH were lysed in 0.1% 
v/v Triton-X in 150 mM NaCl, diluted 10x in water, and assayed according to the manufacturer’s 
instructions against standards of known cell numbers with cell free hydrogel samples run as blanks. 
Aliquots for the Bradford protein assay were digested in papain (7 mM cysteine, 5 mM EDTA, 62.5 mU.ml-
1 papain, 150 mM NaCl) for 8 hours. 20 µl sample was then mixed with 780 µl water, 200 µl Bradford 
reagent was added and the tubes were vortexed well. Within 30 minutes the absorbance was read at 595 
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nm alongside BSA standards and a cell-free hydrogel sample (all in identical solutions including the 
papain buffer).  
 
4.2.13 Histology  
Gels were analysed by histology at timepoints specified in the results section. The gels were fixed for 1 
hour in 10% v/v NBF and sliced into approximately 1 mm sections. For immunostaining of cartilage 
matrix constituents, fixed sections were permeabilised for 20 minutes with 0.1% v/v Triton-X, and 
blocked for 2 hours in 3% w/v BSA. All solutions and rinsing steps were in TBS, all steps were carried out 
on an orbital shaker, and the gels were rinsed for 20 minutes between each step. Gels were probed 
overnight at 4°C on a rocker in primary antibody solutions (Rb anti-Collagen II at 1:100, Rb anti-Collagen 
I at 1:100, Rb anti-Collagen VI at 1:200). Gels were rinsed for 1 hour then incubated for 1 hour at room 
temperature in secondary antibody solution at 1:2000 (Gt anti-Rb IgG-AlexaFluor 488 and Gt anti-Ms IgG-
AlexaFluor 568). After rinsing for 30 minutes, gels were stained in DAPI (1.8 µM in water) for 10 minutes 
and stored in TBS. Gels were imaged by confocal microscopy as described on page 86. Negative control 
(no primary antibody) gels ensured that the fluorescent signal was due to specific staining. Single fields or 
stacks at 5 µm intervals were collected, as appropriate for each set of samples. Additionally, DAPI 
fluorescence was later imaged at 4x objective magnification on an Olympus IX51 inverted microscope 
equipped with a mercury lamp and DAPI filter.  
 
Eosin staining was performed on 1 mm thick fixed gel sections by soaking for a few minutes in eosin stain, 
then destaining overnight in several changes of TBS. Gels were embedded in paraffin wax, 10 µm sections 
were cut, and slides were stained with picrosirius red and haematoxylin and eosin (performed by Ms. 
Lorraine Lawrence, Imperial College Histology service). Samples were imaged on an Olympus IX51 
inverted microscope using 4x, 10x and 20x objective lenses. Images were cropped and resized using 
Adobe Photoshop CS5.  
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4.2.14 Statistics and data manipulation  
Analysis of Variance with Tukey’s post-tests, and Independent samples T-tests were used except for all 
data except the free and latent TGF-β stability experiment and the timed release of TGF-β from PEG 
hydrogels, for which (non-parametric) Kruskal-Wallis and Mann-Whitney U tests were used. All statistical 
tests were run on SPSS for Windows version 12.0, and p < 0.05 was considered significant. All data 
manipulation including chart generation was performed using Microsoft Excel.  
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4.3 Results and Discussion 1: Adsorption and biological response to LTGF-β 
4.3.1 LTGF-β adsorbs to surfaces less readily than free TGF-β  
To explore the possible benefits of using LTGF-β within TE scaffolds, first of all the concentrations of free 
and latent TGF-β were measured over 48 hours in vitro, as an indicator of the tendencies of free and latent 
TGF-β to adsorb to TCP surfaces. Measured concentrations of free and latent TGF-β in BSA-coated well 
plates differed significantly (p = 0.05) after 8 hours incubation and beyond. At this point LTGF-β 
concentrations were unchanged, but free concentrations had diminished by 25% (Figure 4.3). By 48 
hours the amount of free protein had fallen to 61% of the starting concentration, whereas no decrease 
was seen for LTGF-β (105% of starting values).  
 
 
Figure 4.3: In vitro concentrations of free and latent TGF-β over time. Concentrations of free and 
latent TGF-β over 48 hours in DMEM on BSA-coated 6-well plates, as determined by ELISA. n = 3, mean 
and range of values shown. * Free versus latent TGF-β concentrations p = 0.05.  
 
TGF-β is a hydrophobic, ‘sticky’ protein tending to adhere strongly to surfaces (manufacturer’s 
instructions), raising concerns over protein handling during scaffold fabrication or loading, and possible 
fouling or denaturing during slow release over days to weeks. However, LAP binding to TGF-β induces 
extensive structural rearrangements in both proteins, burying several hydrophobic residues to create a 
hydrophobic interface stabilised by van der Waals interactions and π-bonding (227)(225)(231). These 
results suggest that the use of LTGF-β should allow greater confidence over protein integrity during 
processing steps and over long periods in culture or in the body.   
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4.3.2 LTGF-β is relatively inactive; implications for burst release from scaffolds  
In dosing TE scaffolds with growth factors, the desire for long-term action must be balanced against the 
need to limit the exposure of cells to high concentrations. Recall from Chapter 2 that burst release of high 
doses of VEGF is associated with aberrant vasculature (page 36) (232). Dysregulated TGF-β activity is 
implicated in OA and other disorders of joint tissues (233). In an extreme example, intra-articular 
injection of high doses of TGF-β (three deliveries of 200 ng into murine knee joints) induced OA-like 
changes incuding zone-specific changes to proteoglycan levels, osteophyte formation, and macroscopic 
cartilage lesions (234). Elsewhere, elevated TGF-β signalling stemming from increased TGF-β 
bioavaibaility was found to cause a transition from growth to apotosis of bone marrow stromal cells in 
biglycan and decorin deficient mice, with consequently decreased bone mass (235). Therefore, it was of 
great interest to illustrate the diminished potency of LTGF-β compared to free TGF-β.  
 
Cellular response to TGF-β was assessed by immunostaining for the phosphorylated form of Smad3 
(phosphoSmad3) in human foreskin fibroblasts (HFF-1). A dose response was performed at TGF-β 
concentrations (free or free equivalent) between 0.001 ng.ml-1 and 10 ng.ml-1. Free equivalent 
concentrations were determined in advance by ELISA on activated LTGF-β samples. In cells treated with 
free TGF-β, a robust signalling response was seen for concentrations of 0.01 ng.ml-1 and upwards, as 
indicated by strong nuclear staining for phosphoSmad3 (Figure 4.4). Meanwhile cells exposed to LTGF-β 
remained unresponsive at concentrations below 10 ng.ml-1, at which point nuclear fluorescence was 
observed. Therefore, LTGF-β prior to activation appears to have around 0.1% of the activity of the full 
protein, which is consistent with the dose-dependent inhibition of TGF-β bioactivity (growth inhibition 
and luciferase assays) by LAP (231)(225). Our approach therefore is of interest as a means by which to 
load high levels of TGF-β into scaffolds without subjecting cells to excessively high doses of active growth 
factor. Ideally for TE, the encapsulated cells would then activate the TGF-β over a period of days to weeks, 
thereby achieving sustained release without an initial burst of excessive activity. Therefore, having 
confirmed the relative inactivity of the commercial LTGF-β, the next task was to explore its activation by 
cells.  
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Figure 4.4: Signalling response to different concentrations of free and latent TGF-β by human 
foreskin fibroblasts (HFF-1). Cells were incubated in the presence of free or latent TGF-β at the 
indicated concentrations for 1 hour prior to fixing. Confocal microscopy; scale = 200 µm.  
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4.3.3 Response to LTGF-β was not diminished by inhibition of protease activity, integrin 
binding, or contractility  
As already discussed, latent TGF-β can be activated by cells in a variety of protease- and/or integrin-
dependent pathways. Cell-mediated release of growth factors from fibrin and PEG hydrogels has been 
shown to result in high quality blood vessel formation (232)(122)(236). Therefore the positive signalling 
response of HFF-1 to LTGF-β at free equivalent concentrations of 10 ng.ml-1 was investigated further, to 
ascertain whether this reflected cell-mediated LTGF-β activation. HFF-1 were stimulated with 10 ng.ml-1 
TGF-β (free or free equivalent) in the presence of a selection of inhibitors. Protease-dependent pathways 
were targeted by a custom cocktail of MMP and serine protease inhibitors (ALMC; Table 4.2), and 
integrin-dependent pathways by a competitive RGD peptide and blebbistatin, a potent inhibitor of 
nonmuscle myosin II (hence cellular contractility). A small molecule inhibitor of TβRI, SB-431542 
(TGFBRI), was run as an additional control, and inhibitor treatments were performed on negative (no 
TGF-β) and positive (free TGF-β) control wells in case they perturbed Smad signalling independently of 
any effects on LTGF-β activation.  
 
Protease 
Inhibitor 
Aprotinin Leupeptin Marimastat CP471474 
MMP-2   • • 
MMP-3    • 
MMP-9   • • 
MMP-13    • 
MMP-14 (MT-1 MMP)   •  
Plasmin •    
Thrombin  •   
Urokinase  •    
Tissue-type plasminogen activator •    
Elastase •    
Chymase  •   
Tryptase  •   
Furin      
 
Table 4.2: TGF-β-activating proteases and pharmacological inhibitors used. List of proteases 
compiled from (91) and (220); specificity of proteases based on manufacturer’s information.  
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As before, stimulation of HFF-1 with 10 ng.ml-1 free or latent TGF-β for 1 hour led to the nuclear 
accumulation of phosphoSmad3 (Figure 4.5). The addition of soluble RGD, or the protease inhibitor 
cocktail ALMC, or both treatments in combination with blebbistatin, did not diminish the intensity of 
staining. In contrast, the TGFBRI completely abolished the phosphorylation response, both with free and 
latent TGF-β.  
 
A similar experiment was performed on bovine chondrocytes to confirm and extend these observations. 
Freshly isolated chondrocytes showed strong nuclear phosphoSmad3 staining even after serum 
starvation, therefore cells were used at passage 4. In addition to the custom ALMC cocktail, a commercial 
protease inhibitor cocktail was used. EDTA-free tablets were used because EDTA interfered with cell 
attachment to the slide. EDTA is included in such cocktails to inhibit MMPs (by chelating their namesake 
zinc ions), therefore the commercial formulation was additionally supplemented with the MMP inhibitors 
Marimastat and CP471474 (Table 4.2) to form a novel cocktail, PIMC. Some non-specific staining was 
seen on immunostained samples although a clear positive signalling response to TGF-β was seen for both 
latent and free TGF-β at 10 ng.ml-1 (Figure 4.6). The Western blot membranes showed bands close to the 
expected molecular weight of 48 KDa (manufacturer’s information; apparent Mw 55 KDa). On both slides 
and Western blot membranes no difference in Smad3 phosphorylation was seen between samples treated 
with LTGF-β with or without ALMC. Although some loss in fluorescence/band intensity was seen with the 
PIMC cocktail, this occurred with both free and latent TGF-β-treated wells, indicating an inhibitory effect 
via a mechanism other than TGF-β activation. Again, the TGFBRI abolished Smad3 phosphorylation, as 
seen from the Western blot membrane.  
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Figure 4.5: Signalling response by human foreskin fibroblasts (HFF-1) to 10 ng.ml-1 free and latent 
TGF-β in the presence of inhibitors of TGF-β activation. - = no inhibitor; RGD = soluble RGD peptide; 
ALMC = aprotinin, leupeptin, Marimastat, CP471474; TGFBRI = TGF-β receptor inhibitor. Scale = 200 µm.  
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Figure 4.6: Signalling response by passage 4 bovine articular chondrocytes to 10 ng.ml-1 free and 
latent TGF-β in the presence of protease inhibitors. (Top) immunostaining for phosphoSmad3. Scale = 
200 µm. (Bottom) Western blot membrane showing phosphoSmad3, and total Smad3 after stripping. 
Abbreviations as per Figure 4.5, plus PIMC = Roche protease inhibitor cocktail, Marimastat, CP471474.  
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The failure of any of the inhibitor treatments to diminish the phosphoSmad3 signal intensity suggests that 
the Smad3 phosphorylation response seen at high concentrations of LTGF-β may not be due to cell-
mediated activation of the complex. The HFF-1 dose response (Figure 4.4) indicated that the response 
threshold for the LTGF-β was somewhere between 1 and 10 ng.ml-1, therefore the assay should have been 
relatively sensitive to inhibition. Alternative possibilities are that the formulation may include a small 
amount of impurity (i.e. free TGF-β), or that the TGF-β retains some limited ability to bind its receptor 
even when associated with the LAP, which only becomes apparent at high doses. ELISA on unactivated 
LTGF-β samples typically gave concentration readings of around 1% of the activated total, although this is 
difficult to interpret without information regarding the recognition sites of the antibodies in this kit.  
 
Whether or not the signalling response to 10 ng.ml-1 LTGF-β represents bona fide activation by HFF-1 and 
chondrocytes, however, is of limited concern for the present application. Indeed, for cartilage TE it is 
preferable for the TGF-β to become active only gradually, over far longer timescales than the 1 hour 
exposure used here. Furthermore, stretch-dependent activation of LTGF-β delivered in solution would 
not be expected: tractional force across the SLC is required for this to occur, which may conceivably be 
enabled by tethering of the LTGF-β to a surface or hydrogel matrix (229)(91). The work described below 
aimed to discover whether LTGF-β tethered within a three-dimensional hydrogel scaffold would 
stimulate chondrogenic activity over four to five week culture periods. The general approach was to 
prepare PEG-HA hydrogels with tethered LTGF-β, for the encapsulation of bovine chondrocytes. The first 
step was to develop the means by which to link the LTGF-β to the hydrogel matrix.  
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4.4 Results and discussion 2: Conjugation of PEGDA to LTGF-β 
4.4.1 PEGylation of proteins was achieved using Traut’s reagent  
To immobilise LTGF-β within hydrogels it was necessary to introduce a reactive group(s) to LAP that 
would enable subsequent reaction with the hydrogel polymer. The hydrogels used for TE (vide infra) 
consisted of thiolated HA crosslinked with PEGDA, which occurs via a Michael-type addition reaction. 
Therefore the chosen strategy was to modify the LTGF-β with PEGDA (PEGylation), leaving a free acrylate 
to react with the HA using the same chemistry as the crosslinking reaction.  
 
Traut’s reagent was chosen as a linker between LTGF-β and PEGDA. According to this scheme, the Traut’s 
reagent targets primary amines belonging to amino acid sidegroups. Both lysine (K) and arginine (R) 
residues carry amine sidegroups, but only lysines are expected to react due to charge delocalisation on 
arginine sidechains. This introduces a free thiol to the LTGF-β (SH-LTGF-β), which combines with the 
PEGDA acrylate endgroups via Michael addition (shown schematically in Figure 4.7). A high acrylate: 
thiol ratio (13:1) was used to favour Michael addition between SH-LTGF-β and PEGDA over disulphide 
bond formation between SH-LTGF-β.  
 
 
  Traut’s reagent Primary amine 
molecule 
   Modification producing a 
   terminal sulfhydryl group 
 
 
Figure 4.7: Conjugation chemistry. (Top) Traut’s reagent reacts with primary amines (lysines) to 
introduce thiols to proteins. (Bottom) Co-reacting a protein (LTGF-β shown) with Traut’s reagent and 
PEGDA causes the SH-LTGF-β to react with PEGDA, producing a PEGylated protein.  
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The model proteins BSA, cytochrome C, and lysozyme were chosen to develop the reaction conditions. 
Although Mw of the LAP dimer is similar to that of BSA (LAP ~80 KDa before glycosylation, versus BSA 
~70 KDa), the two smaller proteins are closer in terms of the number of lysines (LAP 20, BSA 60, 
cytochrome C 7, lysozyme 14; Table 4.3). It should be noted that the TGF-β dimer itself contains in total 
16 lysines, which are also potential unintended targets of the PEGylation reaction.  
 
Protein Species 
Approx. 
Mw (kDa) 
Lysines 
NCBI Reference 
Sequence 
Bovine serum albumin Bos taurus 70 60 NP_851335.1 
Cytochrome C Bos taurus 12 7 NP_001002891 
Lysozyme Gallus gallus 15 14 NP_990612.1 
Latency associated 
peptide β1 (dimer) 
Homo sapiens 
40 x 2 10 x 2 
NP_000651.3 
TGF-β1 (dimer) 12.5 x 2 8 x 2 
 
Table 4.3: Protein information for the model proteins bovine serum albumin, cytochrome C, 
lysozyme, LAP-β1, and TGF-β1. Approximate molecular weight (Mw) and number of lysines shown. 
Note that LAP-β1 and TGF-β1 come from the same gene product and are dimeric. (237)(238)(239)(240) 
 
The influence of EDTA on the PEGylation reaction was investigated because the manufacturer’s 
instructions for Traut’s reagent stipulate the inclusion of EDTA at 2-5 mM to chelate metal ions. This 
prevents the oxidation of sulfhydryl groups and hence disulphide bond formation between SH-LTGF-β. 
However, since deprotonation also favours Michael addition it was possible that EDTA might inhibit 
coupling to PEGDA. Therefore, three conditions were tested: EDTA was either left out of the pH 8.0 
sodium phosphate (SPB) reaction buffer, or included at either 5 mM (SPEB) or 100 mM (SPEB+). The high 
EDTA (SPEB+) buffer was tested because BSA preparations often contain high levels of iron from 
haemoglobin, which may overwhelm small amounts of EDTA; 0.1 M EDTA is sometimes recommended 
when working with BSA to maintain sulfhydryl stability (241).  
 
SDS-PAGE results for all three model proteins confirmed the efficacy of the PEGylation procedure (Figure 
4.8). As expected according to the reasoning above, the most extensive modification occurred in SPB 
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buffer (no EDTA), but paradoxically, less modification happened with 5 mM EDTA than 100 mM. The 
reason for this is not clear. Michael addition is sensitive to pH, but buffer pH was corrected after the 
addition of EDTA, so this is unlikely to have been an issue. 
 
 
Figure 4.8: PEGylation of model proteins. (Top) attempt 1; (Bottom) attempt 2. Unmodified protein (-) 
and reactions carried out in sodium phosphate buffer (SPB), SPB with 5 mM EDTA (SPEB), or SPB with 
100 mM EDTA (SPEB+).  
 
SPB buffer was chosen for the LTGF-β PEGylation reactions due to the higher efficiency of the reaction. 
Under these conditions BSA showed an increase in Mw from ~70 KDa to a range of Mws of around 100-
170+ KDa. This indicated the addition of at least 7-25 PEGDA molecules, which is a sizeable proportion of 
the total number of lysines (60). Reacted lysozyme showed discrete bands corresponding to around 20, 
25, and 30-35 KDa, from an initial known Mw of 15 KDa (apparent Mw ~13 KDa). These bands 
presumably represent mono-, di-, and tri-PEGylated protein (from 14 total lysines). At the first attempt, 
Cytochrome C was modified to the extent of 35-170 KDa from 12 KDa, which was cause for concern as it 
far exceeded the ~30 KDa Mw increase expected if all 7 lysines were modified. A repeat under the same 
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conditions yielded Mw increases to around 20-45 KDa, although the staining was weak and the bands 
difficult to read in this gel. This emphasised the importance of inspecting PEGylated protein batches 
before use. The different susceptibilities of the model proteins to PEGylation also demonstrates the 
importance of factors other than the total number of lysines – for example, the steric accessibility of 
lysines, and the chemical nature of adjoining sidegroups.  
 
4.4.2 Latency associated peptide was PEGylated using Traut’s reagent 
As indicated in Table 4.3 and detailed in Figure 4.9, each LAP monomer contains 10 lysine residues, 
some of which may be available to react with Traut’s reagent leading to LTGF-β PEGylation. LAP 
additionally carries several endogenous cysteine residues, most of which are involved in disulphide 
linkages. However, the cysteine at position 33 (within a STCKT sequence near to the N terminus of the 
peptide; Figure 4.9) normally mediates linkage to LTBPs, raising the intriguing possibility that within the 
isolated SLC it may be available to react directly with PEGDA. Furthermore, the pKa of cysteine SH groups 
(~8.1-8.9) is reduced when the cysteine is flanked by positively charged amino acids (242). The +1 charge 
on the adjacent lysine is thus expected to increase the likelihood of reaction with PEGDA by favouring 
deprotonation. Coupling specifically and solely to this cysteine residue would preserve the full 
functionality of the TGF-β, and presumably ensure presentation of the TGF-β in a physiological 
orientation. To address this possibility, therefore, LTGF-β samples were reacted with PEGDA alone (no 
Traut’s reagent), in addition to those reacted with Traut’s reagent as described above.  
 
ORIGIN       
1 MPPSGLRLLP LLLPLLWLLV LTPGRPAAGL STCKTIDMEL VKRKRIEAIR GQILSKLRLA 
61 SPPSQGEVPP GPLPEAVLAL YNSTRDRVAG ESAEPEPEPE ADYYAKEVTR VLMVETHNEI 
121 YDKFKQSTHS IYMFFNTSEL REAVPEPVLL SRAELRLLRL KLKVEQHVEL YQKYSNNSWR 
181 YLSNRLLAPS DSPEWLSFDV TGVVRQWLSR GGEIEGFRLS AHCSCDSRDN TLQVDINGFT 
241 TGRRGDLATI HGMNRPFLLL MATPLERAGH LQSSRHRRAL DTNYCFSSTE KNCCVRQLYI 
301 DFRKDLGWKW IHEPKGYHAN FCLGPCPYIW SLDTQYSKVL ALYNQHNPGA SAAPCCVPQA 
361 LEPLPIVYYV GRKPKVEQLS NMIVRSCKCS 
 
Figure 4.9: Primary sequence of TGF-β1 propeptide. Grey letters correspond to signal peptide 
(residues 1-29), blue letters to LAP (residues 30-278; 249 amino acids), and black to TGF-β1 (residues 
279-390; 112 amino acids). The eighteen lysine residues (K) are highlighted in red, and cysteines (C) in 
gold. (240)  
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Unmodified LTGF-β run on SDS-PAGE under reducing and denaturing conditions produces bands at 12.5 
KDa and 40-45 KDa, corresponding to the TGF-β and LAP monomers, respectively (Figure 4.10). Where 
LTGF-β was reacted with PEGDA but no Traut’s reagent, no Mw increase was apparent in the LAP. If 
anything, the LAP band appeared to have travelled further than in control samples (see batch a) 
suggesting that the presence of PEG may affect the movement of protein through the gel, compromising 
interpretation.  
 
 
Figure 4.10: PEGylation of LTGF-β. Positions of LAP and free TGF-β are indicated. LTGF-β was run 
either alone or after reacting for 1 hour with PEGDA +/- Traut’s reagent (Traut’s). Batches (a-c) are 
indicated.  
 
LAP reacted with PEGDA and Traut’s reagent showed clear Mw increases, indicative of PEGylation, in 
accordance with the results for the model proteins. Three batches were run (a-c), and once more the 
extent of modification was seen to vary from batch to batch, in the order b>a>c. Moderate changes were 
seen in batches a and c, of up to around 30 KDa and 15 KDa respectively. Final Mws of >>100 KDa were 
seen in batch b, which may indicate protein aggregation, for example by disulphide bridging between SH-
LTGF-β, or uncontrolled reaction of Traut’s reagent, perhaps with arginine residues. Free TGF-β was too 
faint to resolve following the reactions with PEGDA and Traut’s reagent (vide infra).  
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To confirm LTGF-β PEGylation and investigate further the possibility of specific coupling via LAP Cys-33, 
LTGF-β was incorporated into UV photopolymerised PEGDA hydrogels and diffusional release of TGF-β 
measured by ELISA; PEGylated protein should become covalently tethered inside the gel via free 
acrylates. Acid was added at 24 hours to dissociate the TGF-β dimer from the LAP, and further release 
was measured at 48 hours. 
 
Over the first 8 hours of swelling, 61% of unreacted LTGF-β diffused out of the gel (Figure 4.11). By 24 
hours 70% had been released, and acid treatment liberated a further 31%, so that by 48 hours all of the 
TGF-β was accounted for. LTGF-β reacted with PEGDA but no Traut’s reagent (to target Cys-33) showed 
significantly (p < 0.05), but only marginally (54% released versus 70%), greater retention over 24 hours; 
and by 48 hours 98% of the TGF-β had been released. It therefore seems possible that the PEGDA had 
reacted with the Cys-33 in a minority of LAP molecules, but if so, this was not enough to prevent most of 
the protein being lost from the gel within a day. The possibility of hijacking endogenous cysteine residues 
to tether the LTGF-β in a defined, biologically relevant orientation was therefore not well-supported by 
the SDS-PAGE and ELISA timed release results. This apparent failure may be due to incorrect pairing of 
LAP Cys-33 with a free cysteine in TGF-β, which has been suggested to occur when the SLC is exported 
without LTBPs (225).  
 
 
Figure 4.11: Release of latent TGF-β from UV photopolymerised PEGDA hydrogels over time. Acid 
was added at 24 hours (arrow) and concentrations measured by ELISA. LTGF-β was either unmodified, or 
reacted with PEGDA for 1 hour +/- Traut’s reagent (Traut’s). LTGF-β from the batch c reaction was used. 
Effect of reaction conditions p < 0.05 from 0.25 - 24 hours. * LTGF-β versus LTGF-β + PEGDA p < 0.05.  
 
* 
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In contrast, only 12% of the LTGF-β reacted with Traut’s reagent diffused out of the gel within 24 hours, 
confirming that PEGylation had occurred, and that the PEG in turn was linking the protein directly to the 
polymer scaffold. Furthermore, upon acidification another 58% of the total TGF-β diffused out of the gel, 
to a total release of 70%. This was very encouraging, because if the TGF-β itself had become extensively 
PEGylated, it too would have remained tethered inside the gel following acid treatment. In light of these 
promising findings, it was decided that the Cys-33 coupling approach would be discarded, and the cell 
work described in the following sections would proceed using LTGF-β PEGylated using Traut’s reagent 
(PEG-LTGF-β).  
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4.4.3 Latent TGF-β is either lost or modified during PEGylation reaction 
Consistently, there was a loss in staining intensity of TGF-β and LAP after the conjugation reactions, both 
with and without Traut’s reagent (Figure 4.10). In addition, post-reaction ELISA readings gave 
diminished signals (Table 4.4), suggesting that TGF-β concentrations had fallen to 0.09-0.20 of original 
levels. This suggests that during the PEGylation reaction, TGF-β protein is either lost – for example by 
adsorption to the sides of the tube – and/or modified – i.e. PEGylated. The aim of the cell work described 
in the next section was to clarify how the PEGylation reaction affected TGF-β biofunctionality, using PEG-
LTGF-β batches a and b. The relative measured concentrations of 0.15 and 0.20 after PEGylation with 
Traut’s reagent were used to derive correction factors (i.e. 6.7 and 5 times original concentrations) for 
loss of protein or of protein activity when Traut’s reagent was used. Conversely, for LTGF-β reacted with 
PEGDA alone (no Traut’s reagent), the concentration readings were essentially unchanged in two of three 
batches. The TGF-β dimer was assumed not to have been modified in these reactions, therefore the 
relative concentration readings for this condition (Table 4.4) were used to correct for possible protein 
adsorption to the sides of the tube during the reaction. The concentrations so calculated will be denoted 
HIGH and LOW respectively (see Table 4.4), and it will be made explicit in the text and diagrams which 
batches and concentration estimations were used.  
 
Batch 
Relative amount 
PEGDA + Traut’s 
Correction factor 
HIGH 
Relative amount 
PEGDA 
Correction factor 
LOW 
a 0.15 6.7 0.50 2 
b 0.20 5 1.03 1 
c 0.09 N/A 0.90 N/A 
 
 
Table 4.4: Relative apparent concentrations of LTGF-β after 1 hour reacting with PEGDA +/- 
Traut’s reagent. LTGF-β was reacted either with PEGDA or with PEGDA and Traut’s reagent for 1 hour, 
and the concentrations before and afterwards were read by ELISA (‘Relative amount = concentration 
after reaction/concentration before reaction’). The inverse of these ratios defines a correction factor for 
each condition, used to calculate concentrations (denoted HIGH and LOW as indicated) for use in selected 
experiments in the next section. N/A – batch c was not used in subsequent cell work.  
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4.5 Results and discussion 3: Biological activity of PEG-LTGF-β 
4.5.1 PEG-LTGF-β induces Smad3 phosphorylation in fibroblasts, but with some loss of activity 
Immunostaining and Western blot for phosphoSmad3 and total Smad3 were used to investigate whether 
PEG-LTGF-β retains its biological activity. In the first experiment, free equivalent concentrations of TGF-β 
were uncorrected for loss or modification of TGF-β during the reactions. HFF-1 were stimulated with 
stock LTGF-β and PEG-LTGF-β (batch b) at 1 and 10 ng.ml-1, and additionally two modes of LTGF-β 
activation were attempted: acid treatment was performed on samples at 0.1 and 1 ng.ml-1; and 
manganese chloride (MnCl2, 500 µM) included with LTGF-β at 1 ng.ml-1. Low pH causes dissociation of 
TGF-β from LAP, as already discussed, while MnCl2 promotes integrin binding and can be used to enhance 
integrin-mediated activation of TGF-β (229).  
 
As before, 10 ng.ml-1 (free equivalent) unmodified LTGF-β led to Smad3 activation while 1 ng.ml-1 failed to 
elicit a strong response (Figure 4.12). However in this instance there did seem to be a very low level of 
Smad3 phosphorylation at 1 ng.ml-1. When the same doses of PEGylated protein were used, nuclear 
phosphoSmad3 staining appeared less intense than control, indicating that the protein was still functional 
but that some loss of activity had occurred. Acid activated, unmodified LTGF-β at 0.1 and 1 ng.ml-1 elicited 
a robust phosphorylation response. Convincing nuclear staining was also seen for PEG-LTGF-β under the 
same conditions, confirming that some functionality was unquestionably retained. This was especially 
encouraging given that SDS-PAGE results for the batch used (b; Figure 4.10) had revealed very large Mw 
increases, suggesting that this had been more extensively PEGylated than the other batches. MnCl2 did not 
appear to increase the response to 1 ng.ml-1 latent TGF-β in either the control or PEGylated group.  
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Figure 4.12: Signalling response to LTGF-β and PEG-LTGF-β by HFF-1. Cells were exposed to LTGF-β 
and PEG-LTGF-β (batch b) at the indicated concentrations for 1 hour. + ACID = acid activation of LTGF-β; 
+ Mn++ = 500 µM MnCl2. Free equivalent concentrations of LTGF-β are shown, without correction for loss 
or modification of protein during PEGylation reactions. Confocal microscopy; scale = 200 µm.  
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The next two experiments attempted to assess whether the concentration corrections described earlier 
(Table 4.4) could provide a good approximation of the activity of unmodified protein. Initially, a high 
concentration (10 ng.ml-1) of LTGF-β was chosen and both HIGH and LOW concentration corrections were 
used as per Table 4.4. Immunostaining for phosphoSmad3 of HFF-1 treated with PEG-LTGF-β batch b for 
1 hour appeared brighter than control (unmodified LTGF-β) when the HIGH concentration correction was 
used, and less intense than control when the LOW concentration was used (Figure 4.13).  
 
Western blotting was performed for HFF-1 treated with batches a and b at HIGH and LOW concentrations 
(Figure 4.13). No staining for phosphoSmad3 was seen in the no TGF-β control lanes. Free and latent 
TGF-β controls produced clear bands at 55 KDa, although the staining was more intense for free TGF-β. 
The loading control of total Smad3 was similar for all samples. As expected, the intensity of staining for 
the experimental samples was weaker when the LOW correction was used than for the HIGH correction. 
For batch a, staining for the LOW correction was roughly similar to that for the unmodified LTGF-β while 
the HIGH correction led to more intense staining than control. Conversely for batch b, staining for the 
HIGH concentration correction was similar to control while the signal from the LOW concentration 
correction was weaker. These results suggest that the higher Mw seen on SDS-PAGE for batch b may be 
associated with greater loss of activity than for batch a (Figure 4.10). The lack of agreement over 
whether the HIGH or LOW correction would give a similar response to control suggested that attempts to 
use ELISA readings to approximate biological activity were likely to prove inaccurate.  
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Figure 4.13: Signalling response to PEG-LTGF-β by human foreskin fibroblasts (HFF-1) and 
comparison to unmodified LTGF-β at different concentration corrections. HIGH and LOW refer to 
concentration corrections detailed in Table 4.4 and explained in the accompanying text. Estimated 
concentrations (free or free equivalent) were 10 ng.ml-1 for all conditions. (Top) Immunostaining for 
phosphoSmad3, PEG-LTGF-β batch b used. Confocal microscopy; scale = 200 µm. (Bottom) Western blot 
membranes – two repeats from the same experiment. (a) and (b) refer to PEG-LTGF-β batches. For 
consistency, the lane order of the top right membrane was altered in Photoshop. Membranes are also 
shown after being stripped to remove phosphoSmad3 antibody.  
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Finally, it was of interest to determine whether PEG-LTGF-β retained its ability to be activated by cells, for 
example by proteases. The attempt to stimulate integrin-mediated TGF-β activation by adding MnCl2 to 
the medium had not led to increased signalling in either unmodified or PEGylated LTGF-β samples 
(Figure 4.12), therefore a protease-dependent mechanism of activation was explored (plasmin digest). 
Following Pedrozo et al, LTGF-β was digested for 90 and 180 minutes in 0.01 U.ml-1 plasmin and stopped 
using 7.5 µg.ml-1 aprotinin (243). Smad3 phosphorylation in response to control and PEGylated LTGF-β 
was then assessed as before. Acid treatment was also performed as a control. Batch b was used with the 
HIGH concentration correction to ensure a strong response, and for all conditions 1 ng.ml-1 (free or free 
equivalent) TGF-β was used.  
 
Immunostaining and Western blotting confirmed that unmodified LTGF-β had limited to no activity 
(Figure 4.14). Exposure to acid activated samples, however, led to a strong Smad3 phosphorylation 
response, which in the immunostained samples was seen to be localised to the nucleus. The level of 
staining was similar for unmodified and PEGylated LTGF-β. Plasmin-digested samples, however, failed to 
activate Smad3 signalling in both control and PEGylated samples, indicating that the conditions used by 
Pedrozo et al may not have been directly applicable to this experimental system. The experimental 
samples in their case were prepared from decellularised ECM and therefore contained naturally 
deposited LTGF-β, which would have largely been present as part of the LLC.  
 
In conclusion, PEG-LTGF-β retained some level of biological activity (ability to stimulate Smad3 
phosphorylation), although some loss of activity was seen following PEGylation with Traut’s reagent. This 
is not surprising given that the reaction randomly targets lysine residues, of which TGF-β contains 16, 
some of which are likely to become involved in the reaction. The activity of batch b – which showed a 
more extensive modification than batch a (Figure 4.10) – appeared to be lower than batch a. Correcting 
PEG-LTGF-β concentrations based on ELISA readings, to compensate for loss of activity post-reaction, did 
not match the activity of unmodified protein in a consistent way, therefore the activity of PEG-LTGF-β 
cannot be quantified with confidence from these results. Attempts to stimulate integrin- and plasmin-
dependent activation of stock and experimental samples were unsuccessful. Having confirmed that PEG-
LTGF-β is biologically active, the potential of LTGF-β for cartilage TE was assessed by culturing bovine 
chondrocytes in PEG-HA hydrogels, as described in the following section.   
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Figure 4.14: Signalling response to PEG-L TGF-β by human foreskin fibroblasts (HFF-1) [continued] 
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Membranes are also shown after being stripped to remove phosphoSmad3 antibody.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Figure 4.14 continued] with acid activation and plasmin digestion. Estimated concentrations (free or 
free equivalent) were 1 ng.ml-1 for all conditions, and the PEG-LTGF-β (batch b) was corrected using the 
HIGH concentration estimation (Table 4.4). + acid = acid activation; + P90 = plasmin digestion for 90 
minutes; + P180 = plasmin digestion for 180 minutes. (Top) Immunostaining for phosphoSmad3. 
Confocal microscopy; scale = 200 µm. (Bottom) Western blot membranes – two repeats from the same 
experiment. Membranes are also shown after being stripped to remove phosphoSmad3 antibody.  
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4.6 Results and discussion 4: Cartilage tissue engineering  
4.6.1 No increase in proliferation or matrix synthesis was seen with 50 ng.ml-1 PEG-LTGF-β  
To evaluate the potential of LTGF-β for cartilage TE, bovine chondrocytes at passage 2 were encapsulated 
into PEG-HA hydrogels and cultured for 4 weeks. Gels were prepared with or without 50 ng.ml-1 PEG-
LTGF-β. As previously mentioned, the remaining free acrylate groups on the conjugated PEG molecules 
can react with thiols in Glycosil™, tethering the PEG-LTGF-β to the hydrogel. ‘PEG-LTGF-β’ and ‘no TGF-β’ 
groups were fed with serum-free chondrogenic medium minus TGF-β. The ‘free TGF-β’ positive control 
group (gels prepared without LTGF-β) received medium supplemented with 10 ng.ml-1 free TGF-β, which 
was added freshly at each medium change (every two days) for the duration of the study.  
 
The alamarBlue® assay for metabolic activity was performed at several timepoints to assess chondrocyte 
proliferation. Cells provided with free TGF-β doubled their activity over the first seven days in culture 
(Figure 4.15). Cell number declined thereafter until, at day 28, activity was similar to starting levels. 
Metabolic activity of ‘no TGF-β’ chondrocytes peaked at 3 days with approximately a 45% increase on day 
1 values. Activity then declined steadily to day 21 (~30% of starting values), but showed some minor 
recovery at day 28. Activity of the ‘PEG-LTGF-β’ group closely resembled that of the ‘no TGF-β’ control 
group. From days 10 to 21, activity was significantly (p < 0.05) higher for PEG-LTGF-β than for no TGF-β, 
but these differences were small (15-23% of no TGF-β starting values) and of questionable biological 
relevance.  
 
Used medium was collected and assayed for LDH released by dead cells. Cell death in the ‘free TGF-β’ 
group peaked around days 1, 12, and 24-26 (Figure 4.15). The initial peak was shared by the other two 
experimental groups and presumably reflects stresses associated with the encapsulation procedure and 
adaptation to new environmental conditions. The onset of the latter two peaks, at days 6 and 21, 
correspond to peaks in metabolic activity (Figure 4.15); increasing LDH release thus closely coincides 
with declining metabolic activity. The cause of this decline may be related to metabolic demands, possibly 
indicating that nutrient diffusion into the gels could not keep pace with consumption, and/or that the 
volume of medium used was insufficient to sustain these cells for two days. Aside from a difference at day 
1, the pattern and extent of cell death was virtually identical in the ‘no TGF-β’ and ‘PEG-LTGF-β’ groups, 
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showing a gradual decline from peak activity at days 1 and 3. LDH release was very low over the final two 
and a half weeks, presumably reflecting low total cell numbers at this point.  
 
 
Figure 4.15: Viability of bovine chondrocytes cultured for 28 days in PEG-HA gels with and without 
TGF-β. (Top) Total metabolic activity as indicated by alamarBlue® reduction, reflecting cell proliferation. 
Effect of gel p < 0.001; effect of ‘free TGF-β’ versus ‘no TGF-β’ and ‘PEG-LTGF-β’ p < 0.001; effect of ‘PEG-
LTGF-β’ versus ‘no TGF-β’ p = 0.72. * ‘no TGF-β’ versus ‘PEG-LTGF-β’ p < 0.05; ** ‘no TGF-β’ versus ‘PEG-
LTGF-β’ p < 0.001. (Bottom) LDH release from cultured hydrogels, reflecting cell lysis. Effect of ‘free TGF-
β’ versus ‘no TGF-β’ and ‘PEG-LTGF-β’ p < 0.001. Experimental groups here and for all subsequent figures 
are as described on page 116. Mean ± SD, n = 5.  
 
Various histological analyses of hydrogel samples were carried out at days 7, 14, 21 and 28, to evaluate 
ECM deposition by chondrocytes. The general collagen stain picrosirius red, and an anti-collagen II 
antibody were used on wax embedded and hydrated gel samples, respectively (Figure 4.16). Marked 
differences were seen in collagen staining between, on the one hand, ‘free TGF-β’ gels, and on the other, 
‘no TGF-β’ and ‘PEG-LTGF-β’ gels. After seven days of treatment with free TGF-β, chondrocytes were 
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large, round, and laden with collagen as indicated by vivid staining with picrosirius red. At day 13 
abundant pericellular collagen II was seen, and by day 28 this had formed a relatively uniform, 
continuous matrix. Conversely, ‘no TGF-β’ and ‘PEG-LTGF-β’ chondrocytes at day 7 were small and weakly 
stained; collagen II at days 13 and 28 was still confined to the immediate cell environment, with virtually 
no interstitial staining.  
 
 
Figure 4.16: Collagen staining of PEG-HA hydrogels with encapsulated chondrocytes cultured for 
up to 28 days. (Top) Picrosirius red staining of wax-embedded sections fixed on day 7 of culture. 
Brightfield microscopy; 10x magnification; scale = 200 µm. (Bottom) Confocal images of hydrogels 
immunostained with collagen II (green) plus DAPI (blue). 20x magnification; scale = 100 µm.  
 
Eosin Y staining was performed on fixed, hydrated gels to highlight general features. In accordance with 
the previous observations, ‘free TGF-β’ gels contained larger chondrocytes and stained more intensely 
than ‘no TGF-β’ and ‘PEG-LTGF-β’ gels (Figure 4.17). Nuclei stained with DAPI were brightest and most 
numerous in ‘free TGF-β’ gels at all timepoints, indicating higher cell numbers (Figure 4.18). 
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Additionally, DAPI binds to RNA, albeit with a weaker fluorescent signal than with DNA (quantum yield 
DAPI/RNA ~20% that of DAPI/dsDNA, manufacturer’s information), so the brighter fluorescence of ‘free 
TGF-β’ nuclei may in part reflect higher transcription in these cells. ‘Free TGF-β’ gels after 28 days of 
culture were semi-opaque, firm in consistency and could easily be handled, whereas ‘no TGF-β’ and ‘PEG-
LTGF-β’ gels were transparent and friable (Figure 4.19). Taken together, the alamarBlue®, LDH, and 
histology results indicate that the inclusion of PEG-LTGF-β under these experimental conditions did not 
stimulate cellular proliferation, or enhance cartilage matrix synthesis by the encapsulated chondrocytes.  
 
 
Figure 4.17: Eosin staining of PEG-HA hydrogels with encapsulated chondrocytes cultured for 21 
and 28 days. Brightfield microscopy; 4x and 10x magnification as indicated; scale = 500 µm for 4x 
magnification, and 200 µm for 10x magnification.  
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Figure 4.18: DAPI staining of PEG-HA hydrogels with encapsulated chondrocytes cultured for up to 
28 days. Fluorescent microscopy; 4x magnification; scale = 500 µm.  
 
 
Figure 4.19: Macroscopic appearance of PEG-HA hydrogels after 28 days of culture. Some residual 
colour is left over from the alamarBlue® assay. Membrane diameter = 12 mm.  
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4.6.2 High loading of PEG-LTGF-β stimulated metabolic activity over 5 weeks  
Given that no improvements in viability nor matrix synthesis were detected with PEG-LTGF-β compared 
to no TGF-β under the previous experimental conditions, the following modifications were made to the 
experimental setup.  
 A higher density of cells was seeded into the gels (4.5 x 107 cells.ml-1 versus 5 x 106 cells.ml-1). It 
was reasoned that higher concentrations of secreted proteases might promote TGF-β release 
from LTGF-β.  
 The scaffolds were loaded with a higher dose of PEG-LTGF-β than before (500 ng.ml-1 versus 50 
ng.ml-1, free equivalent). In accordance with the dose responses shown in Figure 4.4, the 
biological activity of the LTGF-β would have been only a fraction of that of the free growth factor, 
and as discussed in the section 4.5 Results and discussion 3: Biological activity of PEG-LTGF-
β, some loss of activity would have occurred post-conjugation.  
 A longer experimental timeframe was chosen (34 days versus 28 days). In the first experiment, 
PEG-HA hydrogels began to liquefy between weeks 3 and 4. During this period the hydrogels 
began to lose their integrity and became unable to support their own weight (Figure 4.19). It 
seemed possible that gel degradation should increase the availability of tethered PEG-LTGF-β, 
therefore the experiment was extended to include more time for gel breakdown to occur.  
 Finally, as a general procedural improvement bovine chondrocytes were freshly harvested and 
used 24 hours post-plating (i.e. 48 hours post-isolation, passage 0, versus passage 2, 48 hours 
post-thawing). It is well-known that chondrocytes quickly lose their rounded morphology and 
undergo phenotypic changes on two-dimensional TCP (244). Using the cells freshly and before 
spreading had occurred ought to promote more physiological behaviour.  
Similarly to the earlier findings, chondrocytes receiving free TGF-β proliferated over the first nine days of 
culture (alamarBlue® assay, Figure 4.20). Metabolic activity climbed to 65% over day 1 levels by day 9, 
then stabilised at 43-55% over day 1 levels from day 14 onwards. Activity in the ‘no TGF-β’ group was 
stable up to day 15, but dropped during the third week to a new plateau of around 53-65% of day 1 
values. Comparing this profile to the precipitous decline seen in the first experimental repeat 
(alamarBlue®, Figure 4.15) suggests that the use of freshly isolated chondrocytes led to a more vigorous 
culture. Beneficial paracrine signalling may also have been enhanced by the higher cell seeding density.  
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Figure 4.20: Viability of bovine chondrocytes in PEG-HA gels with and without TGF-β. (Top) Total 
metabolic activity (alamarBlue® assay) of bovine chondrocytes encapsulated in PEG-HA hydrogels over a 
5 week culture period. Effect of gel p < 0.001 (all intergroup comparisons p < 0.001). * ‘PEG-LTGF-β’ 
versus ‘no TGF-β’ p < 0.01; ** ‘PEG-LTGF-β’ versus ‘no TGF-β’ p < 0.001. (Bottom) Total LDH activity of 
chondrocytes cultured in hydrogels for 34 days, reflecting number of live cells. * p < 0.001 versus ‘no TGF-
β’, p < 0.01 versus ‘PEG-LTGF-β’. Mean ± SD, n = 8 (alamarBlue®), n = 7 (LDH).  
 
Interestingly, chondrocytes in ‘PEG-LTGF-β’ gels exhibited an apparently bimodal response in metabolic 
activity, which peaked at days 5-9, and again at day 27, and overall was significantly higher than in ‘no 
TGF-β’ gels (p < 0.001). One interpretation of this data is that chondrocytes responded to and possibly 
activated the LTGF-β present in their local environment during the first week and a half of culture. Once 
exhausted, a period of relative quiescence ensued until the gel began to break down. At this point more 
distant stores of LTGF-β were released, becoming newly available to the cells. Despite these effects, total 
LDH at day 34 – reflecting total cell number – was no different between ‘PEG-LTGF-β’ and ‘no TGF-β’ gels 
(Figure 4.20). On average over twice as many chondrocytes were ultimately present in the ‘free TGF-β’ 
group than in the other gels. This suggests that the putative period of TGF-β starvation during the late 
second and third weeks was decisive in determining final cell number.  
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4.6.3 High loading of PEG-LTGF-β led to altered matrix synthesis 
Matrix synthesis by encapsulated chondrocytes was next evaluated by histology. Collagen II was intra- 
and pericellularly distributed in all three groups at day seven, with very limited staining between cells 
(Figure 4.21). More protein was seen between cells at day 21, although staining was still more intense in 
the immediate vicinity of the cells. The pericellular staining was brightest in the ‘PEG-LTGF-β’ gels and 
least intense in the ‘no TGF-β’ group, suggesting highest and lowest production of collagen II, respectively. 
Interstitial collagen II was more homogeneously distributed in ‘free TGF-β’ gels than in the other groups, 
and by day 34 in this group, positively stained chondrocytes populated lacunae within a dense, uniform 
matrix of collagen II. The collagen II laid down by ‘no TGF-β’ chondrocytes was less abundant, largely 
confined to interstitial regions, and in general was no longer associated with the cells. The cells were 
surrounded by concentric zones empty of collagen II, suggesting that the cartilage matrix may have been 
displaced at later timepoints by more recently deposited material. The distribution of collagen II in ‘PEG-
LTGF-β’ gels was very similar to that of ‘no TGF-β’ gels, but apparently present in greater quantities (i.e. 
brighter fluorescence); this was later confirmed by conventional histology (vide infra).  
 
 
Figure 4.21: Collagen II staining of PEG-HA hydrogels with encapsulated chondrocytes [continued] 
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Collagen I was probed as an indicator of the hyaline versus fibrocartilagenous nature of the neocartilage 
matrix. Collagen I distribution at day 7 in all groups was similar to that of collagen II, being mostly present 
within chondrocytes and/or their immediate surroundings (Figure 4.22). ‘Free TGF-β’ and ‘PEG-LTGF-β’ 
gels, however, stained more brightly than ‘no TGF-β’ gels, which may reflect generally higher levels of 
protein synthesis, in association with their higher metabolic activity over the first ten days of the 
experiment (Figure 4.20). By day 34, however, very little collagen I was detected, and this was mostly 
confined to interstitial regions – suggesting that production of collagen I had ceased, and possibly that 
some of the protein deposited earlier had been remodelled. Overall, the presence of collagen I in the 
matrix suggests that the neomatrix may more closely resemble fibrocartilage than hyaline cartilage, 
although more in-depth biochemical analysis is needed to fully characterise the generated tissue.  
 
 
 
Figure 4.22: Collagen I staining of PEG-HA hydrogels with encapsulated chondrocytes cultured for 
up to 34 days. Collagen I = green, DAPI = blue; confocal microscopy; 20x magnification; scale = 100 µm.  
 
 
 
 
 
 
 
[Figure 4.21 continued] cultured for up to 34 days. Collagen II = green, DAPI = blue; confocal 
microscopy; 20x magnification; scale = 100 µm.  
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Collagen VI was also investigated as in normal cartilage it has a restricted and well-defined distribution, 
within the chondron. It is considered an essential component of the pericellular niche, and is quickly (2-3 
days) deposited by chondrocytes upon their introduction to a new environment – including TE scaffolds 
(245). Indeed by day 7, chondrocytes in all three groups had elaborated a collagen VI-rich pericellular 
matrix (Figure 4.23). By day 21 the protein had spread interstitially, which in human articular cartilage 
is generally considered a hallmark of osteoarthritic changes to the middle and deep zones (246)(247). On 
the other hand, the distribution of collagen VI in bovine articular cartilage undergoes age-related changes 
and in young animals it is widely present throughout the interstitial matrix of the superficial zone (245). 
The chondrocytes in the present study were derived from a young calf, which may account for the 
abundance of collagen VI in these TE constructs. Not until day 34 did clear differences emerge between 
the experimental groups. ‘Free TGF-β’ gels displayed a relatively uniform interstitial distribution of 
collagen VI throughout the gel, with higher pericellular concentrations as expected. The abundance of 
collagen VI may be related to the known stimulatory effect of TGF-β on its production (248). The 
appearance of ‘no TGF-β’ gels was highly abnormal, with concentrated foci of collagen VI displaying no 
obvious relationship to chondrocytes, and large (tens to hundreds of micrometers) regions devoid of 
collagen VI. This distribution recalled the appearance of the collagen II staining (Figure 4.21), again 
giving the appearance of having been displaced by more recently deposited material. ‘PEG-LTGF-β’ gels 
were similar in appearance to ‘no TGF-β’ gels, but showed less extensive interstitial accumulations, and 
overall greater co-localisation of collagen VI with cells.  
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Figure 4.23: Collagen VI staining of PEG-HA hydrogels with encapsulated chondrocytes cultured 
for up to 34 days. Collagen VI = green, DAPI = blue; 20x magnification; scale = 100 µm.  
 
Further histological and biochemical analyses were performed at the end of culture (day 34). 
Macroscopically, all gels were firm and semi-opaque, in contrast to the fragile state of ‘no TGF-β’ and 
‘PEG-LTGF-β’ gels at day 28 of the first experimental repeat (Figure 4.24 versus Figure 4.19). Again, the 
use of a high density of fresh, passage 0 chondrocytes appeared to have promoted a healthier culture.  
 
 
 
Figure 4.24: Macroscopic appearance of PEG-HA hydrogels after 34 days of culture. Base 
(membrane) diameter = 6 mm.  
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Conventional histology confirmed that the intense staining for collagen II in the day 34 ‘PEG-LTGF-β’ gel 
(Figure 4.21) genuinely reflected more abundant protein (Figure 4.25): both picrosirius red and 
haematoxylin & eosin highlighted more concentrated interstitial protein deposits than were seen in either 
of the other groups. Protein within the ‘free TGF-β’ gel was in general less concentrated but more evenly 
distributed than in the ‘PEG-LTGF-β’ gel. Both stains suggested increasing protein content in the order ‘no 
TGF-β’ < ‘free TGF-β’ ~ ‘PEG-LTGF-β’. Results from the Bradford assay for total protein confirmed these 
findings, as ‘PEG-LTGF-β’ gels were found to contain a similar amount of protein as ‘free TGF-β’ gels, and 
significantly (p < 0.01) more than the ‘no TGF-β’ group (Figure 4.26). Taken together, the results suggest 
that matrix deposition was favoured by loading the PEG-HA hydrogel scaffolds with high doses of 
tethered LTGF-β.  
 
Despite these promising findings, abnormal cell morphology was observed within day 34 ‘PEG-LTGF-β’ 
and ‘no TGF-β’ gel samples. These cells were irregularly shaped, some were elongated, and many 
displayed large protrusions – as opposed to the evenly rounded form of the ‘free TGF-β’ chondrocytes 
(Figure 4.27, Figure 4.25). Furthermore the neutral red counterstain to alcian blue revealed that the ‘no 
TGF-β’ and ‘PEG-LTGF-β’ chondrocytes were diffusely surrounded by a basophilic substance(s) which 
may represent either necrotic cell debris such as leached nucleic acids, or alternatively secretory 
products such as sulphated carbohydrates (Figure 4.25) (249). The positioning of this substance and of 
collagens II and VI (Figure 4.21, Figure 4.23, Figure 4.25) appear inverted with respect to the cells, 
again suggesting that the initial cartilage matrix produced in ‘no TGF-β’ and ‘PEG-LTGF-β’ gels was 
displaced by material deposited later on. Whatever the precise identity and origin of this substance, 
chondrocyte viability within all gels at this timepoint was excellent: numerous live chondrocytes and very 
few dead cells were visualised by LIVE/DEAD® reagent (Figure 4.27).  
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Figure 4.25: Histology of PEG-HA hydrogels with encapsulated chondrocytes cultured for 34 days 
(wax-embedded sections). Stains are as labelled; brightfield microscopy; 4x and 10x labels indicate 
magnification; ‘zoom’ shows close-ups of 4x images; scale = 500 µm for 4x magnification, 200 µm for 10x 
magnification, and 125 µm for zooms of 4x images.  
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Figure 4.26: Total protein in PEG-HA hydrogels after 34 days of culture. * p < 0.01 versus ‘no TGF-β’. 
Mean ± SD, n = 7.  
 
 
 
Figure 4.27: LIVE/DEAD® staining of bovine chondrocytes within PEG-HA hydrogels after 34 days 
of culture. Live cells appear green and dead cells red. Confocal microscopy; scale = 100 µm.  
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Overall, these results clearly demonstrate a biological effect of PEG-LTGF-β on chondrocyte response to 
encapsulation in PEG-HA hydrogels. Based on the collected data, this response may be interpreted as 
consisting of three phases:  
 An initial period of TGF-β responsiveness, lasting for approximately nine days. This period was 
associated with increased metabolic activity, and possibly with increased ECM protein synthesis 
(see e.g. collagen I staining at day 7, Figure 4.22).  
 A period of declining metabolic activity from around days 9-21, which may have set in as local 
stores of PEG-LTGF-β were exhausted. Despite this decline, day 21 chondrocytes stained more 
intensely for collagen II than either control group suggesting that matrix synthesis remained 
high.  
 A period of relative metabolic recovery (days 21-34), which may be related to greater mobility of 
tethered PEG-LTGF-β as the PEG-HA hydrogels began to break down. This recovery did not fully 
compensate for the cell death seen during the previous phase, as cell number at day 34 was 
similar to the ‘no TGF-β’ group. Some of the previously accumulated matrix was displaced by 
basophilic material during this phase, leaving collagens II and VI confined to interstitial regions. 
The hydrogels were populated by numerous live chondrocytes at day 34, and overall more 
protein had accumulated in this group than in ‘no TGF-β’ gels.1  
The data presented in this section therefore demonstrates that LTGF-β can be deployed in TE scaffolds to 
biological effect. The success of the PEG-LTGF-β chondrogenesis did not match that of the ‘free TGF-β’ 
group, but this was not expected given the stringency of this control (fresh free TGF-β provided 
continuously throughout the culture period), and any improvement over the negative control is to be 
taken as a success. Although the data is encouraging, a number of key question remain which should be a 
priority in future work, as detailed shortly.   
                                                                    
1 The apparent discrepancy between the results for day 34 LDH activity (‘PEG-LTGF-β’ ~ ‘no TGF-β’) and 
total protein (‘PEG-LTGF-β’ > ‘no TGF-β’) is resolved by the fact that the protein assay accounts for 
cumulative matrix production whereas LDH activity (with the protocol used here) derives only from cells 
which were alive at the final timepoint.  
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4.7 Summary and future directions  
4.7.1 Latent TGF-β offers several possible benefits for tissue engineering 
Returning to the potential benefits to TE of LTGF-β identified in the introduction to this chapter, the 
results presented herein serve to illuminate some of these points.  
 It was proposed that the in vitro handling and long-term conformational stability of TGF-β would 
be improved were the TGF-β to be used in its latent form, as this is how TGF-β is stored long-
term in ECM. Consistent with this was the observation that the concentration of free TGF-β on 
BSA-coated tissue culture plastic was depleted by around 25% after eight hours, and almost 40% 
by 48 hours, presumably due to adsorption to surfaces (Figure 4.3). Meanwhile the 
concentration of LTGF-β was essentially unchanged.  
 The HFF-1 Smad3 phosphorylation responses to a range of doses of free and latent TGF-β 
confirm the relative inactivity of LTGF-β (Figure 4.4).  This supports the proposition that high 
doses of LTGF-β could be loaded into scaffolds – to ensure that enough growth factor is present 
to support chondrogenesis for many days to weeks – while avoiding exposing cells to excessive 
amounts of active TGF-β.  
 It was suggested that stores of inactive LTGF-β loaded within scaffolds could gradually become 
liberated by the actions of cells. Evidence was sought for cell-mediated LTGF-β activation 
through protease- and integrin-dependent means by treatment with inhibiting compounds, but 
none of the treatments diminished the signalling response to LTGF-β (Figure 4.5, Figure 4.6). 
This may be due to the LTGF-β requiring longer periods of time, tethering to an immovable 
substrate, or particular environmental stimuli, to become active.  
 LTGF-β provides an opportunity to tether TGF-β within TE scaffolds without directly modifying 
the TGF-β itself, thereby preserving more of its biological activity. The PEGylation procedure 
used in this study somewhat diminished the potency of the LTGF-β (Figure 4.12, Figure 4.13), 
but nonetheless the TGF-β was able to diffuse out of hydrogels following dissociation from 
tethered LAP (Figure 4.11). This suggests that the TGF-β dimer can be held in place following 
indirect (to LAP) rather than direct (to itself) covalent modification.  
Taken together with the TE results reported in the previous section, these findings qualify this novel TE 
approach for further exploration. To confirm and more fully explore the potential advantages of LTGF-β, 
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several important channels of investigation should be pursued. These opportunities are elaborated in the 
next section under the topics of, respectively: biological effects of burst exposure to free and latent TGF-β; 
characterisation of LTGF-β activation by cells; LTGF-β conjugation strategy; and optimising chondrocyte 
response to LTGF-β for cartilage TE.  
4.7.2 Several key questions are a priority for future research 
Exposing cells to high concentrations of TGF-β is arguably best avoided due to the association of TGF-β 
dysregulation with several disease states including OA (234)(233). However, the diminished signalling 
response to latent as compared to free TGF-β (Figure 4.4), and the compounding effect of PEGylation on 
biological activity (Figure 4.12, Figure 4.13) were taken as justification for incorporating a high dose of 
PEG-LTGF-β (500 ng.ml-1 free equivalent) into TE scaffolds without undue concern over an aberrant 
cellular response. This was judged necessary as no improvement had been seen when 50 ng.ml-1 was used 
(free equivalent). One area for further investigation, then, is in the comparative responses by 
chondrocytes and/or other cell types to varying doses of free and latent TGF-β over longer timeframes 
(several days) in culture. The effects of exposure to high and low concentrations of either could easily be 
assessed in terms of proliferation (e.g. total DNA, LDH, alamarBlue®), ECM synthesis (e.g. hydroxyproline 
incorporation, total protein), and apoptosis (e.g. staining for Caspase, Blc-2, or Terminal deoxynucleotidyl 
transferase dUTP nick end labelling – TUNEL).  
 
As reported in the section 4.3.3 HFF-1 response to LTGF-β was not diminished by inhibition of 
protease activity, integrin binding, or contractility, attempts to inhibit the Smad3 phosphorylation 
response of HFF-1 and bovine chondrocytes were unsuccessful. Although not central to the study, it 
would be reassuring to demonstrate activation of the commercial SLC used in these studies. Time-
dependency of activation might be explored, for example. In the present project, preliminary experiments 
were attempted in which HFF-1 were exposed to free and latent TGF-β at 1 ng.ml-1 (or free equivalent) for 
up to 24 hours to determine whether the LTGF-β would become active over this period. Smad3 
phosphorylation was seen at all timepoints for cells receiving free TGF-β, but no activation was apparent 
in cells exposed to LTGF-β (data not shown). If further observations were to confirm these findings, then 
the possibility that tension-dependent activation is required could be explored (Figure 2.3). In vitro 
schemes to enable tension-dependent activation are easily envisaged, and would require fixation of the 
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LAP to a relatively immovable surface – for example a glass slide or tissue culture plastic, or even a stiff 
hydrogel (> 10 KPa) – in a manner that preserves the RGD site on LAP so that coupling to integrins can 
occur. Controls should include treatments to enhance or abolish contractility (e.g. ATP, blebbistatin, 
cytochalasin D, nocadozole). Beyond this, digestion of LTGF-β could be attempted with different proteases 
from Table 4.1 with varying concentrations and digest times, in an extension of the work described 
earlier (Figure 4.14). Liberation of free TGF-β could be measured by ELISA and confirmed with biological 
assays (because antibody binding sites could still be masked by bound fragments of LAP post-digestion). 
Such an approach was attempted in the current study using plasmin, but active TGF-β was not detected 
by the ELISA. Ultimately, however, proof of concept relies on detecting a positive effect in cartilage TE 
experiments. It may be that, under these conditions, only a small fraction of the LTGF-β need be activated 
at any one time in order to achieve a favourable final outcome. This suggestion is based on the fact that, as 
seen in Figure 4.4, a signalling response was elicited by just 0.01 ng.ml-1 free TGF-β. Hence, future efforts 
should be directed at optimising the conjugation strategy, hydrogel properties, and culture conditions for 
TE.  
 
The conjugation strategy described in this work, while effective, gave variable results from batch to batch 
(Figure 4.10) and did not allow for precise control over PEGylation sites and by extension the orientation 
of the tethered complex. As discussed in the section 4.4 Results and discussion 2: Conjugation of 
PEGDA to LTGF-β, it was hoped that an endogenous cysteine residue (Cys-33) within LTGF-β could be 
directly reacted with PEGDA, but the experimental findings were unpromising (Figure 4.10, Figure 
4.11). Strategies to access Cys-33 or to target other specific residues could potentially be beneficial both 
in terms of preserving the function of the TGF-β and larger complex, and presenting the LTGF-β within 
hydrogels in a defined orientation. Zisch and colleagues in the Hubbell group tackled a similar issue by 
introducing an extra cysteine residue at the C-terminus of a recombinant VEGF variant; the purified 
protein was then tethered within PEG-vinylsulphone hydrogels via Michael addition (236). Alternatively, 
this difficulty might be circumvented if the LLC were to be used in place of the SLC as per this study. 
LTBPs are immobilised within ECM via transglutaminase linkages as shown in Figure 4.2. As it happens, 
the transglutaminase action of factor XIIIa has been utilised by the same group to incorporate a mutant 
VEGF variant into fibrin hydrogels, suggesting that a similar approach with the LLC may be feasible (109). 
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Use of the LLC would also dispel concern over possible unphysiological processing and export of the 
isolated SLC (225).  
 
As the TE results stand, it is encouraging that the chondrocytes within PEG-LTGF-β hydrogels showed 
increased metabolic activity and protein deposition compared to ‘no TGF-β’ controls (Figure 4.20, Figure 
4.26). When fully optimised, this strategy may prove to be an efficient way of supporting cartilage 
formation, by using a single initial loading which only gradually becomes available to the cells. The total 
amount of TGF-β loaded into these scaffolds (25 ng per gel, free equivalent; 500 ng.ml-1 final 
concentration) was close to the amount of free TGF-β (20 ng per well) added to the ‘free TGF-β’ gels at 
every single medium change, of which there were eighteen. For comparison, in the study by Lee and 
colleagues described earlier (page 77) in which cartilage was generated over an entire articular condyle 
by recruiting host cells, a single loading of 10 ng.ml-1 free TGF-β was used prior to in vivo implantation. On 
the other hand, in recently published work from the Burdick group free TGF-β was released from 
nanofilm-coated alginate microspheres into HA hydrogels in a dose equivalent to 2 µg.ml-1 (100 ng per 50 
µl hydrogel) – four times higher than in the present work (223). When MSCs were encapsulated in the 
hydrogel, this led to the in vitro formation of neocartilage with similar Young’s modulus, and collagen, 
DNA and GAG content to hydrogels receiving TGF-β thrice weekly in the culture medium. When implanted 
subcutaneously in mice, TGF-β delivered via the microspheres supported convincing neocartilage 
formation, whereas very little matrix was produced when the TGF-β was simply blended with the HA 
before gel crosslinking. Considering the doses used in each, the gain from PEG-LTGF-β in the present 
work was less striking than in these two examples, therefore it seems there is room for optimisation of 
the LTGF-β approach if maximum benefit is to be attained.  
 
A role of scaffold degradation in modulating exposure of the chondrocytes to TGF-β was inferred from the 
temporal profile of chondrocyte metabolic activity in Figure 4.20, alongside observations over hydrogel 
degradation. This suggests that engineering continuous exposure to TGF-β by controlling scaffold 
degradation could offer one plausible route to optimising performance. Although HA is degradable by 
hyaluronidase enzymes, the PEG-HA hydrogel scaffolds degrade relatively slowly, beginning to liquefy 
between weeks 3 and 4 (Figure 4.19). In order to effect more precise control over this important 
property, Chung and co-workers have recently experimented with hydrolytically degradable 
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methacrylated caprolactone hyaluronic acid hydrogels for cartilage TE, finding that matrix synthesis and 
ultimate mechanical properties were superior in the hydrolytically degradable gels (250). Their system 
allows for tunable control over hydrogel degradation, suggesting one possible way to investigate the 
effect of degradation dynamics on chondrocyte response to PEG-LTGF-β. Another important factor to 
explore in future work is the conditioning of seeded hydrogels with cyclic mechanical loading. The 
potential benefits of this treatment are threefold: cyclic loading may enhance the stretch-induced 
activation of LTGF-β; published data suggests that it may act synergistically with TGF-β in stimulating 
matrix synthesis; and finally it has been reported to stimulate the expression of catabolic enzymes 
(229)(251)(252)(253). This treatment may therefore not only improve the sensitivity of chondrocytes to 
TGF-β, but also increase its activation by both proteolytic- and integrin-dependent mechanisms. Overall, 
the results presented in this chapter illustrate several potential benefits of LTGF-β for cartilage TE, and 
suggest several intriguing avenues for the further development of this concept.  
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4.8 Conclusions 
Latent TGF-β adsorbs to TCP less readily than free TGF-β and is relatively inactive, with a concentration 
threshold for Smad3 phosphorylation (in HFF-1) around a thousand times higher than free TGF-β. Cell-
mediated release of TGF-β via protease- and/or integrin-dependent mechanisms was not demonstrated 
but may be dependent on longer timeframes and/or optimised materials properties and culture 
conditions. PEG-LTGF-β enhanced proliferation and matrix synthesis by chondrocytes encapsulated in 
PEG-HA hydrogel scaffolds, and several means of optimising this novel TE system are immediately 
apparent. Ultimately LTGF-β may offer the advantages of improved stability over long culture periods, 
diminished cellular response to initial high growth factor concentrations, gradual release by cells, and 
indirect immobilisation in scaffolds, with preservation of TGF-β biological activity.  
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Chapter 5  
 
Conclusions 
 
5.1 Bioactive scaffolds and commercial tissue engineering  
As we have seen from the numerous examples throughout this thesis, TE has the potential to restore 
function in a wide range of medical conditions involving tissue loss or dysfunction. Tremendous progress 
has been made over the past decade towards not only generating functional tissue substitutes, but also 
doing so in a commercially viable manner. The stream of products currently proceeding through clinical 
trials, and the patients already benefiting from TE technology, are cause for celebration. Yet the TE 
literature details many innovative new scaffold materials that go beyond anything currently being used 
clinically. Here, biomimetic principles – with inspiration coming principally from natural ECM, tissue 
homeostasis, and development – are being used to inform the design of biologically instructive scaffolds. 
The promise is of a new generation of materials that can help to unlock and augment the body’s own 
capacity for repair.  
 
Materials can now be made to engage with cells in biologically-meaningful ways, for example by 
proliferating or differentiating in response to cues encoded in the physical and chemical fabric of the 
scaffold. It is now possible for completely synthetic materials to participate in processes akin to natural 
tissue remodelling: PEG hydrogels crosslinked with synthetic peptides containing protease-digestible 
sites can be degraded by cellular enzymes (18); the inclusion of integrin-binding (or other cell surface 
receptors) peptides to such materials enables cell attachment, which may generate survival signals as 
well as tractional forces for migration (35). A simple RGD-modified alginate hydrogel was seen in one 
study to facilitate the organisation of co-transplanted osteoblasts and chondrocytes into growth plate-like 
structures (Figure 2.2) (72). In another exciting example, spinal cord regeneration was facilitated by a 
hydrogel presenting an epitope from laminin (IKVAV), a prominent glycoprotein involved in axon 
guidance as well as being found in basement membranes throughout the body (42). Furthermore it 
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appears that a few key ECM biomolecules can be adaptable to many TE contexts, as demonstrated by the 
Extracel system from Glycosan (63). The recognition of the importance of physical factors such as 
topography, strain, pressure, and matrix stiffness has also opened new avenues for eliciting desirable 
responses from cells.  
 
The simplification of ECM and biomolecular information is being taken to extremes in some groups, with 
growth factor activity, certain functions of glycosaminoglycans (such as growth factor binding and 
modulation of activity), and cell-cell adhesions being recreated in some way via purely synthetic 
approaches (126)(254). Even basic chemical considerations such as hydrophilicity, or simple chemical 
functional groups can significantly affect the adsorption and conformation of proteins, or influence stem 
cell differentiation by as yet poorly understood means (145)(67). This approach has been taken to the 
extreme in studies which have systematically explored cellular responses to literally hundreds or even 
thousands of synthetic polymers at once, with the aim of identifying those that strongly favour particular 
behaviours (148).  
 
Even certain ions can strongly influence cell activity. Chapter 3 described the evaluation of strontium- and 
zinc-alginate hydrogels for bone tissue engineering applications. Strontium was selected because it can 
promote bone formation by osteoblasts while inhibiting resorption by osteoclasts – leading to decreased 
fracture risk in osteoporotic patients (186)(187). Zinc acts as a cofactor for alkaline phosphatase, an 
enzyme important (although mysteriously so) for bone mineralisation (188). Initially, stiffness, swelling 
and degradation, and ion release were compared between calcium- and strontium-alginate gels. Calcium- 
and strontium-alginate had similar initial stiffness (170 ± 7 KPa for 2G.Ca versus 186 ± 7 KPa for 2G.Sr; 
gel codes are given in Table 3.1) indicating that the degree of crosslinking was unchanged between 
conditions. In stark contrast, 3G.Sr gels had a lifespan almost fifteen times longer than that of 3G.Ca gels: 
3G.Ca gels persisted for just 4 ± 0 days in PBS before beginning to lose mass, whereas the lifespan of the 
corresponding strontium gel was 58 ± 5 days. This was expected given that published work describes 
strontium as having a higher affinity for alginate with a high proportion of G residues than calcium (40). 
Although the lifespan of strontium gels could be reduced to 4 ± 1 days by using 1 % w/v gels instead of 
3% w/v, further flexibility came in the form of an interaction between the crosslinking ion and the 
alginate type. Although G blocks are selective for strontium over calcium, this relationship does not 
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extend to M blocks (40). Thus, switching AlgG for AlgM virtually abolished the enhancement in gel 
stability seen with strontium substitution (3M.Sr lifespan 15 ± 1 days). This interaction is of considerable 
practical utility as it means that the biological and materials effects of the crosslinking ions can be 
decoupled. Specifically, the desirable effects of strontium can be exploited in applications requiring both 
high and low gel stabilities by using high G or high M alginate, respectively. A final finding from the gel 
characterisation phase was that strontium release from the gels appeared to be of a physiologically 
relevant magnitude (although the release estimates cannot directly predict release in in vitro cell culture 
or in vivo). Strontium was released from AlgM gels at a higher rate than from AlgG, which correlated with 
the faster degradation of these gels.  
 
Three-dimensional culture of Saos-2 cells within RGD-containing AlgG and AlgM gels demonstrated that 
the persistence of the AlgG strontium-containing gels impeded proliferation, as revealed by slight 
decreases in LDH activity to day 7 and confirmed by alamarBlue® data. Proliferation within strontium-
containing gels was rescued by using AlgM, which supported Saos-2 proliferation from the earliest 
timepoints, and viability was sustained for the full three weeks of the study. qPCR on cells cultured within 
AlgM gels revealed upregulation of the osteoblast marker genes COL1A1 (collagen I), BSP (bone 
sialoprotein) and RUNX2 (the transcription factor) at day 21. Although these genes were more highly 
expressed than on TCP, there were no significant differences between groups. ALP activity at days 7 and 
21, however, was highest in Sr100 gels (p < 0.05 compared to all other gel groups). Although inconclusive 
(especially with respect to the qPCR data), overall these results seem promising and demonstrate the 
potential of alginate hydrogels – and perhaps of other polysaccharides such as pectin, which have 
different selectivities for cations – to provide slow release reservoirs for bioactive ions including calcium, 
strontium, zinc, and cobalt (40). Furthermore this strategy is technically simple and inexpensive, and is 
amenable to being combined with existing strategies for bone TE – such as blending with collagen I or 
ceramics, which in themselves may be engineered to have favourable ion release profiles (187)(190).  
 
Another major theme of this thesis has been the controlled release of growth factors within scaffolds. 
These potent molecules operate key roles during development, wound healing, and normal tissue 
homeostasis. Thus they have become standard tools in differentiation protocols for adult and embryonic 
stem cells, and a huge volume of literature documents their use in TE to improve cell survival, 
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proliferation, differentiation, matrix production, and homing. The soaring commercial success of 
Medtronic’s INFUSE® demonstrates the potential impact of these schemes (12). However, due to this 
same potency, they must be used with care. Convincing evidence suggests that the manner of growth 
factor delivery can have a decisive influence on TE success. This is well illustrated by two examples 
pertaining to angiogenesis. Here, stable blood vessels formed in response to, in one case, a recombinant 
VEGF variant which could be immobilised into fibrin hydrogels and released by cellular proteolytic 
activity; and secondly by dual delivery of VEGF and PDGF-BB from alginate hydrogels 
(232)(122)(236)(123). In the latter study sequential release was achieved, apparently due to different 
passive affinities of the two growth factors for alginate.  
 
Other documented strategies for growth factor release include the tailoring of polymer diffusional 
properties and degradation kinetics, release from polymer microspheres, the inclusion of 
glycosaminoglycans such as heparin (or synthetic mimetics thereof, as described in the Chapter 2 section 
‘simplifying biomolecules’) and tethering of the protein, perhaps via a spacer arm such as PEG 
(100)(106)(108)(114)(236). The experiments reported in Chapter 4 made use of a covalent conjugation 
strategy (PEGylation) as part of the evaluation of a novel approach to TGF-β presentation and release. In 
this work, TGF-β was loaded into hydrogel scaffolds as part of the SLC, which consists of the TGF-β dimer 
wrapped in its own pro-peptide, the LAP (91). One advantage of this approach is the superior stability of 
latent TGF-β compared to free TGF-β. In a simple experiment to assess the tendencies of each to adsorb to 
TCP, the concentration of LTGF-β was unchanged from starting levels after 48 hours incubation, whereas 
the concentration of free TGF-β fell by 39%. Another possible benefit is that high doses can be loaded into 
scaffolds, becoming available to the cells only gradually via active processes. Advanced growth factor 
presentation and release strategies often lead to better TE outcomes: for example, blood vessels formed 
in response to the controlled release of VEGF in a chick chorioallantoic membrane model of angiogenesis 
were of higher quality than the malformed and leaky blood vessels formed in response to burst release of 
VEGF (236). As described on page 134, the controlled release of free TGF-β from coated alginate 
microspheres vastly improved the quality of neocartilage compared to simple mixing with the hydrogel 
polymer (223). To confirm the relative inactivity of the LTGF-β, a dose response evaluation was 
performed using human fibroblasts (HFF-1). The cells’ response to TGF-β was evaluated by 
immunostaining for the phosphorylated form of Smad3, which becomes active downstream of TGF-β 
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binding to its receptor. Evidence of a signalling response was found at concentrations of 0.01 ng.ml-1 with 
free TGF-β, but only 10 ng.ml-1 with LTGF-β, confirming the relative inactivity of the latent protein and 
dispelling concern over exposing cells to high concentrations of growth factor during encapsulation and 
the early stages of culture. It was also of interest to investigate whether the response seen with 10 ng.ml-1 
LTGF-β derived from LTGF-β activation by cells. Attempts to perturb proteolytic and 
integrin/contractility-dependent activation pathways led to no discernible effect on the HFF-1 response – 
a finding that was confirmed (for inhibition of proteases) with bovine chondrocytes, leading to the 
conclusion that the observed responses did not stem from active release mechanisms. However, it was 
possible that the TGF-β would become active over longer timeframes (days to weeks), under different 
culture conditions, or by different cell types.  
 
To assess LTGF-β for cartilage TE, bovine chondrocytes were seeded into PEGDA-HA hydrogels with 
tethered LTGF-β. Thiolated HA (Glycosil™) was crosslinked by PEGDA to form the hydrogels, but could 
also react with monoacrylates left over after protein modification with PEGDA. LTGF-β was PEGylated in 
a reaction optimised using the model proteins bovine serum albumin, lysozyme, and cytochrome C. A one 
pot reaction between the protein of interest, PEGDA, and Traut’s reagent was used, leading to Mw 
increases observable by SDS-PAGE. Timed release of growth factor from PEG gels demonstrated that 88% 
of PEG-LTGF-β was retained within the gel over 24 hours, but that 58% of this TGF-β diffused out of the 
gel upon treatment with acid (which disrupts the association with LAP). Thus, the use of LTGF-β may 
allow conjugation via the LAP rather than the growth factor itself, which diminishes biological activity 
(108). To investigate the biological action of PEG-LTGF-β, phosphoSmad3 immunostaining and Western 
blotting was carried out on HFF-1 stimulated with unmodified and PEGylated LTGF-β. The PEG-LTGF-β 
was demonstrated to retain its biological activity, but some loss of activity had occurred, and the extent of 
loss of activity was batch-specific. Bovine chondrocytes encapsulated in PEG-HA hydrogels with 50   
ng.ml-1 (free equivalent) tethered PEG-LTGF-β showed no increase in metabolic activity or matrix 
deposition over control hydrogels containing no TGF-β. When a higher dose (500 ng.ml-1 free equivalent) 
was loaded, benefits in metabolic activity and ECM synthesis were seen over an almost five week period. 
Specifically, alamarBlue° activity showed two peaks in comparison to the negative control group, around 
days 5-10 and during the late fourth to early fifth week of culture. These peaks in activity may correspond 
to, initially, an effect of PEG-LTGF-β in the local cell environment, and subsequently, an effect caused by 
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the liberation of stored PEG-LTGF-β during gel breakdown. Total LDH at 34 days was no different to that 
of the negative control group, but total protein was similar to the positive control group (free TGF-β 
delivered continuously over the entire culture period). This was confirmed histologically, although the 
distribution of ECM protein differed between groups: whereas treatment with free TGF-β led to a 
homogeneously distributed collagenous matrix, PEG-LTGF-β gels showed intensely stained accumulations 
of protein. In the future it will be important to optimise the hydrogel culture conditions in order to fully 
realise the potential benefits of this novel TE approach. Overall, the innovations described in this thesis 
correspond to current TE trends, which seek to use biomimetic principles to evoke regenerative 
responses from transplanted or host cells, but to do so using technically and commercially feasible means. 
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Appendices to Chapter 3 
I. Validation of LDH sample preparation 
Due to the high stability of AlgG strontium gels (Figure 3.7), conventional methods of dissolving alginate 
gels, to enable biochemical analysis, were not effective on these formulations. For example, the strontium 
gels were resistant to incubation with sodium citrate, EDTA, and high phosphate buffers. Mechanical 
disruption in a bead mill homogeniser (QIAGEN TissueLyser II) followed by treatment with Triton X-1000 
was more effective at breaking down gels than purely chemical means. However, such harsh treatment 
may expose proteins to shear forces with possible deleterious effects on protein conformation. 
Additionally, because gel consistency varied considerably between different groups and timepoints, 
systematic errors seemed possible. LDH standard curves were therefore constructed with known cell 
numbers in gelled or ungelled (by calcium) alginate, homogenised for 15 minutes at 30 Hz (Figure A.I).  
 
Figure A.I: LDH standard curve results for Saos-2 homogenised in alginate solution and gels.  
 
Two important findings arose:  
 A linear relationship between cell number and absorbance was maintained (R2 for crosslinked 
alginate 0.95, ungelled alginate 0.88), indicating that the method can reliably be used to estimate 
cell number.  
 The consistency of the gel (here taken to the extreme with gelled versus ungelled alginate) did 
not seem to influence the result: the gradients of the curves were 0.0005 in both cases, and 
closely matched to the eye.  
These findings were taken as validation of the sample preparation method.   
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II. RNA extraction troubleshoot 
Prior to the qPCR experiment described in the main chapter, investigations were made into RNA 
extraction techniques from alginate hydrogels to ensure that good quality RNA was available for this 
work. RNA quantity and quality was assessed by taking UV absorbance spectra on a Nanodrop 1000. Pure 
RNA has an absorbance maximum at 260 nm and a 260/280 nm ratio of ~2.0, and the 260/230 nm ratio 
should additionally be around 2 (255). Figure A.II shows examples of high and low quality RNA 
preparations, and Table A.I lists some common contaminating compounds and their effects on RNA 
absorbance spectra and ratios.  
 
   
 
Figure A.II: UV absorbance spectra of (left) pure RNA and (right) a contaminated preparation. The 
pure sample has a 260/280 ratio of 2.02 and a 260/230 ratio of 2.06, and the contaminated sample has 
260/280 and 260/230 ratios of 2.02 and 0.27 respectively. Note the absorbance maxima at 260 nm 
(vertical lines). Screenshots are from NanoDrop software.  
 
Compound Characteristic absorbance Effect(s) on spectrum 
DNA 280 nm 260/280 ratio < 2.0 (~1.8 for pure DNA) 
Protein 280 nm (tryptophan, tyrosine) 
220 nm (peptide bond) 
Low 260/280 ratio 
Low 260/230 ratio 
Trizol reagent, phenol 270 nm 
224 nm 
Overestimation of RNA quantity 
Absorbance maximum shifted towards 270, 
minimum shifted to 240 nm 
Guanidine salts 230 nm Low 260/230 ratio 
Table A.I: List of common contaminating compounds in RNA preparations and their characteristic 
absorbances. Guanidine salts are common in RNA isolation buffers, for example guianidine thiocyanate 
(absorbance at ~260 nm) is a component of the RNeasy buffers RLT and RW1. (255) 
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For these investigations, 200 µl 2% w/v AlgG gels containing, typically, 2 million Saos-2 cells.ml-1 were 
swollen for 1 hour or overnight before RNA extraction was attempted. Initial isolation attempts generally 
resulted in poor RNA yield (< 20 ng.µl-1) and very low 260/230 ratios (< 1). Various troubleshooting steps 
were performed, the results of which are described below and summarised in Table A.II along with 
briefly described methods.  
 
Initially, a conventional method for dissolving alginate gels was attempted, followed by RNeasy extraction 
on the pelleted cells. Although this method worked well for the calcium gels, the higher stability of the 
strontium gels meant that cell recovery, and consequently RNA yield, was low (Method 1, Table A.IIa). 
Proper homogenisation is a critical step in isolating RNA from tissues, so from this point onwards the gels 
were disrupted in a bead-mill homogeniser (TissueLyser II, QIAGEN), and several means of improving gel 
breakdown were tested (Methods 2-4, Table A.IIa). Although 10-15 minutes in the TissueLyser 
ultimately proved effective at homogenising gels, the RNA at this stage was generally of low abundance 
and quality (consistently, contamination was detected at 230 nm). It was also confirmed that similar 
problems were found with photopolymerised PEG hydrogels (PEG molecular weights 4000 and 700; 
Methods 5-6, Table A.IIa), although in one instance more promising samples were collected (discussed 
below).  
 
Next, possible ways of removing contamination were pursued. Homogenised gels were centrifuged to 
precipitate insoluble matter including particles of gel, and various means of removing contaminants were 
tested (Methods 7-9, Table A.IIb). It was noted at this stage that the extractions from strontium gels 
generally produced higher quality samples than calcium gels. It seemed likely that this was related to the 
higher stability of strontium binding to alginate (Figure 3.7, Figure 3.2), as crosslinked gel particles 
sedimented better during centrifugation leading to more complete removal of the alginate. Further 
evidence in favour of this notion was the observation that the low molecular weight PEG gels (PEG700), 
produced more compact, firmer pellets than the PEG4K gels (Method 5, Table A.IIa), and also better RNA. 
Attempts were therefore made to remove alginate from the lysate by adding strontium to aggregate the 
polymer (Methods 10-11, Table A.IIb) – but to no avail.  
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With these findings in mind, the homogenisation was next performed in Trizol reagent. Both alginate and 
PEG gels were less soluble in Trizol than in RLT buffer, and sometimes required longer homogenisation 
times, but the corollary of this was that centrifugation was more effective at removing gel debris. RNA 
isolated from PEG gels using the standard Trizol procedure had low 260/280 and 260/230 ratios, and 
apparently was not abundant enough to suffer some inevitable loss during the RNeasy cleanup procedure 
(Methods 12-13, Table A.IIIc). However, when combined with on-column RNeasy purification the 
purification from both ungelled alginate and strontium-alginate gels appeared satisfactory. Method 14 
was ultimately used in the qPCR experiment described in Chapter 3.  
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III. qPCR primer validation 
Quantitect (QIAGEN) exon spanning primers were purchased for the human genes GAPDH, COL1A1, BSP, 
and RUNX2. Standard curves were performed on these primer sets using 10x serial dilutions of cDNA 
from the cell type of interest (Saos-2), followed by agarose gel electrophoresis on the reaction products. 
All primers had efficiencies close to 1, indicating almost perfect doubling of DNA with each cycle (Table 
A.III). Melt curve analysis showed a single peak in all cases, and electrophoresis revealed a single reaction 
product. Representative examples are shown in Figure A.III (for BSP).  
 
Gene 
Working 
range (Ct) 
Working 
range 
(dilution) 
Efficiency R2 
GAPDH Up to 25-30 10 – 106 1.04 > 0.99 
COL1A1 Up to 25-30 10 – 104 1.09 > 0.99 
BSP Up to 30-35 10 – 105 1.01 > 0.99 
RUNX2 Up to 30-35 10 – 104 0.99 > 0.99 
 
Table A.III: Standard curve results for qPCR primers. Working range and dilution indicate the Ct and 
dilution ranges over which the indicated efficiency and R2 values were generated.  
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Figure A.III: Primer validation for BSP. (Top) Raw (cycling) fluorescence for serial dilutions of cDNA, 
showing intervals of ~ 3.3 Cts between 10x dilutions. (Middle) Melt curve analysis of samples, showing a 
single peak (amplicon). (Bottom) Agarose gel electrophoresis of reaction products, showing a single 
specific band (amplicon). NTC = no template control (water), No RT = no reverse transcriptase control; 
numbers indicate ten fold dilutions of cDNA.   
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IV. Pilot experiments in cell viability  
Prior to the viability studies reported in the main chapter (Figure 3.10, Figure 3.11, Figure 3.12), pilot 
experiments were conducted in order to assess and optimise Saos-2 viability within alginate gels. Saos-2 
were encapsulated at a density of 2.5 x 106 cells.ml-1 in 2% and 3% w/v AlgG hydrogels, using Ca100, Sr20 
and Sr100 crosslinking solutions (Table 3.2). AlgG was supplemented where indicated with a commercial 
GRGDS-coupled alginate (NOVATECH-RGD; Novamatrix, Commonwealth Biotechnologies, Inc.) to a final 
RGD concentration of 150 µM RGD (72). All other reagents and the encapsulation procedure were as 
described in the main chapter. Gels were cultured for one and five days. On the day of analysis, gels were 
sliced thinly, and stained with LIVE/DEAD® reagent and imaged as described. Five random fields per gel 
were photographed after determining exposure times using a negative control (Triton-X treated cells). 
Live and dead cells were counted using ImageJ software (NIH), after manual thresholding. The particle 
size range was set based on the ability to detect only those cells in the plane of focus while excluding 
smaller or larger objects such as distant or out of focus cells.  
 
Saos-2 seeded in unmodified AlgG displayed excellent (88 ± 3% to 95 ± 3%) viability at day 1 (Figure A.IV). 
This was followed by a large decline to day 5 (p < 0.001), at which point viability was estimated at around 
29 ± 3% to 54 ± 12%, with no significant differences between groups. The lesser stability of the Ca100 
gels (Figure 3.7) led to sample breakage and probably an underestimate of cell number compared to the 
Sr20 and Sr100 formulations, so the data on number of cells per field are not to be interpreted too 
literally. However the qualitative finding of drastically reduced cell numbers corroborates the viability 
data and is likely to reflect a genuine trend (Figure A.IV). No significant differences in viability between 
2% and 3% w/v gels were detected. 2% w/v gels were chosen for the following experiments as this is 
close to standard concentrations used in the literature and the lower concentration may permit freer 
metabolite transport (72)(256)(168).  
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Figure A.IV: Viability and numbers of Saos-2 in alginate gels at days 1 and 5 of culture, as 
determined by quantification of LIVE/DEAD® stained cells. 2% and 3% w/v unmodified AlgG gels. 
(Top) Percentage live cells within gels. Effect of day 1 versus day 5 p < 0.001. (Bottom) Total number of 
cells per image. Mean ± SD, n = 6. 5 random fields were analysed per gel.  
 
NOVATECH-RGD alginate was included in the next experiment with the aim of improving survival by 
providing integrin attachment sites (72). In addition, the ImageJ particle parameters were set more 
rigorously than before to ensure exclusion of particulate debris – hence, lower cell numbers were 
recorded. Therefore the two data sets cannot be directly compared, particularly with respect to the 
estimated cell numbers per field. Despite this, some helpful and sound observations can be made, based 
on differences between days 1 and 5 within each experiment.  
 
The drastic decline in cell viability and cell number seen between days 1 and 5 in the original study was 
not replicated. Day 1 viability in this study was estimated at 76 ± 5% to 80 ± 4%, and viability at day 5 
remained relatively robust over approximately a 10 percent range, from 64 ± 7% to 73 ± 7% (Figure 
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A.V). This supported the hypothesis that the inclusion of RGD peptide would sustain higher cell viability 
than unmodified AlgG, in accordance with the findings of others (72). Cell number again declined to day 5, 
but less catastrophically than before. Therefore an in-house RGD-coupled alginate was used for all 
subsequent experiments.  
 
 
 
Figure A.V: Viability and numbers of Saos-2 in alginate gels at days 1 and 5 of culture, as 
determined by quantification of LIVE/DEAD® stained cells. 2% w/v AlgG + NOVATECH-RGD gels. 
(Top) Percentage live cells within gels. Effect of day 1 versus day 5 p < 0.001. (Bottom) Total number of 
cells per image. Five random fields were analysed per gel. Mean ± SD, n = 6.  
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Figure 1.1: TE approaches. In traditional TE, cellularised scaffolds are given time to mature in vitro 
before being introduced into the patient, while for in vivo TE, the scaffold is implanted directly into the 
patient, with or without cells. These approaches are currently being applied in therapy for a range of 
tissues and organs, including those indicated (not an exhaustive list). 
Figure 1.2: Tissue engineering timeline. TE gained in profile through the nineties, hitting a peak 
around the turn of the millennium, but several early commercial ventures failed and large-scale private 
financing was withdrawn. Improved business planning and a sounder scientific base have since propelled 
TE towards a new era of success (7)(13)(15)(12)(16). 
Figure 2.1: TE scaffolds, and hydrogel crosslinking. (Top) Hydrogel, fibrous and porous scaffolds are 
used in TE. Custom morphologies can be created using SFF techniques. (Bottom) Permanent, covalent 
links between polymer chains can be created by UV irradiation or through the use of reactive groups, with 
or without initiators, creating ‘chemical’ gels (bottom left). Physical crosslinks are reversible bonds based 
on a variety of non-covalent interactions, and this approach can be extended through the use of biological 
agents such as complementary oligonucleotides and oppositely charged peptides. Custom and porous 
scaffold images are from (31) and (48), respectively. 
Figure 2.2: Cell adhesive hydrogels. Formation of growth-plate-like structures in RGD-modified 
alginate hydrogels with co-transplanted osteoblasts and chondrocytes, showing cartilage (left), transition 
(middle), and bone and marrow space (right) regions. Magnification x200. From ref (72). 
Figure 2.3: Force-dependent activation of TGF-β. (Left) TGF-β is sequestered in the ECM within a pro-
peptide (black) containing an RGD sequence, to which cell surface integrins can bind. (Middle) 
Contraction of the actin cytoskeleton against a stiff (> 10 kPa) substrate can cause the propeptide to 
undergo a conformational change, resulting in TGF-β release. (Right) On a soft (< 5 kPa) substrate, 
cytoskeletal contraction results in deformation of the matrix rather than the pro-peptide, and the TGF-β is 
not relinquished. Modified from ref (91). TGF-β latency and activation is discussed in detail in Chapter 4. 
Figure 2.4: Presentation and release of growth factors from TE scaffolds. Anticlockwise, from top: 
growth factors within TE scaffolds may be loaded into polymers whose rate of degradation or diffusive 
properties can be modulated to tailor release rate, and which may be combined into systems releasing 
multiple factors with distinct kinetics (99)(100). The exposure of cells to different growth factors with 
time may therefore imitate developmental pathways and healing responses. An alternative to presenting 
growth factors in soluble form is to bind them to a surface in either random or specific orientations, with 
the possible use of a spacer molecule (106)(107)(108). Non-covalent associations with matrix 
178 
 
components, particularly glycosaminoglycans (GAGs), can effect slow release and in some cases may 
potentiate binding to membrane receptors (114)(115). Cell demanded release is based on the presence of 
protease-sensitive peptide sequences within the growth factor protein (116)(109). 
Figure 2.5: Vascularisation of tissue engineering scaffolds. Centre/bottom: new blood vessels form 
initially by endothelial cell organisation into tubes, which are later stabilised by smooth muscle cells and 
pericytes. From left: many attempts to induce this process within TE scaffolds have involved the use of 
vascular endothelial growth factor (VEGF). A low level of sustained release is demanded as burst release 
results in the formation of unstable, leaky vessels (120). Subsequent release of platelet-derived growth 
factor-BB (PDGF-BB) helps to recruit smooth muscle cells, which favours vessel maturation (123). 
Materials strategies for releasing growth factors are indicated in Figure 3. Gene transfer has been used to 
generate populations of cells that constitutively express either VEGF, or a stabilised variant of hypoxia-
inducible factor 1α (HIF-1α). In the latter case, the protein translocates to the nucleus where it initiates a 
hypoxic response involving the activation of a host of genes and upregulation of angiogenic growth 
factors (124). Co-culture of different cell types leads to paracrine and membrane interactions that can 
enhance angiogenesis. Endothelial cells (EC) and pericytes in co-culture increase the production of tissue 
inhibitor of metalloprotease (TIMP) -2 (EC) and -3 (pericytes), which inhibits tube regression (119). 
Figure 2.6: Synthetic mimics of biological structures. Many characteristics of ECM macromolecules 
have been reproduced in simpler compounds with biologically inspired structures. (a) Certain protein 
functions, including integrin binding for cell attachment and protease degradability, can be isolated to 
short amino‑acid sequences. These sequences can be combined with synthetic polymers or incorporated 
into complex peptides to enable cells to attach to or break down the material, respectively 
(43)(68)(69)(154)(81)(82). (b) Some glycoproteins involved in bone mineralization, such as bone 
sialoprotein, possess runs of negatively charged amino acids. Peptides that incorporate these sequences, 
and synthetic polymers with negatively charged chemical groups, can display improved 
mineral‑nucleating activity (149)(149)(150)(155)(156). (c) Growth factor action has been demonstrated 
in peptides possessing receptor‑binding domains; heparin binding sequences may also be included to aid 
growth factor sequestration (125)(126). Random peptide libraries have allowed the identification of 
peptides with affinity to particular receptors, and dimerization of these molecules in some cases can 
improve receptor binding and physiological response (128). Growth factor action is sometimes 
potentiated through the actions of glycosaminoglycans (GAGs) such as the binding of heparan sulphate to 
the FGF‑1/FGF receptor 2 complex. This specific interaction can be achieved using short heparin 
oligosaccharides (137). (d) Furthermore, the protein‑binding function of ECM GAGs such as chondroitin 
sulphate can be mimicked by grouping sulphated oligosaccharides by polymerization, by sulphating 
natural carbohydrates such as dextran, or by sulphonating synthetic polymers 
(111)(133)(134)(135)(136)(157). 
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Figure 3.1: Alginate structure and gelation. (Left) Alginate monomers showing (1,4)-linkages, and 
polysaccharide fragment (159). G = α-L-guluronate, M = β-D-mannuronate. (Right) Idealised schematic of 
calcium binding to alginate in egg-box dimers and intra-cluster associated multimers. Zigzag lines 
represent G blocks, wavy lines represent M and MG blocks, and circles represent calcium (or other 
divalent /multiva multivalent) ions. Note that in the dimer structure, the ratio of calcium to G residues 
(and hence COOH groups) is 0.25, whereas in the multimer it is 0.5.  
Figure 3.2 Correlation between affinity for 92% G and 92% M alginates and ionic radii of some 
metal ions. Note that 92% G alginate is mostly composed of G blocks and the 92% M of mostly M blocks. 
Affinity data is from ref. (40), and ionic radii are from ref. (185). 
Figure 3.3: Experimental concept. Alginate solution is crosslinked into a hydrogel by calcium, 
strontium, and zinc ions. The ions are gradually released as the gel degrades, leading to sustained 
biological action on encapsulated or nearby cells. 
Figure 3.4: Representative stress-strain plot for alginate gels over first 1 mm (~10%) strain. 3G.Ca 
gel shown. Modulus = 345 KPa, R2 = 0.9999. 
Figure 3.5: Modulus (E) of alginate hydrogels crosslinked with calcium and strontium over first 1 
mm of compressive deformation (~10% strain). Effect of alginate type P < 0.001; Effect of crosslinking 
ion P = 0.044. Mean ± SD, n ≥ 5. 
Figure 3.6: Weight profiles of alginate gels swollen in PBS. a) Calcium-alginate gels, b) Strontium-
alginate gels. Note that time is plotted on a log axis. Mean ± SEM, n = 6. 
Figure 3.7: Gel lifespan (day of peak swelling) for alginate gels of different compositions. Effect of 
alginate type P < 0.001; effect of crosslinking ion P < 0.001; interaction between ion and alginate type P < 
0.001. Mean ± SD, n = 6. 
Figure 3.8: Cumulative strontium release from alginate gels as measured by ICP. Crosses indicate 
the day of maximum swelling, i.e. the onset of gel degradation. 
Figure 3.9: Toxicity of potential crosslinking solutions. Relative total metabolic activity (alamarBlue® 
fluorescence) of Saos-2 cells 24 hours after 30 minute exposure to potential crosslinking solutions. Total 
molarity of crosslinking solutions including ZnCl2 = 100 mM. Effect of zinc p < 0.001. * 1 mM ZnCl2 versus 
no zinc p < 0.001. Mean ± SD, n = 6. 
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Figure 3.10: LDH activity of Saos-2 cells encapsulated in 2% w/v RGD-alginate gels and grown on 
TCP, relative to day 0 gels. Results for AlgG gels, AlgM gels, and TCP are displayed separately for clarity. 
Effect of crosslinking ion p < 0.001; * strontium-containing gels vs non strontium-containing gels at day 7 
p < 0.001. Effect of crosslinking ion p = 0.082. Effect of alginate type at all time points p < 0.001. Mean ± 
SD, n = 6. 
Figure 3.11: AlamarBlue® reduction by Saos-2 cells, encapsulated in 2% w/v RGD-alginate gels 
and grown on TCP, relative to day 1 TCP (background subtracted). Results for AlgG gels, AlgM gels, 
and TCP are displayed separately for clarity. Effect of alginate type at 1 day N.S. (p = 0.864) and 7 days p < 
0.001. For AlgG gels at day 7, effect of Sr versus no Sr p < 0.01 and effect of ion p < 0.05. * Sr versus Ca and 
Zn gels at day 7 p < 0.05. For AlgM gels at day 7, effect of Sr versus no Sr N.S. (p = 0.526) and effect of ion 
N.S. (p = 0.129).Mean ± SD, n = 6. 
Figure 3.12: LIVE/DEAD® images of clusters of Saos-2 cells within 2% w/v AlgM RGD-alginate gels 
after 21 days of culture. Live cells appear green and dead cells red. Arrows indicate isolated dead cells, 
and arrowheads point to clusters of live cells. Fluorescent microscopy; 40x magnification; scale = 200 µm. 
Figure 3.13: Gene expression of Saos-2 cells grown on TCP or in 2% w/v AlgM RGD-alginate gels at 
day 21, relative to day 0 TCP. COL1A1, BSP and RUNX2 shown, as indicated. Mean ± full range of values, 
n ≥ 3 from two independent experiments. * Effect of TCP versus gels p < 0.001 for all genes; effect of 
crosslinking ion: COL1A1 p = 0.91, BSP p = 0.53, RUNX2 p = 0.26. 
Figure 3.14: Alkaline phosphatase (ALP) activity per cell of Saos-2 grown on TCP or in 2% w/v 
AlgM RGD-alginate gels with different crosslinking ions. The dotted line represents baseline (day 0) 
activity, determined for Saos-2 in Ca100 gels. Mean ± SD, n = 6. Effect of gels versus TCP P < 0.001. * Sr100 
vs Sr20 and SrZn P < 0.05; ** Sr100 vs Ca100 and TCP P < 0.001; * Zn versus Ca100 P < 0.05. 
Figure 4.1: TGF-β signal transduction. TGF-β binding to TβRII leads to phosphorylation of TβRI (Alk5). 
Phosphorylated TβRI in turn phosphorylates Smad proteins (Smad2 and Smad3). These are thought to 
associate in a trimer with Smad4, also known as the co-Smad. Further association with transcription 
factors (TF) and transport through nuclear pores result in transcriptional regulation (57). 
Figure 4.2: TGF-β latent complex and ECM association. Latency associated peptide (LAP) and 
transforming growth factor beta (TGF-β) comprise the small latent complex (SLC). The large latent 
complex (LLC) additionally includes latent TGF-β binding proteins (LTBPs). Based on a figure from (91). 
Figure 4.3: In vitro concentrations of free and latent TGF-β over time. Concentrations of free and 
latent TGF-β over 48 hours in DMEM on BSA-coated 6-well plates, as determined by ELISA. n = 3, mean 
and range of values shown. * Free versus latent TGF-β concentrations p = 0.05. 
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Figure 4.4: Signalling response to different concentrations of free and latent TGF-β by human 
foreskin fibroblasts (HFF-1). Cells were incubated in the presence of free or latent TGF-β at the 
indicated concentrations for 1 hour prior to fixing. Confocal microscopy; scale = 200 µm. 
Figure 4.5: Signalling response by human foreskin fibroblasts (HFF-1) to 10 ng.ml-1 free and latent 
TGF-β in the presence of inhibitors of TGF-β activation. - = no inhibitor; RGD = soluble RGD peptide; 
ALMC = aprotinin, leupeptin, Marimastat, CP471474; TGFBRI = TGF-β receptor inhibitor. Scale = 200 µm. 
Figure 4.6: Signalling response by passage 4 bovine articular chondrocytes to 10 ng.ml-1 free and 
latent TGF-β in the presence of protease inhibitors. (Top) immunostaining for phosphoSmad3. Scale = 
200 µm. (Bottom) Western blot membrane showing phosphoSmad3, and total Smad3 after stripping. 
Abbreviations as per Figure 4.5, plus PIMC = Roche protease inhibitor cocktail, Marimastat, CP471474. 
Figure 4.7: Conjugation chemistry. (Top) Traut’s reagent reacts with primary amines (lysines) to 
introduce thiols to proteins. (Bottom) Co-reacting a protein (LTGF-β shown) with Traut’s reagent and 
PEGDA causes the SH-LTGF-β to react with PEGDA, producing a PEGylated protein. 
Figure 4.8: PEGylation of model proteins. (Top) attempt 1; (Bottom) attempt 2. Unmodified protein (-) 
and reactions carried out in sodium phosphate buffer (SPB), SPB with 5 mM EDTA (SPEB), or SPB with 
100 mM EDTA (SPEB+). 
Figure 4.9: Primary sequence of TGF-β1 propeptide. Grey letters correspond to signal peptide 
(residues 1-29), blue letters to LAP (residues 30-278; 249 amino acids), and black to TGF-β1 (residues 
279-390; 112 amino acids). The eighteen lysine residues (K) are highlighted in red, and cysteines (C) in 
gold. (240)  
Figure 4.10: PEGylation of LTGF-β. Positions of LAP and free TGF-β are indicated. LTGF-β was run 
either alone or after reacting for 1 hour with PEGDA +/- Traut’s reagent (Traut’s). Batches (a-c) are 
indicated. 
Figure 4.11: Release of latent TGF-β from UV photopolymerised PEGDA hydrogels over time. Acid 
was added at 24 hours (arrow) and concentrations measured by ELISA. LTGF-β was either unmodified, or 
reacted with PEGDA for 1 hour +/- Traut’s reagent (Traut’s). LTGF-β from the batch c reaction was used. 
Effect of reaction conditions p < 0.05 from 0.25 - 24 hours. * LTGF-β versus LTGF-β + PEGDA p < 0.05. 
Figure 4.12: Signalling response to LTGF-β and PEG-LTGF-β by HFF-1. Cells were exposed to LTGF-β 
and PEG-LTGF-β (batch b) at the indicated concentrations for 1 hour. + ACID = acid activation of LTGF-β; 
+ Mn++ = 500 µM MnCl2. Free equivalent concentrations of LTGF-β are shown, without correction for loss 
or modification of protein during PEGylation reactions. Confocal microscopy; scale = 200 µm. 
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Figure 4.13: Signalling response to PEG-LTGF-β by human foreskin fibroblasts (HFF-1) and 
comparison to unmodified LTGF-β at different concentration corrections. HIGH and LOW refer to 
concentration corrections detailed in Table 4.4 and explained in the accompanying text. Estimated 
concentrations (free or free equivalent) were 10 ng.ml-1 for all conditions. (Top) Immunostaining for 
phosphoSmad3, PEG-LTGF-β batch b used. Confocal microscopy; scale = 200 µm. (Bottom) Western blot 
membranes – two repeats from the same experiment. (a) and (b) refer to PEG-LTGF-β batches. For 
consistency, the lane order of the top right membrane was altered in Photoshop. Membranes are also 
shown after being stripped to remove phosphoSmad3 antibody. 
Figure 4.14: Signalling response to PEG-LTGF-β by human foreskin fibroblasts (HFF-1) with acid 
activation and plasmin digestion. Estimated concentrations (free or free equivalent) were 1 ng.ml-1 for 
all conditions, and the PEG-LTGF-β (batch b) was corrected using the HIGH concentration estimation 
(Table 4.4). + acid = acid activation; + P90 = plasmin digestion for 90 minutes; + P180 = plasmin 
digestion for 180 minutes. (Top) Immunostaining for phosphoSmad3. Confocal microscopy; scale = 200 
µm. (Bottom) Western blot membranes – two repeats from the same experiment. Membranes are also 
shown after being stripped to remove phosphoSmad3 antibody. 
Figure 4.15: Viability of bovine chondrocytes cultured for 28 days in PEG-HA gels with and without 
TGF-β. (Top) Total metabolic activity as indicated by alamarBlue® reduction, reflecting cell proliferation. 
Effect of gel p < 0.001; effect of ‘free TGF-β’ versus ‘no TGF-β’ and ‘PEG-LTGF-β’ p < 0.001; effect of ‘latent 
TGF-β’ versus ‘no TGF-β’ p = 0.72. * ‘no TGF-β’ versus ‘PEG-LTGF-β’ p < 0.05; ** ‘no TGF-β’ versus ‘PEG-
LTGF-β’ p < 0.001. (Bottom) LDH release from cultured hydrogels, reflecting cell lysis. Effect of ‘free TGF-
β’ versus ‘no TGF-β’ and ‘PEG-LTGF-β’ p < 0.001. Mean ± SD, n = 5. 
Figure 4.16: Collagen staining of PEG-HA hydrogels with encapsulated chondrocytes cultured for 
up to 28 days. (Top) Picrosirius red staining of wax-embedded sections fixed on day 7 of culture. 
Brightfield microscopy; 10x magnification; scale = 200 µm. (Bottom) Confocal images of hydrogels 
immunostained with collagen II (green) plus DAPI (blue). 20x magnification; scale = 100 µm. 
Figure 4.17: Eosin staining of PEG-HA hydrogels with encapsulated chondrocytes cultured for 21 
and 28 days. Brightfield microscopy; 4x and 10x magnification as indicated; scale = 500 µm for 4x 
magnification, and 200 µm for 10x magnification. 
Figure 4.18: DAPI staining of PEG-HA hydrogels with encapsulated chondrocytes cultured for up to 
28 days. Fluorescent microscopy; 4x magnification; scale = 500 µm. 
Figure 4.19: Macroscopic appearance of PEG-HA hydrogels after 28 days of culture. Some residual 
colour is left over from the alamarBlue® assay. Membrane diameter = 12 mm. 
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Figure 4.20: Viability of bovine chondrocytes in PEG-HA gels with and without TGF-β. (Top) Total 
metabolic activity (alamarBlue® assay) of bovine chondrocytes encapsulated in PEG-HA hydrogels over a 
5 week culture period. Effect of gel p < 0.001 (all intergroup comparisons p < 0.001). * ‘PEG-LTGF-β’ 
versus ‘no TGF-β’ p < 0.01; ** ‘PEG-LTGF-β’ versus ‘no TGF-β’ p < 0.001. (Bottom) Total LDH activity of 
chondrocytes cultured in hydrogels for 34 days, reflecting number of live cells. * p < 0.001 versus ‘no TGF-
β’, p < 0.01 versus ‘PEG-LTGF-β’. Mean ± SD, n = 8 (alamarBlue®), n = 7 (LDH). 
Figure 4.21: Collagen II staining of PEG-HA hydrogels with encapsulated chondrocytes cultured for 
up to 34 days. Collagen II = green, DAPI = blue; confocal microscopy; 20x magnification; scale = 100 µm. 
Figure 4.22: Collagen I staining of PEG-HA hydrogels with encapsulated chondrocytes cultured for 
up to 34 days. Collagen I = green, DAPI = blue; confocal microscopy; 20x magnification; scale = 100 µm. 
Figure 4.23: Collagen VI staining of PEG-HA hydrogels with encapsulated chondrocytes cultured 
for up to 34 days. Collagen VI = green, DAPI = blue; 20x magnification; scale = 100 µm. 
Figure 4.24: Macroscopic appearance of PEG-HA hydrogels after 34 days of culture. Base 
(membrane) diameter = 6 mm. 
Figure 4.25: Histology of PEG-HA hydrogels with encapsulated chondrocytes cultured for 34 days 
(wax-embedded sections). Stains are as labelled; brightfield microscopy; 4x and 10x labels indicate 
magnification; ‘zoom’ shows close-ups of 4x images; scale = 500 µm for 4x magnification, 200 µm for 10x 
magnification, and 125 µm for zooms of 4x images. 
Figure 4.26: Total protein in PEG-HA hydrogels after 34 days of culture. * p < 0.01 versus ‘no TGF-β’. 
Mean ± SD, n = 7. 
Figure 4.27: LIVE/DEAD® staining of bovine chondrocytes within PEG-HA hydrogels after 34 days 
of culture. Live cells appear green and dead cells red. Confocal microscopy; scale = 100 µm. 
Figure A.I: LDH standard curve results for Saos-2 homogenised in alginate solution and gels.  
Figure A.II: UV absorbance spectra of (left) pure RNA and (right) a contaminated preparation. The 
pure sample has a 260/280 ratio of 2.02 and a 260/230 ratio of 2.06, and the contaminated sample has 
260/280 and 260/230 ratios of 2.02 and 0.27 respectively. Note the absorbance maxima at 260 nm 
(vertical lines). Screenshots are from NanoDrop software.  
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Figure A.III: Primer validation for BSP. (Top) Raw (cycling) fluorescence for serial dilutions of cDNA, 
showing intervals of ~ 3.3 Cts between 10x dilutions. (Middle) Melt curve analysis of samples, showing a 
single peak (amplicon). (Bottom) Agarose gel electrophoresis of reaction products, showing a single 
specific band (amplicon). NTC = no template control (water), No RT = no reverse transcriptase control; 
numbers indicate ten fold dilutions of cDNA. 
Figure A.IV: Viability and numbers of Saos-2 in alginate gels at days 1 and 5 of culture, as 
determined by quantification of LIVE/DEAD® stained cells. 2% and 3% w/v unmodified AlgG gels. 
(Top) Percentage live cells within gels. Effect of day 1 versus day 5 p < 0.001. (Bottom) Total number of 
cells per image. Mean ± SD, n = 6. 5 random fields were analysed per gel.  
Figure A.V: Viability and numbers of Saos-2 in alginate gels at days 1 and 5 of culture, as 
determined by quantification of LIVE/DEAD® stained cells. 2% w/v AlgG + NOVATECH-RGD gels. 
(Top) Percentage live cells within gels. Effect of day 1 versus day 5 p < 0.001. (Bottom) Total number of 
cells per image. Five random fields were analysed per gel. Mean ± SD, n = 6.  
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Table 3.1: Gel formulations used for materials characterisation, including gel codes referred to in 
the text. 
Table 3.2: Composition of alginate crosslinking solutions used in cell studies, including gel codes 
referred to in the text. The alginate concentration was 2% (w/v), and the type of alginate (AlgG or AlgM) 
is specified in the main text as appropriate. 
Table 3.3: Average linear correlation factors (R2) values for first 1mm deformation of alginate gels 
under compression.  
Table 3.4: Rates of calcium and strontium release from alginate gels, in µM per gram of gel per day. 
R2 values are given in brackets as an indicator of steady release from day 10. Rates of Ca++ and Sr++ release 
are shown for days 1-5, days 5-10, and from day 10 onward. N/A = not applicable (gels had degraded by 
day 10).  
Table 4.1: Physical and molecular factors involved in latent TGF-β activation. Also shown (in grey) 
are integrins known to bind, but not necessarily activate, latent TGF-β. Compiled from information in 
(91), (220) and (230).  
Table 4.2: TGF-β-activating proteases and pharmacological inhibitors used. List of proteases 
compiled from (91) and (220); specificity of proteases based on manufacturer’s information.  
Table 4.3: Protein information for the model proteins bovine serum albumin, cytochrome C, 
lysozyme, LAP-β1, and TGF-β1. Approximate molecular weight (Mw) and number of lysines shown. 
Note that LAP-β1 and TGF-β1 come from the same gene product and are dimeric. (237)(238)(239)(240) 
Table 4.4: Relative apparent concentrations of LTGF-β after 1 hour reacting with PEGDA +/- 
Traut’s reagent. LTGF-β was reacted either with PEGDA or with PEGDA and Traut’s reagent for 1 hour, 
and the concentrations before and afterwards were read by ELISA (‘Relative amount = concentration 
after reaction/concentration before reaction’). The inverse of these ratios defines a correction factor for 
each condition, used to calculate concentrations (denoted HIGH and LOW as indicated) for use in selected 
experiments in the next section. N/A – batch c was not used in subsequent cell work.  
Table A.I: List of common contaminating compounds in RNA preparations and their characteristic 
absorbances. Guanidine salts are common in RNA isolation buffers, for example guianidine thiocyanate 
(absorbance at ~260 nm) is a component of the RNeasy buffers RLT and RW1. (255) 
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Table A.II: Summary of troubleshooting steps for RNA extraction from alginate and PEG hydrogels. 
(a – above) Troubleshooting steps in gel honogenisation. (b – page 148) Troubleshooting steps in 
removing gel debris and other contaminants. (c – page 149) Extractions using Trizol reagent.  Brief 
methods and reasons for taking each step are given. Bold typeface highlights the notable points for each 
attempt. Alg = ungelled alginate; Ca-Alg = Ca100 gel; Sr-Alg = Sr100 gel; PEG700 = photopolymerised 
PEGDA Mw = 700; PEG4K = photopolymerised PEGDA Mw = 4000. RNA concentration, and 260/280 and 
260/230 nm ratios are stated, and an overall judgement on the success of the extraction is indicated in 
the far right column:  = method has significant potential (typical yield > 20 ng.ml-1, 260/280 ratio ~ 2, 
260/230 ratio >> 1); x = RNA does not meet the required standard; ~ = RNA does not meet the required 
standard, but some samples or parameters show promise. Sources: manufacturer’s information (Trizol, 
RNeasy) and reference (255).  
Table A.III: Standard curve results for qPCR primers. Working range and dilution indicate the Ct and 
dilution ranges over which the indicated efficiency and R2 values were generated.  
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